PROTEÍNA DE FUSÃO, ANTICORPO, ÁCIDO NUCLEICO ISOLADO, CÉLULA HOSPEDEIRA, MÉTODO E COMPOSIÇÃO FARMACÊUTICA
Fusion proteins with bispecific antigen-binding domains target IFN-α2 to tumor cells by binding to PD-L1, preventing receptor activation in healthy cells, thus enhancing cancer treatment efficacy and reducing side effects.
Patent Information
- Application Number
- BR112025024355
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-08
- Filing Date
- 2024-05-06
- Publication Date
- 2026-11-10
AI Technical Summary
The therapeutic use of IFN-α for cancer treatment can cause significant side effects due to its activity in both tumor and healthy cells, necessitating targeted therapies that prevent IFN-α from binding to its receptor outside the tumor microenvironment.
Fusion proteins comprising human IFN-α2 fused to a bispecific antigen-binding domain capable of binding to both PD-L1 and IFN-α2, which self-regulate by preventing IFN-α2 from binding to its receptor in the absence of PD-L1, thereby activating the IFN-α pathway only in the presence of PD-L1.
The fusion proteins effectively target IFN-α2 to tumor cells while minimizing side effects by inhibiting its activity in healthy cells, enhancing therapeutic efficacy and reducing toxicity.
Abstract
Description
[0001] The present invention relates to fusion proteins comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1 and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, and methods of using them. Background of the Invention
[0002] Type I interferons (IFNs) are a family of cytokines that play a key role in inflammation, immune regulation, tumor cell recognition, and T cell response. Interferon alpha (IFN-α) is a type I interferon naturally produced by the immune system to attack viruses and cancer cells. It has been extensively studied and found to be effective in treating certain types of cancer, such as melanoma, renal cell carcinoma, and chronic myeloid leukemia. The mechanism of action of IFN-α involves inhibiting the growth of tumor cells and increasing the immune system's ability to recognize and destroy cancer cells.
[0003] The term “IFN-α” refers to a family of cytokines comprising several subtypes, including IFN-α1, IFN-α2, and several others. IFN-α1 and IFN-α2 differ in their amino acid sequence, but both IFN-α1 and IFN-α2 have similar biological activities and are used clinically for the treatment of cancer and viral infections. IFN-α2 has been shown to be more potent than IFN-α1 in terms of antiviral and antiproliferative activities.
[0004] The mode of action of IFN-α involves binding to its receptor IFNAR, which is composed of the subunits IFNAR1 and IFNAR2, a crucial step in the activation of the JAK-STAT signaling pathway. This leads to transcription Petition 870250102232, dated 07 / 11 / 2025, pp. 318 / 702 2 / 333 of genes involved in the activation of immune cells and in the apoptosis of cancer cells. The binding of IFN-α to its receptor is a key molecular event that underlies the therapeutic efficacy of IFN-α in cancer treatment.
[0005] However, the therapeutic use of IFN-α can have significant side effects, including flu-like symptoms such as fever, chills, and fatigue. For this reason, targeting IFN-α to tumor cells and immune cells in the tumor microenvironment (TME) is a highly promising approach. Targeted therapies use agents such as antibodies or antigen-binding domains to specifically target cancer cells based on their unique molecular characteristics, such as the overexpression of certain tumor markers on their surface. By selectively targeting cancer cells and immune cells in the TME, damage to healthy cells and / or tissues is avoided, reducing the incidence and severity of undesirable side effects. Furthermore, due to their specificity, targeted therapies can achieve high response rates and better patient outcomes.Overall, the benefits of tumor-targeted therapy suggest that this approach has the potential to significantly improve outcomes for cancer patients while minimizing the toxicity and inconvenience associated with traditional chemotherapy.
[0006] In the case of IFN-α, however, targeting alone may not be sufficient to prevent IFN-α from exerting its activity also in the periphery, that is, in healthy cells and tissues. Therefore, new therapeutic agents capable of preventing IFN-α from acting on its receptor are needed, unless the molecule is close to a tumor cell.
[0007] Document WO 2021 / 231773 provides protein complexes comprising a sensor domain and a therapeutic domain linked by a ligand, and methods for their use. The therapeutic domain can be Petition 870250102232, dated 07 / 11 / 2025, pp. 319 / 702 3 / 333 IFN-α. The therapeutic domain activity is dependent on the binding of the sensory domain to target markers, such as PD-L1. Brief Description of the Invention
[0008] The invention provides fusion proteins comprising a human IFN-α2 (huIFN-α2) or variant thereof, a first antigen-binding domain capable of binding to human PD-L1 (huPD-L1), and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, and methods for using the same. These fusion proteins provided in this document are characterized in that the second antigen-binding domain is a bispecific Fab and the human IFN-α2 is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain.
[0009] It has been discovered that the human IFN-α2 fusion proteins provided in this document function in a self-regulated manner, i.e., they show a therapeutic effect predominantly in the presence of the target molecule PD-L1 and remain inactive in its absence. Furthermore, the fusion proteins described in this document comprise a bispecific antigen-binding domain that is capable of binding to both human PD-L1 and human IFN-α2, i.e., it has affinity for both human IFN-α2 and human PD-L1, such that human IFN-α2 and human PD-L1 compete for binding to the bispecific antigen-binding domain. In addition, the binding of the bispecific antigen-binding domain to IFN-α2 prevents IFN-α2 from binding to IFNAR. As long as no human PD-L1 is present, the bispecific antigen-binding domain binds to the human IFN-α2 portion of the fusion protein, preventing it from binding to its IFNAR receptor and thus activating the IFNα pathway.In the presence of human PD-L1, the second antigen-binding domain binds to human PD-L1, and the human IFN-α2 portion is no longer bound to the bispecific antigen-binding domain, now being able to bind to the receptor. Petition 870250102232, dated 07 / 11 / 2025, pages 320 / 702 4 / 333 IFNAR triggers the activation of the IFN-α pathway in the target cell.
[0010] One aspect of the invention is a fusion protein comprising: a. a first antigen-binding domain capable of binding to human PD-L1; b. a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2; and c. a human IFN-α2; in which i. the second antigen-binding domain is a bispecific Fab; and ii. the human IFN-α2 is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain.
[0011] In one embodiment of the invention, the first antigen-binding domain capable of binding to human PD-L1 is monospecific for human PD-L1.
[0012] In one embodiment, the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 is able to block human IFN-α2 from binding to IFNAR. In a specific embodiment, the second antigen-binding domain is able to block the binding of huIFN-α2 to the IFNAR2 subunit of IFNAR.
[0013] One embodiment of the invention is a fusion protein comprising: a. a first antigen-binding domain capable of binding to human PD-L1; b. a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2; and Petition 870250102232, dated 07 / 11 / 2025, pp. 321 / 702 5 / 333 c. a human IFN-α2; in which i. the second antigen-binding domain is a bispecific Fab; and ii. the human IFN-α2 is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain; whereby the bispecific Fab is blocked from binding to PD-L1 when bound to human IFN-α2 and is blocked from binding to human IFN-α2 when bound to PD-L1, and / or whereby human IFN-α2 is blocked from binding to IFNAR when bound to the bispecific Fab and is able to bind to IFNAR when the bispecific Fab is bound to PD-L1.
[0014] In one aspect of the invention, the first antigen-binding domain of the fusion protein capable of binding to human PD-L1 is monospecific for human PD-L1. In one embodiment, the first antigen-binding domain of the fusion protein capable of binding to human PD-L1 is a Fab. In one embodiment, the affinity of the first antigen-binding domain for PD-L1 is distinguished by a Kd of 1.1 nM or less, as measured using a BIACORE® surface plasmon resonance assay at 25 °C.
[0015] In one embodiment of the fusion protein provided in this document, the first antigen-binding domain or the second antigen-binding domain is a cross-linked Fab molecule in which the variable or constant regions of the Fab light chain and the Fab heavy chain are exchanged.
[0016] In one embodiment, the amino acid at position 124 in the constant domain CL of one of the Fab fragments of the fusion protein is Petition 870250102232, dated 07 / 11 / 2025, pages 322 / 702 6 / 333 is independently replaced by lysine (K), arginine (R) or histidine (H) (numbering according to the EU Kabat index), and in the constant domain CH1 the amino acids at positions 147 and 213 are independently replaced by glutamic acid (E) or aspartic acid (D) (numbering according to the EU Kabat index).
[0017] In one embodiment, the amino acid at position 123 (EU numbering) in the constant CL domain of one of the Fab fragments of the fusion protein was replaced by arginine (R) and the amino acid at position 124 (EU numbering) was replaced by lysine (K) and the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) in one of the CH1 domains were replaced by glutamic acid (E).
[0018] In one embodiment, the amino acid at position 124 in the constant domain CL of the Fab fragment comprising the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 is independently replaced by lysine (K), arginine (R), or histidine (H) (numbering according to the EU Kabat Index), and the amino acids at positions 147 and 213 in the constant domain CH1 of the Fab fragment comprising the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 are independently replaced by glutamic acid (E) or aspartic acid (D) (numbering according to the EU Kabat Index).
[0019] In one embodiment, the amino acid at position 123 (EU numbering) in the constant CL domain of the Fab fragment comprising the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 was replaced by arginine (R) and the amino acid at position 124 (EU numbering) was replaced by lysine (K) and the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) in one of the CH1 domains of the Fab fragment comprising the antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 were replaced by acid Petition 870250102232, dated 07 / 11 / 2025, pp. 323 / 702 7 / 333 glutamic (E).
[0020] In one embodiment, the fusion protein described herein comprises no more than one human IFN-α2. In one embodiment, the fusion protein described herein comprises exactly one human IFN-α2. In one embodiment, the human IFN-α2 comprised in the fusion protein is selected from human IFN-α2a, human IFN-α2b, or functional variants thereof. In one embodiment, the human IFN-α2 comprised in the fusion protein comprises an amino acid sequence selected from SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, and SEQ ID NO:82, preferably selected from SEQ ID NO:79 and SEQ ID NO:80. In one embodiment, the human IFN-α2 comprised in the fusion protein provided herein comprises the amino acid sequence of SEQ ID NO:79. In one embodiment, the human IFN-α2 comprised in the fusion protein comprised in this document comprises one or more mutations that modify the binding of human IFN-α2 to the IFNAR1 / 2 receptor.
[0021] In one embodiment, the human IFN-α2 comprised in the fusion protein provided in this document is fused at its N-terminus or its C-terminus to the bispecific Fab via a peptide linker. In another embodiment, the human IFN-α2 comprised in the fusion protein provided in this document is fused at its C-terminus to the N-terminus of the bispecific Fab light chain. In certain embodiments, the peptide linker has a length of 16 to 24 amino acids, particularly 20 amino acids. In one embodiment, the peptide linker is a glycine serine (GS) linker comprising an amino acid sequence selected from the group consisting of (GS)n, (GSGGS)n (SEQ ID NO:96), (GGGS)n (SEQ ID NO:97), (GSGGG)n (SEQ ID NO:98), (GGGSG)n (SEQ ID NO:99), (GSSSG)n (SEQ ID NO:100), (GGGGS)n (SEQ ID NO:101), (GGSGG)n (SEQ ID NO:102), where n represents an integer of at least 1, preferably from 4 to 6. In another embodiment, Petition 870250102232, dated 07 / 11 / 2025, pp. 324 / 702 8 / 333 the peptide linker comprises an amino acid sequence selected from GGSGGGSGGGSGGGSGGGSG (SEQ ID NO:103), GSGSGGSGSGGSG SGGSGSGGSGSG (SEQ ID NO:104), GSGGGG SGGGGSGGGGSGGG (SEQ ID NO:105), GGGSGGGGSGGGGSGGGGSGGGGSG (SEQ ID NO:106), GSSS GGSSSGGSSSGGSSSG (SEQ ID NO:107), GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:108), GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:109) and GGSGGGG SGGGGSGGGGSGG (SEQ ID NO:110).
[0022] In one particular embodiment, the bispecific Fab comprised in the second antigen-binding domain of the fusion protein provided in this document is a DutaFab.
[0023] In one embodiment, the affinity of bispecific Fab to human PDL1 is 1 to 10 times, in particular 2 to 5 times the affinity to human IFNα2.
[0024] In one embodiment, the affinity of bispecific Fab to human PDL1 is characterized by a Kd of 1 nM to 10 nM and the affinity to human IFN-α2 is distinguished by a Kd of 10 nM to 20 nM, as measured by means of a BIACORE® surface plasmon resonance assay at 25 °C. In one embodiment, the affinity of bispecific Fab to human PD-L1 is distinguished by a Kd of 1 nM to 10 nM and the affinity to human IFN-α2 is characterized by a Kd of 10 nM to 20 nM, wherein the affinity to human PD-L1 is measured using a BIACORE® surface plasmon resonance assay at 25 °C, as described in Example 8 g) and wherein the affinity to human IFN-α2 is measured using a BIACORE® surface plasmon resonance assay on a Biacore 8K instrument or 8K at 25 °C using unlabeled huIFNa2a (SEQ ID NO:79), as described in Example 8 h).
[0025] In one embodiment, the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 comprises Petition 870250102232, dated 07 / 11 / 2025, pp. 325 / 702 9 / 333 a paratope of human IFN-α2 and a paratope of human PD-L1 within a cognate pair of a variable light chain domain (VL domain) and a variable heavy chain domain (VH domain), where: a) the human IFN-α2 paratope comprises amino acid residues of CDR-H2, CDR-L1, and CDR-L3 from the antigen-binding domain, and the human PD-L1 paratope comprises amino acid residues of CDR-H1, CDR-H3, and CDR-L2 from the antigen-binding domain, or b) the human PD-L1 paratope comprises amino acid residues of CDR-H2, CDR-L1 and CDR-L3 from the antigen-binding domain, and the human IFN-α2 paratope comprises amino acid residues of CDR-H1, CDR-H3 and CDR-L2 from the antigen-binding domain.
[0026] In one embodiment, the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 comprises a human IFN-α2 paratope and a human PD-L1 paratope within a cognate pair of a variable light chain domain (VL domain) and a variable heavy chain domain (VH domain), wherein the human IFN-α2 paratope comprises amino acid residues of CDR-H2, CDR-L1, and CDR-L3 of the antigen-binding domain, and wherein the human PD-L1 paratope comprises amino acid residues of CDR-H1, CDR-H3, and CDR-L2 of the antigen-binding domain. [0 027] In one aspect, the fusion protein additionally comprises an Fc domain composed of a first and a second subunit. In a further aspect, the Fc domain is an IgG Fc domain, particularly an IgG1 Fc domain or an IgG4 Fc domain. In another aspect, the Fc domain comprises one or more amino acid substitutions that reduce binding to an Fc receptor, particularly the Fcy receptor. In certain embodiments, the Fc domain is a human IgG1 subclass Fc domain with the amino acid mutations L234A, L235A and P329G (numbering of Petition 870250102232, dated 07 / 11 / 2025, pp. 326 / 702 10 / 333 according to the EU Kabat index). In some embodiments, the first subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S, L368A and Y407V (numbering according to the EU Kabat index) and the second subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (numbering according to the EU Kabat index).
[0028] In one embodiment, the fusion protein further comprises an Fc domain composed of a first and a second subunit, and the first antigen-binding domain comprised in the fusion protein is a Fab and is fused at the C-terminal of the Fab heavy chain to the N-terminal of the first subunit of the Fc domain, and the second antigen-binding domain is a bispecific Fab, in particular a DutaFab, and is fused at the C-terminal of the Fab heavy chain to the N-terminal of the second subunit of the Fc domain, and human IFN-α2 is fused at its C-terminal to the N-terminal of the bispecific Fab light chain of the second antigen-binding domain.
[0029] In one embodiment, the invention is a fusion protein comprising: a. a first antigen-binding domain capable of binding to human PD-L1; b. a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2; and c. a human IFN-α2; in which i. the second antigen-binding domain is a bispecific Fab; and ii. human IFN-α2 is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain; and in that the second antigen-binding domain is capable of becoming Petition 870250102232, dated 07 / 11 / 2025, pp. 327 / 702 11 / 333 bind to human PD-L1 and human IFN-α2, comprising: a. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; or b. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:9, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; or c. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; or d. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:13, (b) CDR-H2 comprising the amino acid sequence of SEQ ID Petition 870250102232, dated 07 / 11 / 2025, pp. 328 / 702 12 / 333 NO:14, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:15, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:16, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:17, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:18.
[0030] In one embodiment, the invention is a fusion protein comprising a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2, and a human IFN-α2, wherein the second antigen-binding domain is a bispecific Fab and the human IFN-α2 is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain, wherein the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 comprises: a. a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:8; b. a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:10; c. a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:12; or d. a VH domain comprising the amino acid sequence of SEQ ID NO:19 and a VL domain comprising the amino acid sequence of SEQ ID NO:20.
[0031] In one embodiment, the invention is a fusion protein comprising a first antigen-binding domain capable of binding Petition 870250102232, dated 07 / 11 / 2025, pp. 329 / 702 13 / 333 to human PD-L1, a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2, and a human IFN-α2, wherein the second antigen-binding domain is a bispecific Fab and the human IFN-α2 is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain, wherein the first antigen-binding domain capable of binding to human PD-L1 comprises: a. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:26; or b. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:29, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:30, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:31, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:32, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:33, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:34.
[0032] In one embodiment, the invention is a fusion protein comprising a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2, and a human IFN-α2, wherein the second antigen-binding domain is a bispecific Fab and IFN-α2 Petition 870250102232, dated 07 / 11 / 2025, pp. 330 / 702 14 / 333 human is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain, wherein the first antigen-binding domain capable of binding to human PD-L1 comprises: a. a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28; or b. a VH domain comprising the amino acid sequence of SEQ ID NO:35 and a VL domain comprising the amino acid sequence of SEQ ID NO:36.
[0033] In one embodiment, the invention provides a fusion protein comprising a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2, and a human IFN-α2, wherein the second antigen-binding domain is a bispecific Fab and the human IFN-α2 is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain, wherein: a. The first antigen-binding domain capable of binding to human PD-L1 is a crossed Fab molecule in which the variable or constant regions of the Fab light chain and the Fab heavy chain are exchanged and comprises: i. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (f) CDR-L3 Petition 870250102232, dated 07 / 11 / 2025, pp. 331 / 702 15 / 333 comprising the amino acid sequence of SEQ ID NO:26; or ii. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:29, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:30, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:31, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:32, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:33, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:34; and b. The second antigen-binding domain, which is capable of binding to human PD-L1 and human IFN-α2, comprises: i. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; ii. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:9, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; iii. a variable heavy chain (VH) domain that Petition 870250102232, dated 07 / 11 / 2025, pp. 332 / 702 16 / 333 comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; or iv.a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:13, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:14, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:15, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:16, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:17, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:18; and. c. the fusion protein additionally comprises an Fc domain composed of a first and a second subunit.
[0034] In a specific embodiment of the fusion protein provided in this document, the first antigen-binding domain capable of binding to human PD-L1 is fused at the C-terminal of its Fab heavy chain to the N-terminal of the first Fc domain subunit, and the second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2 is fused at the C-terminal of its Fab heavy chain to the N-terminal of the second Fc domain subunit, and human IFN-α2 is fused at its C-terminal to the N-terminal of the Fab light chain of the second antigen-binding domain.
[0035] In one embodiment, the invention is a fusion protein comprising a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of Petition 870250102232, dated 07 / 11 / 2025, pp. 333 / 702 17 / 333 bind to human PD-L1 and human IFN-α2, and a human IFN-α2, wherein the second antigen-binding domain is a bispecific Fab and the human IFN-α2 is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain, wherein: a. The first antigen-binding domain capable of binding to human PD-L1 comprises: a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:26; and b. The second antigen-binding domain, which is capable of binding to human PD-L1 and human IFN-α2, comprises: a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; and c. the fusion protein additionally comprises an Fc domain composed of a first and a second subunit.
[0036] In a specific embodiment of the fusion protein provided in this document, the first antigen-binding domain is fused. Petition 870250102232, dated 07 / 11 / 2025, pp. 334 / 702 18 / 333 at the C-terminal of its Fab heavy chain to the N-terminal of the first Fc domain subunit, and the second antigen-binding domain is fused at the C-terminal of its Fab heavy chain to the N-terminal of the second Fc domain subunit, and interferon alpha is fused at its C-terminal to the N-terminal of the Fab light chain of the second antigen-binding domain.
[0037] In one embodiment, the fusion protein comprises a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2, and a human IFN-α2, wherein the second antigen-binding domain is a bispecific Fab and the human IFN-α2 is fused at its C-terminal to the N-terminal of the heavy chain or light chain of the second antigen-binding domain, wherein: The second antigen-binding domain capable of binding to human PDL1 and human IFN-α2 comprises: a. a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:8; b. a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:10; c. a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:12; or d. a VH domain comprising the amino acid sequence of SEQ ID NO:19 and a VL domain comprising the amino acid sequence of SEQ ID NO:20; and the first antigen-binding domain capable of binding to human PDL1 comprises: Petition 870250102232, dated 07 / 11 / 2025, pages 335 / 702 19 / 333 a. a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28; or b. a VH domain comprising the amino acid sequence of SEQ ID NO:35 and a VL domain comprising the amino acid sequence of SEQ ID NO:36.
[0038] In one embodiment, the invention is a fusion protein comprising a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2, and a human IFN-α2, wherein the second antigen-binding domain is a bispecific Fab and the human IFN-α2 is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain, wherein the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 comprises a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:8, and wherein the first antigen-binding domain capable of binding to human PD-L1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28.
[0039] In one embodiment, the invention is a fusion protein comprising: a. a first antigen-binding domain capable of binding to human PD-L1; b. a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2; c. a human IFN-α2; and Petition 870250102232, dated 07 / 11 / 2025, pp. 336 / 702 20 / 333 d. an Fc domain composed of a first and a second subunit; wherein the first antigen-binding domain is a Fab and the second antigen-binding domain is a bispecific Fab, preferably a DutaFab; wherein the first and second antigen-binding domains are each composed of a heavy chain and a light chain; and wherein the fusion protein is composed of: (a) a first polypeptide comprising (a1) the heavy chain of the first antigen-binding domain, fused at its C-terminus to the N-terminus of one of the subunits (e.g., the first subunit) of the Fc domain, and (a2) one of the subunits (e.g., the first subunit) of the Fc domain; (b) a second polypeptide, comprising the light chain of the first antigen-binding domain; (c) a third polypeptide, comprising (c1) the heavy chain of the second antigen-binding domain, fused at its C-terminus to the N-terminus of the other subunit (e.g., the second subunit) of the Fc domain, and (c2) the other subunit (e.g., the second subunit) of the Fc domain; and (d) a fourth polypeptide, comprising (d1) human IFN-α2, fused at its C-terminus to the N-terminus of the light chain of the second antigen-binding domain, and (d2) the light chain of the second antigen-binding domain.
[0040] In one embodiment, the fusion protein comprises: a first polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:37; Petition 870250102232, dated 07 / 11 / 2025, pp. 337 / 702 21 / 333 a second polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:38; a third polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:39; and a fourth polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40.
[0041] In one embodiment, the fusion protein comprises four polypeptides, wherein: The first polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41; The second polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:42; The third polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:43; and the fourth polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:44.
[0042] In one embodiment, the fusion protein comprises four polypeptides, wherein: The first polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:45; Petition 870250102232, dated 07 / 11 / 2025, pp. 338 / 702 22 / 333 The second polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:46; The third polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:47; and the fourth polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:48.
[0043] In one embodiment, the fusion protein comprises four polypeptides, wherein: The first polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:49; The second polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:50; The third polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:51; and the fourth polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:52.
[0044] In one embodiment, the fusion protein comprises four polypeptides, wherein: The first polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:53; Petition 870250102232, dated 07 / 11 / 2025, pp. 339 / 702 23 / 333 the second polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:54; The third polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55; and the fourth polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:56.
[0045] In one embodiment, the fusion protein comprises four polypeptides, wherein: The first polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:57; The second polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:58; The third polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:59; and the fourth polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:60.
[0046] These fusion proteins have highly valuable properties, such as their binding properties, in particular the high affinity of the second antigen-binding domain to human IFN-α2α, and their blocking properties, which ensure that the IFN-α2α portion is reliably prevented (“masked”) from activating the IFNAR receptor as long as there is no Petition 870250102232, dated 07 / 11 / 2025, pages 340 / 702 24 / 333 target molecule PD-L1 present or insufficient. Another valuable property is the ability of the first antigen-binding domain and the second antigen-binding domain in some embodiments of the fusion protein provided in this document to bind to the C-terminal domain of PD-L1, thus not competing with other therapeutic anti-PD-L1 antibodies, such as Atezolizumab, for PD-L1 binding, but still having the ability to block the PD-L1 / PD1 interaction. This effect can be observed particularly at high concentrations and is probably caused by steric hindrance. Due to this property, the fusion proteins of the invention may be able to achieve a therapeutic effect beyond IFNα activation by blocking the PD-L1 / PD1 interaction. They are also ideal for use in combination therapy with known therapeutic anti-PD-L1 antibodies that bind to the N-terminal of PD-L1.
[0047] Other valuable properties of the fusion proteins of the invention are their comparatively low tendency to form undesirable dimers, their high thermostability, their low propensity for degradation, and their ability to inhibit tumor growth, particularly in tumors expressing PD-L1. Another valuable property of the fusion proteins of the invention is their high potency, i.e., they achieve a high level of activation of the IFN-α2a pathway in PD-L1 high-expression cells at a low dose, while the level of IFN-α2a activity in PD-L1 low-expression cells at the same dose is very low in comparison, as measured, for example, in a human HEK-blue IFNAR1 / 2 reporter cell assay, as described in this document. The first and second antigen-binding domains also show cross-reactivity with cynomolgus PD-L1.Another highly valuable property is its ability to inhibit tumor cell proliferation and tumor growth (including the induction of tumor regression), particularly in tumors or tumor cell lines that express it. Petition 870250102232, dated 07 / 11 / 2025, pp. 341 / 702 25 / 333 PD-L1. Furthermore, the fusion proteins described in this document have good tolerability and a beneficial side effect profile, particularly compared to untargeted and unattenuated IFN-α2, because the second antigen-binding domain that remains bound to IFN-α2 in the absence of target cells expressing PD-L1 prevents unwanted IFN-α2 activity in peripheral tissue and directs IFN-α2 activity in the fusion protein to the target tissue.
[0048] An antibody that binds to human PDL1 is also provided here, wherein the antibody comprises: a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22 and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23; and a variable light chain (VL) domain comprising (d) CDRL1 comprising the amino acid sequence of SEQ ID NO:24, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25 and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:26.
[0049] In one embodiment, the monoclonal antibody that binds to PD-L1 comprises a sequence selected from the group consisting of: (a) a VH sequence with at least 95% sequence identity with the amino acid sequence of SEQ ID NO:27; (b) a VL sequence with at least 95% sequence identity with the amino acid sequence of SEQ ID NO:28; and (c) a VH sequence, as defined in (a), and a VL sequence, as defined in (b).
[0050] In one embodiment, the antibody that binds to PD-L1 comprises a VH sequence of SEQ ID NO:27 and a VL sequence of SEQ Petition 870250102232, dated 07 / 11 / 2025, pp. 342 / 702 26 / 333 ID NO:28.
[0051] In one embodiment, the antibody that binds to PD-L1 comprises a heavy chain with SEQ ID NO:142 and a light chain with SEQ ID NO:143.
[0052] These antibodies have highly valuable properties, such as their binding properties, in particular their high affinity for PD-L1 and their ability to bind to the C-terminal domain of PD-L1, therefore not competing with other therapeutic anti-PD-L1 antibodies, such as Atezolizumab, for PD-L1 binding, but surprisingly still having the ability to block the PD-L1 / PD1 interaction, particularly at high concentrations. Due to this property, the antibodies of the invention may be able to achieve an enhanced therapeutic effect by blocking the PD-L1 / PD1 interaction. They are also ideal for use in combination therapy with known therapeutic anti-PD-L1 antibodies that bind to the N-terminal of PD-L1. They are also suitable for diagnostic purposes, for example, to detect PD-L1 in assays that test the blocking effect of anti-PD-L1 antibodies, as these generally bind to the N-terminal domain of PD-L1.The anti-PD-L1 antibodies of the invention also show cross-reactivity with cynomolgus PD-L1.
[0053] In one embodiment, the antibody that binds to PD-L1 binds specifically to PD-L1. In one embodiment, the antibody that binds to PD-L1 is a monoclonal antibody. In one embodiment, the antibody that binds to PD-L1 is a humanized or chimeric antibody. In one embodiment, the antibody that binds to PD-L1 is a full-length IgG1 antibody.
[0054] In certain embodiments, the antibody that binds to PD-L1 is a PD-L1-binding antibody fragment. In one embodiment, the antibody that binds to PD-L1 is a DutaFab.
[0055] In one embodiment, the antibody binds to PD-L1 with a Petition 870250102232, dated 07 / 11 / 2025, pp. 343 / 702 27 / 333 affinity of 1.1 nM or less, preferably 0.6 nM or less, as measured by a BIACORE® surface plasmon resonance assay at 25 °C. In one embodiment, the antibody binds to the C-terminal domain of PD-L1. In one embodiment, antibody binding to PD-L1 blocks PD-L1 and PD1 interaction, as measured by SPR. In one embodiment, the antibody binding to PD-L1 is a multispecific antibody.
[0056] The invention provides an isolated nucleic acid that encodes the fusion protein or antibody described in this document.
[0057] The invention provides a host cell comprising such nucleic acid.
[0058] The invention provides a method for producing a fusion protein or antibody described herein, comprising cultivating the host cell under conditions suitable for the expression of the fusion protein or antibody. The invention provides a method for producing a fusion protein or antibody, which further comprises recovering the fusion protein or antibody from the host cell. The invention also provides a fusion protein or antibody produced by such method.
[0059] The invention provides a pharmaceutical composition comprising the fusion protein or antibody described in this document and a pharmaceutically acceptable carrier.
[0060] The invention provides the fusion protein, antibody or pharmaceutical composition described in this document for use as a medicament.
[0061] The invention provides the fusion protein, antibody or pharmaceutical composition described in this document for use in the treatment of cancer.
[0062] The invention provides the use of the fusion protein, of Petition 870250102232, dated 07 / 11 / 2025, pp. 344 / 702 28 / 333 antibody or pharmaceutical composition described in this document in the manufacture of a drug for cancer treatment.
[0063] The invention provides the use of the fusion protein, antibody or pharmaceutical composition described in this document in the manufacture of a medicament to target a therapeutically active agent to a tumor cell and / or an immune cell in the tumor microenvironment.
[0064] The invention provides a method of treating an individual with cancer, comprising administering to the individual an effective amount of the fusion protein, antibody or pharmaceutical composition described in this document.
[0065] The invention provides a method for inhibiting cell proliferation and / or tumor growth in an individual, comprising administering to the individual an effective amount of the fusion protein, antibody or pharmaceutical composition described in this document to inhibit cell proliferation and / or tumor growth.
[0066] The invention provides a method of modulating the immune system by directly or indirectly inducing the proliferation and / or activation of immune cells in an individual, comprising administering to the individual an effective amount of the fusion protein, antibody or pharmaceutical composition described in this document to modulate the immune system by directly or indirectly inducing the proliferation and / or activation of immune cells. Brief Description of the Figures
[0067] Figure 1 Schematic illustration of the PD-L1-directed IFN-α2α fusion protein used in the Examples. The molecule comprises a CrossFab as a first antigen-binding domain capable of binding to huPD-L1 and a DutaFab as a second antigen-binding domain capable of binding to both huPD-L1 and huIFN-α2α. Both antigen-binding domains are fused through the C-terminus of their heavy chains to the N-terminus of Petition 870250102232, dated 07 / 11 / 2025, pp. 345 / 702 29 / 333 one of the two subunits of an Fc domain. The fusion protein further comprises a huIFN-α2α portion that is fused through its C-terminus to the N-terminus of the light chain of the second antigen-binding domain.
[0068] Figure 1A illustrates the “Dutaflip” principle as a molecular switch: Figure 1A shows the human interferon-α2 fusion protein targeting PD-L1 in a form where the fused huIFN-α2a molecule is linked to the bispecific anti-PD-L1 / anti-IFN-α2a DutaFab. In this form, binding to the bispecific DutaFab would prevent the huIFN-α2a moiety from binding to its natural receptor IFNAR1 / 2. (Black dot: modification in the Fc domain promoting heterodimerization. *: oppositely charged amino acids introduced into the CH and CL domains).
[0069] Figure 1B illustrates the “Dutaflip” principle as a molecular switch: Figure 1B shows the molecule in a form where the fused huIFN-α2a molecule is not bound to the bispecific anti-PD-L1 / anti-IFN-α2a Fab, as would be the case, for example, if the bispecific anti-PDL1 / anti-IFN-α2a ligand had bound to PD-L1, for example, on the surface of a target cell, thus preventing the huIFN-α2a portion from binding to the bispecific DutaFab. (Black dot: modification in the Fc domain promoting heterodimerization. *: oppositely charged amino acids introduced into the CH and CL domains).
[0070] Figure 2 Results of an SPR assay demonstrating lack of competitive binding of several anti-PD-L1 Fabs with Atezolizumab. The tested anti-PD-L1 Fabs were derived from the anti-PD-L1 binding CDRs (H-side) of the bispecific anti-PD-L1 / anti-IFN-α2a DutaFab M14HH17L (parental), as described in Example 7. The sensorgram shows that the tested Fabs did not compete with Atezolizumab binding to PD-L1.
[0071] Figure 3 Results of an SPR assay demonstrating the inhibition of the PD1 / PD-L1 interaction by several anti-PD-L1 Fabs. The two Fabs Petition 870250102232, dated 07 / 11 / 2025, pp. 346 / 702 30 / 333 tested anti-PD-L1 antibodies (P1AI4475 “M14” and P1AI4392) were derived from the anti-PD-L1 binding CDRs (H-side) of the bispecific anti-PD-L1 / anti-IFN-α2a DutaFab M14HH17L (parental), as described in Example 7. The sensorgrams show that the two anti-PD-L1 Fabs derived from M14HH17L (parental) block PD-L1 binding to PD1, as does the Atezolizumab-based anti-PD-L1 Fab (P1AI4841) that was used as a positive control. P1AH0183 is a PD-L1-specific antibody derived from the bispecific DutaFab E06HP7L, which does not block the PD-L1 / PD1 interaction.
[0072] Figure 4 The diagram shows the results of the PD1 / PD-L1 blocking bioassay, demonstrating that anti-PD-L1 Fabs derived from M14HH17L(parental) can block the PD1 / PD-L1 interaction also in a cellular context.
[0073] Figure 5A Schematic illustration of several reference molecules that were used in the examples. Figure 5A shows fusion proteins in which IFN-α2a is fused to the N-terminal end of the DutaFab light chain that binds to PD-L1 / IFN-α2a (P1AH1108, P1AH1111).
[0074] Figure 5B Schematic illustration of several reference molecules that were used in the examples. Figure 5B shows fusion proteins in which IFN-α2a is fused to the C-terminal end of the DutaFab light chain that binds to PD-L1 / IFN-α2a (P1AG9500, P1AG9456, P1AH1122, P1AH1123).
[0075] Figure 5C Schematic illustration of several reference molecules that were used in the examples. Figure 5C shows a fusion protein with IFN-α2a fused to the N-terminal of the heavy chain of the PD-L1 / IFN-α2a binding domain.
[0076] Figure 5D Schematic illustration of several reference molecules that were used in the examples. Figure 5D shows fusion proteins in which the antigen-binding domain linked to PD-L1 / IFN-α2a was Petition 870250102232, dated 07 / 11 / 2025, pp. 347 / 702 31 / 333 was fused to the C-terminal of one Fc domain subunit and IFN-α2α was fused to the C-terminal of the other Fc domain subunit (P1AG4739 and P1AG4740).
[0077] Figure 5E Schematic illustration of several reference molecules that were used in the examples. Figure 5E shows a 2+1 format in which IFN-α2a is fused to the N-terminal of the light chain of a DutaFab linked to PD-L1 / IFN-α2a.
[0078] Figure 5F Schematic illustration of several reference molecules that were used in the examples. Figure 5F shows another 2+1 format in which IFN-α2a is fused to the N-terminal of the light chain of a DutaFab linked to PD-L1 / IFN-α2a.
[0079] Figure 6A Schematic illustration of the reference molecules P1AI0336, P1AI0337 and P1AI0338 (Figure 6 A).
[0080] Figure 6B Schematic illustration of the reference molecules P1AI1297, P1AI1298 (Figure 6 B).
[0081] Figure 6C Schematic illustration of the reference molecule P1AI1326 (Figure 6 C).
[0082] Figure 7A Mass photometry measurement of the P1AI4295 molecule at a concentration of 250 nM (Figure 7 A) revealed a mass of approximately 172 kDa, demonstrating that the fusion protein mainly forms monomers and has no tendency to dimerize.
[0083] Figure 7B Mass photometry measurement of the P1AI4295 molecule at a concentration of 3 μM (Figure 7 B) revealed a mass of approximately 172 kDa, demonstrating that the fusion protein mainly forms monomers and has no tendency to dimerize.
[0084] Figure 8A Schematic illustration of the activity assay of Dutaflip IFN-α2α fusion proteins targeting PD-L1 in low- and high-expression HEK-Blue IFNα / β PD-L1 reporter cells. When there are not enough PD-L1 molecules present on the cell surface (Figure 8A), the Petition 870250102232, dated 07 / 11 / 2025, pp. 348 / 702 32 / 333 IFN-α2 remains bound to DutaFab (“Dutaflip”) and cannot bind to its cell surface receptor IFNAR1 / 2. No activation of reporter cells and, consequently, no expression of the reporter gene is achieved (figure created with BioRender.com).
[0085] Figure 8B Schematic illustration of the activity assay of Dutaflip IFN-α2a fusion proteins targeting PD-L1 in low- and high-expression HEK-Blue IFNα / β PD-L1 reporter cells. When sufficient PD-L1 is expressed on the cell surface (Figure 8B), “Dutaflip” binds to PD-L1 on the cell surface and no longer masks IFN2α. IFN-α2 is now free to bind to the IFNAR1 / 2 receptor on the cell surface and triggers detectable SEAP production from reporter cells (figure created with BioRender.com).
[0086] Figure 9A In vitro activation of parental IFN-α / β HEK-Blue cells (Figure 9 A) by PD-L1-targeted Dutaflip IFN-α2a fusion proteins or recombinant IFN-α2a after 24 hours of incubation. The figure shows the mean percentage of reporter cell activation relative to activation in response to 10 nM recombinant IFN-α2a. n = 4.
[0087] Figure 9B In vitro activation of IFN-α / β HEK-Blue cells transfected with PD-L1 cells (Figure 9 B) by PD-L1-targeted IFN-α2α Dutaflip fusion proteins or recombinant IFN-α2α after 24 hours of incubation. The figure shows the mean percentage of reporter cell activation relative to activation in response to 10 nM recombinant IFN-α2α. n = 4.
[0088] Figure 10 EC50 values calculated from dose-response curves of IFN-α / β HEK-Blue cells transfected with PD-L1 and treated with different concentrations of PD-L1-targeted IFN-α2a Dutaflip fusion proteins or recombinant IFN-α2a for 24 h. n = 4.
[0089] Figure 11A shows direct comparisons of in vitro activation of parental IFN-α / β HEK-Blue cells versus transfected PD-L1 (“Clone Petition 870250102232, dated 07 / 11 / 2025, pp. 349 / 702 33 / 333 0.45”) HEK-Blue IFN-α / β cells to a tested PD-L1-targeted IFN-α2 fusion protein or reference molecule after 24 hours of incubation in a single graph. Values were normalized for activation by setting the response to 10 nM recombinant IFN-α2a to 100%. n = 4.
[0090] Figure 11B shows direct comparisons of in vitro activation of parental IFN-α / β HEK-Blue cells versus PD-L1 transfected (“Clone 045”) IFN-α / β HEK-Blue cells to a tested PD-L1-targeted IFN-α2 fusion protein or reference molecule after 24 hours of incubation in a single graph. Values were normalized for activation by setting the response to 10 nM recombinant IFN-α2α to 100%. n = 4.
[0091] Figure 11C shows direct comparisons of in vitro activation of parental IFN-α / β HEK-Blue cells versus PD-L1 transfected (“Clone 045”) IFN-α / β HEK-Blue cells to a tested PD-L1-targeted IFN-α2 Dutaflip fusion protein or reference molecule after 24 hours of incubation in a single graph. Values were normalized for activation by setting the response to 10 nM recombinant IFN-α2a to 100%. n = 4.
[0092] Figure 11D shows direct comparisons of in vitro activation of parental IFN-α / β HEK-Blue cells versus PD-L1 transfected (“Clone 045”) IFN-α / β HEK-Blue cells to a tested PD-L1-targeted IFN-α2 Dutaflip fusion protein or reference molecule after 24 hours of incubation in a single graph. Values were normalized for activation by setting the response to 10 nM recombinant IFN-α2a to 100%. n = 4.
[0093] Figure 11E shows the difference (Δ) between IFNα activation in low and high PD-L1 expression cells for each plotted molecule relative to the molecule concentration used in the assay. The graph shows that the fusion proteins of the invention already exhibit a significant difference in activation around 10⁻⁴ nM and generally reach their maximum window between IFNα activation in high PD-L1 expression cells and low PD-L1 expression cells. Petition 870250102232, dated 07 / 11 / 2025, pages 350 / 702 34 / 333 expression of PD-L1 at a lower concentration than the reference molecules.
[0094] Figure 12A shows the inhibition of human tumor cell proliferation in vitro by different IFN-α2α fusion proteins Dutaflip targeting PD-L1 (P1AI4295, P1AI4798, P1AI4797, P1AI4748), reference molecule (P1AI1297) or recombinant IFN-α2α in a tumor cell line. Cell confluence was measured every 4 hours for up to ten days, n=2.
[0095] Figure 12B shows the inhibition of human tumor cell proliferation in vitro by different IFN-α2α fusion proteins Dutaflip targeting PD-L1 (P1AI4295, P1AI4798, P1AI4797, P1AI4748), reference molecule (P1AI1297) or recombinant IFN-α2α in a tumor cell line. Cell confluence was measured every 4 hours for up to ten days, n=2.
[0096] Figure 12C shows the inhibition of human tumor cell proliferation in vitro by different IFN-α2α fusion proteins Dutaflip targeting PD-L1 (P1AI4295, P1AI4798, P1AI4797, P1AI4748), reference molecule (P1AI1297) or recombinant IFN-α2α in a tumor cell line. Cell confluence was measured every 4 hours for up to ten days, n=2.
[0097] Figure 13A Induction of CXCL10 (IP-10) by IFN-α2α Dutaflip fusion proteins targeting PD-L1, reference molecule or recombinant IFN-α2α in vitro in different human tumor cell lines. Error bars represent standard deviation. Figure 13A: SK-BR3: 100,000 cells. CXCL10 levels in the supernatant were measured by ELISA after 24 hours of incubation, n=2.
[0098] Figure 13B Induction of CXCL10 (IP-10) by Dutaflip IFN-α2α fusion proteins targeting PD-L1, reference molecule or IFN-α2α Petition 870250102232, dated 07 / 11 / 2025, pp. 351 / 702 35 / 333 recombinant in vitro in different human tumor cell lines. Error bars represent standard deviation. Figure 13B: BT-20: 200,000 cells. CXCL10 levels in the supernatant were measured by ELISA after 24 hours of incubation, n=2.
[0099] Figure 13C Induction of CXCL10 (IP-10) by IFN-α2α Dutaflip fusion proteins targeting PD-L1, reference molecule or recombinant IFN-α2α in vitro in different human tumor cell lines. Error bars represent standard deviation. Figure 13C: HCC1954: 30,000 cells. CXCL10 levels in the supernatant were measured by ELISA after 24 hours of incubation, n=2.
[00100] Figure 14A Induction of MHCI expression (Figure 14A) of HCC1954 over time with Dutaflip IFN-α2α fusion proteins targeting PD-L1 and recombinant human IFN-α2. Figure 14A shows the red (MHCI).
[00101] Figure 14B Induction of PD-L1 expression (Figure 14B) of HCC1954 over time with PD-L1-targeted IFN-α2a Dutaflip fusion proteins and recombinant human IFN-α2. Figure 14B shows the count / image of green objects (PD-L1).
[00102] Figure 15: In vitro IFN-γ secretion induced by Dutaflip IFN-α2α fusion proteins targeting PD-L1, reference molecule or recombinant IFN-α2α in human NK-92 cells after 48 hours of incubation. The figure shows IFN-γ secretion pg / ml dependent on antibody concentration in nM, n=2; error bars represent standard deviation.
[00103] Figure 16A: In vitro expression of human CD80 from pDCs (Figure 16A) by Dutaflip IFN-α2α fusion proteins targeting PD-L1 or recombinant IFN-α2α after 24h of incubation. The figure shows the geometric mean of CD80 expression in different subsets of treated DCs. Petition 870250102232, dated 07 / 11 / 2025, pages 352 / 702 36 / 333 with 10 nM of the indicated antibodies or recombinant IFN-α2α.
[00104] Figure 16B: In vitro expression of human CD80 from DC1 (Figure 16B) by Dutaflip IFN-α2a fusion proteins targeting PD-L1 or recombinant IFN-α2a after 24h of incubation. The figure shows the geometric mean of CD80 expression in different DC subsets treated with 10 nM of the indicated antibodies or recombinant IFN-α2a.
[00105] Figure 16C: In vitro expression of human CD80 from DC2 (Figure 16C) by Dutaflip IFN-α2a fusion proteins targeting PD-L1 or recombinant IFN-α2a after 24h of incubation. The figure shows the geometric mean of CD80 expression in different DC subsets treated with 10 nM of the indicated antibodies or recombinant IFN-α2a.
[00106] Figure 17A: T cell activation after 24 hours of incubation with 10 nM of Dutaflip IFN-α2α fusion proteins targeting PDL1 or recombinant IFN-α2α. The figure shows the percentage of CD69-expressing CD4+ T cells (Figure 17A). Error bars represent standard deviation.
[00107] Figure 17B: T cell activation after 24 hours of incubation with 10 nM of Dutaflip IFN-α2α fusion proteins targeting PDL1 or recombinant IFN-α2α. The figure shows the percentage of CD69-expressing CD8+ T cells (Figure 17B). Error bars represent standard deviation.
[00108] Figure 18A: In vitro secretion of CXCL10 (Figure 18A) in pg / ml of fresh human whole blood (low PD-L1 expression) incubated with indicated PD-L1-targeted IFN-α2a molecules or recombinant human IFN-α2a at a concentration of 4 nM for 24 h. Three independent experiments with a total of 11 donors are shown. Error bars represent the standard deviation.
[00109] Figure 18B: In vitro secretion of IL6 (Figure 18B) Petition 870250102232, dated 07 / 11 / 2025, pages 353 / 702 37 / 333 pg / ml of fresh human whole blood (low PD-L1 expression) incubated with indicated PD-L1-targeted IFN-α2a molecules or recombinant human IFN-α2a at a concentration of 4 nM for 24 h. Three independent experiments with a total of 11 donors are shown. Error bars represent the standard deviation.
[00110] Figure 19: Internalization of IFN-α2α Dutaflip fusion proteins targeting PD-L1 10 nM, reference and control molecules, conjugated to human / mouse Fabfluor red pH labeling reagent, in the human tumor cell line HCC1954 expressing PD-L1. The figure shows the count of red objects per image within 48 hours of incubation. Error bars represent standard deviation.
[00111] Figure 20: Figure 20 shows the results of the efficacy study of IFN-α2α Dutaflip fusion proteins targeting PD-L1 in tumor-bearing huNSG mice. Tumor volume was measured by calibrator twice a week. Figure 20 shows a direct comparison of the results of all subgroups, during a period from day 22 to day 51. Data are presented as tumor volume (median + / -IQR).
[00112] Figure 21A shows the inhibition of human tumor cell proliferation (measured as cell confluence) in vitro by the PD-L1 P1AI4295-targeted IFN-α2α Dutaflip fusion proteins or recombinant huIFN-α2α in the COR-L105 tumor cell line at a protein concentration of 0.1 nM (Figure 21A). Untreated cells were used as a negative control. Cell confluence was measured every 4 hours for up to ten days, n=2.
[00113] Figure 21B shows the inhibition of human tumor cell proliferation (measured as cell confluence) in vitro by the PD-L1 P1AI4295 or huIFN-α2α Dutaflip fusion proteins targeting IFN-α fusion proteins (measured as cell confluence) (measured as cell confluence). Petition 870250102232, dated 07 / 11 / 2025, pp. 354 / 702 38 / 333 recombinant protein was injected into the COR-L105 tumor cell line at a protein concentration of 1 nM (Figure 21 B). Untreated cells were used as a negative control. Cell confluence was measured every 4 hours for up to ten days, n=2.
[00114] Figure 21C shows the inhibition of human tumor cell proliferation (measured as cell confluence) in vitro by the PD-L1 P1AI4295-targeted IFN-α2α Dutaflip fusion proteins or recombinant huIFN-α2α in the COR-L105 tumor cell line at a protein concentration of 10 nM (Figure 21C). Untreated cells were used as a negative control. Cell confluence was measured every 4 hours for up to ten days, n=2.
[00115] Figure 22A shows the inhibition of human tumor cell proliferation in vitro (measured as cell confluence) by the PD-L1 P1AI4295-targeted huIFN-α2a Dutaflip fusion proteins or recombinant huIFN-α2a in the HDLM-2 tumor cell line at a protein concentration of 0.1 nM (Figure 22A). Untreated cells were used as a negative control. Cell confluence was measured every 4 hours for up to ten days, n=2.
[00116] Figure 22B shows the inhibition of human tumor cell proliferation in vitro (measured as cell confluence) by the PD-L1 P1AI4295-targeted huIFN-α2a Dutaflip fusion proteins or recombinant huIFN-α2a in the HDLM-2 tumor cell line at a protein concentration of 1 nM (Figure 22B). Untreated cells were used as a negative control. Cell confluence was measured every 4 hours for up to ten days, n=2.
[00117] Figure 22C shows the inhibition of human tumor cell proliferation in vitro (measured as cell confluence) by the huIFN-α2a Dutaflip fusion proteins targeting PD-L1 P1AI4295 or huIFN-α2a Petition 870250102232, dated 07 / 11 / 2025, pp. 355 / 702 39 / 333 recombinant protein was injected into the HDLM-2 tumor cell line at a protein concentration of 10 nM (Figure 22 C). Untreated cells were used as a negative control. Cell confluence was measured every 4 hours for up to ten days, n=2.
[00118] Figure 23A shows the results of the PD1 / PD-L1 blocking bioassay, demonstrating that the anti-PD-L1 Fabs derived from M14HH17L (parental) retain their ability to block the PD1 / PD-L1 interaction even when used as targeting arms in PD-L1-targeted IFN-α2α fusion proteins.
[00119] Figure 23B shows the results of the PD1 / PD-L1 blocking bioassay, demonstrating that the anti-PD-L1 Fabs derived from M14HH17L (parental) retain their ability to block the PD1 / PD-L1 interaction even when used as targeting arms in PD-L1-targeted IFN-α2α fusion proteins.
[00120] Figure 24A shows the cytokine response elicited by PD-L1-targeted IFN-α2α Dutaflip fusion proteins (labeled “Duta Flip”) (as defined by the log2 x times change compared to untreated) to IP-10, ISG-15, and IFNγ in tumor samples obtained from patients with NSCLC, BLCA, ccRCC, and TNBC. Recombinant HuIFN-α2α (labeled “rec. IFNα”) was used as a positive control.
[00121] Figure 24B shows the cytokine response elicited by PD-L1-targeted IFN-α2α Dutaflip fusion proteins (labeled “Duta Flip”) (as defined by the log2 x times change compared to untreated) to IP-10, ISG-15, and IFNγ in tumor samples obtained from patients with NSCLC, BLCA, ccRCC, and TNBC. Recombinant HuIFN-α2α (labeled “rec. IFNα”) was used as a positive control.
[00122] Figure 25: This figure shows a heat map illustrating the correlation between the frequency of PD-L1 positive cells and Petition 870250102232, dated 07 / 11 / 2025, pp. 356 / 702 40 / 333 CD45-negative cells positive for PD-L1 from all samples, respectively, and elevated cytokine response levels for IP-10, ISG-15, IFNY, GrnzB, IL-6, MIP-1, panIFNα, CXCL13 in tumor samples obtained from patients with NSCLC, BLCA, ccRCC, and TNBC treated with the PD-L1-targeted IFN-α2α fusion protein Dutaflip. Recombinant HuIFN-α2α (labeled “rec. IFNα”) was used as a positive control.
[00123] Figure 26A: The diagram in Figure 26A shows the correlation between the frequency of CD45-negative cells expressing PD-L1 and the ISG-15 response within the study cohort (n=13 patients) for the condition treated with P1AI4295 (“Duta Flip”) (Figure 26A), as a specific instance to illustrate the correlation between two continuous variables.
[00124] Figure 26B: The diagram in Figure 26B shows the correlation between the frequency of CD45-negative cells expressing PD-L1 and the ISG-15 response within the study cohort (n=13 patients) for the condition treated with recombinant human Interferon Alfa 2a (control, Figure 26B), as a specific instance to illustrate the correlation between two continuous variables.
[00125] Figure 27A: UMAP analysis of snRNA-seq data obtained from tumor samples after 3D culture and treatment. UMAP visualization revealed 44 clusters representing different cell subpopulations, based on 351,005 cells derived from 39 samples originating from 7 patients (Figure 27A).
[00126] Figure 27B: UMAP analysis of snRNA-seq data obtained from tumor samples after 3D culture and treatment. Figure 27B shows the cellular composition of the sample, analyzed through the expression of known marker genes within each UMAP cluster.
[00127] Figure 28: This diagram illustrates the examination of an inflammatory genetic signature (ISG15, MX1, XAF1, HERC5, STAT1, IFIT1, IFI6, CXCL11, ISG20, IL10) visualizing the cis-directed activation pattern. Petition 870250102232, dated 07 / 11 / 2025, pp. 357 / 702 41 / 333 to IFN-α in PD-L1 positive and negative tumor cells. Untreated conditions were used as a negative control. Treatment with recombinant IFN-α2a was used as a positive control group. High frequencies of positive cells are indicated by the bubble size, and the increase in mean expression levels of the respective markers is indicated by the grayscale escalation.
[00128] Figure 29: Comparison of PDL1 expression levels in the three test conditions (treated with P1AI4295, treated with recombinant IFN-α2α and untreated).
[00129] Figure 30A: In an immunocompetent hematotoxicity assay, P1AI4295 showed less toxicity in relation to the erythroid cell line (Figure 30 A) than recombinant IFN-α2α (control).
[00130] Figure 30B: In an immunocompetent hematotoxicity assay, P1AI4295 showed less toxicity to granulocyte / monocyte cells (Figure 30B) than recombinant IFN-α2α (control).
[00131] Figure 31A: shows the results of the PBMC immunotoxicity assay. The PD-L1-targeted IFN-α2α fusion protein P1AI4295 shows a reduced CD69% activation profile in PBMC-derived CD4 T cells (Figure 31A), compared to recombinant IFN-α2α as a control.
[00132] Figure 31B: shows the results of the PBMC immunotoxicity assay. The PD-L1-targeted IFN-α2α fusion protein P1AI4295 shows a reduced CD69% activation profile in CD8 T cells (Figure 31B), compared to recombinant IFN-α2α as a control.
[00133] Figure 31C: shows the results of the PBMC immunotoxicity assay. The PD-L1-targeted IFN-α2α fusion protein P1AI4295 shows a reduced CD69% activation profile in B cells (Figure 31C), compared to recombinant IFN-α2α as a control. Petition 870250102232, dated 07 / 11 / 2025, pp. 358 / 702 42 / 333
[00134] Figure 31D: shows the results of the PBMC immunotoxicity assay. The PD-L1-targeted IFN-α2α fusion protein P1AI4295 shows a reduced CD69% activation profile in monocytes (Figure 31D), compared to recombinant IFN-α2α as a control. Detailed Description I. Definitions
[00135] Unless otherwise defined in this document, the scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those skilled in the art. Additionally, unless required otherwise by the context, singular terms should include plurals and plural terms should include the singular. The methods and techniques of this disclosure are generally carried out in accordance with conventional methods well known in the art. Generally, the nomenclatures used in connection with, and techniques of biochemistry, enzymology, molecular and cellular biology, microbiology, genetics, and chemistry and hybridization of proteins and nucleic acids described in this document are those well known and commonly used in the art.
[00136] Unless defined otherwise in this document, the term “include” shall include the term “consist of”.
[00137] The term “about” as used in this document in connection with a specific value (e.g., temperature, concentration, time, and others) shall refer to a variation of + / - 1% of the specific value to which the term “about” refers.
[00138] A “human acceptor framework” for the purposes described herein is a framework comprising the amino acid sequence of a variable light chain (VL) domain framework or a variable heavy chain (VH) domain framework derived from a human immunoglobulin framework or a human consensus framework, Petition 870250102232, dated 07 / 11 / 2025, pp. 359 / 702 43 / 333 as defined below. A human acceptor structure “derived from” a human immunoglobulin structure or a human consensus structure may comprise the same amino acid sequence as the same or may contain alterations in the amino acid sequence. In some respects, the number of amino acid alterations is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some respects, the human acceptor structure VL is identical in sequence to the sequence of the human immunoglobulin structure VL or to the sequence of the human consensus structure.
[00139] “Affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody, an antibody fragment, or an antigen-binding domain) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, “binding affinity” refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary methods for measuring binding affinity are described below.
[00140] An “affinity-matured” antibody refers to an antibody with one or more alterations in one or more complementary determinant regions (CDRs), compared to a parental antibody that does not have such alterations, resulting in an improved affinity of the antibody for the antigen.
[00141] The terms “anti-huPD-L1 antibody”, “an antibody that binds to human PD-L1” and “an antibody that is capable of binding to PD-L1 Petition 870250102232, dated 07 / 11 / 2025, pp. 360 / 702 The terms "human PD-L1" refer to an antibody that is capable of binding to human PD-L1 with sufficient affinity for the antibody to be useful as a diagnostic and / or therapeutic agent in targeting human PD-L1. In one aspect, the extent of binding of an anti-huPD-L1 antibody to an unrelated, non-huPD-L1 protein is less than about 10% of the antibody binding to human PD-L1, as measured, for example, by surface plasmon resonance (SPR). In certain aspects, an antibody that binds to human PD-L1 has a dissociation constant (Kd) of < 1 μM, < 100 nM, < 10 nM, < 1 nM, < 0.1 nM, < 0.01 nM, or < 0.001 nM (e.g., 10⁻⁸ M or less, e.g., from 10⁻⁸ M to 10⁻¹³ M, e.g., from 10⁻⁸ M to 10⁻¹³ M, e.g., from 10⁻¹³ M). 10-9M to 10-13M). An antibody is said to bind specifically to human PD-L1 when the antibody has a Kd of 1μM or less.As used in this document, the term monospecific antibody for human PD-L1 means an antibody that binds, in particular binds specifically, to one antigen or one epitope on human PD-L1, whereas a bispecific antibody, as mentioned in this document, binds to two distinct antigens or two distinct epitopes, in particular two distinct antigens or two distinct epitopes on two distinct target molecules. The terms “human PD-L1” or “anti-human PD-L1” may, for the sake of brevity, be referred to simply as “huPD-L1” or “anti-huPD-L1” in this document, respectively. Similarly, other human proteins, such as “human PD1”, may be referred to as “huPD1”.
[00142] The terms “anti-huPD-L1 antigen-binding domain”, “an antigen-binding domain that binds to human PD-L1” and “an antigen-binding domain that is capable of binding to human PD-L1” refer to an antigen-binding domain that is capable of binding to human PD-L1 with sufficient affinity for the antigen-binding domain to be Petition 870250102232, dated 07 / 11 / 2025, pp. 361 / 702 45 / 333 useful as a diagnostic and / or therapeutic agent in targeting huPDL1. In one aspect, the extent of binding of an anti-huPD-L1 antigen-binding domain to an unrelated, non-PD-L1 protein is less than about 10% of the binding of the antigen-binding domain to PD-L1, as measured, for example, by surface plasmon resonance (SPR). In certain aspects, an antigen-binding domain that binds to huPD-L1 has a dissociation constant (Kd) of < 1 μM, < 100 nM, < 10 nM, < 1 nM, < 0.1 nM, < 0.01 nM or < 0.001 nM (e.g., 10⁻⁸M or less, e.g., from 10⁻⁸M to 10⁻¹³M, e.g., from 10⁻⁹M to 10⁻¹³M). An antigen-binding domain is said to "specifically bind" to human PD-L1 when the antigen-binding domain has a Kd of 1 μM or less. In certain respects, an anti-huPD-L1 antigen-binding domain binds to a PD-L1 epitope that is conserved among huPD-L1 from different species.As used in this document, the term monospecific antigen-binding domain means an antigen-binding domain that binds only to one antigen or epitope.
[00143] The terms “an anti-PDL1 / anti-IFN-α2a antigen-binding domain”, “an anti-huPD-L1 / anti-huIFN-α2a antigen-binding domain” and “an antigen-binding domain capable of binding to human PD-L1 and human IFN-α2a” refer to an antigen-binding domain that is capable of binding to human PD-L1 and human IFN-α2a with sufficient affinity such that the antigen-binding domain is useful as a diagnostic and / or therapeutic agent in targeting huPD-L1 and / or huIFN-α2a. “anti-human-PD-L1 / anti-human-IFN-α2” is, for ease of reading, sometimes also referred to simply as “anti-huPD-L1 / anti-huIFN-α2” in this document. In one aspect, the extent of binding of an anti-huPD-L1 / anti-huIFN-α2a antigen-binding domain to an unrelated, non-PD-L1 or non-IFN-α2a protein is less than about 10% of the binding domain's extent. Petition 870250102232, dated 07 / 11 / 2025, pp. 362 / 702 46 / 333 to the antigen PD-L1 or IFN-α2α, as measured, for example, by surface plasmon resonance (SPR). In certain respects, an anti-huPD-L1 / anti-huIFN-α2α antigen-binding domain has a dissociation constant (Kd) with respect to PD-L1 binding of < 1 μM, < 100 nM, < 10 nM, < 1 nM, < 0.1 nM, < 0.01 nM, or < 0.001 nM (e.g., 10⁻⁸ M or less, e.g., from 10⁻⁸ M to 10⁻¹³ M, e.g., from 10⁻⁹ M to 10⁻¹³ M). An antigen-binding domain is said to “specifically bind” to human PD-L1 when the antibody has a Kd of 1 μM or less. In certain aspects, an anti-huPD-L1 / anti-huIFN-α2a antigen-binding domain binds to a huPD-L1 epitope that is conserved among PD-L1s from different species.In other respects, an anti-huPD-L1 / anti-huIFN-a2a antigen-binding domain has a dissociation constant (Kd) with respect to huIFN-a2a binding of < 1 μM, < 100 nM, < 10 nM, < 1 nM, < 0.1 nM, < 0.01 nM, or < 0.001 nM (e.g., 10⁻⁸ M or less, e.g., from 10⁻⁸ M to 10⁻¹³ M, e.g., from 10⁻⁹ M to 10⁻¹³ M). An antibody is said to bind specifically to huIFN-a2 when the antibody has a Kd of 1 μM or less. In certain respects, an anti-huPD-L1 / anti-huIFN-a2 antigen-binding domain binds to a huIFN-a2 epitope that is conserved among IFN-a2 from different species. The anti-PD-L1 / anti-IFN-α2a antigen-binding domains described in this document bind to PD-L1 and anti-IFN-α2a in a mutually exclusive manner. They also have the ability to block the binding of huIFN-α2 to IFNAR. In one aspect, they have the ability to block the binding of huIFN-α2 to the IFNAR2 subunit of IFNAR.
[00144] The term “antibody” in this document is used in the broadest sense and encompasses various antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, provided they exhibit the desired antigen-binding activity. Petition 870250102232, dated 07 / 11 / 2025, pp. 363 / 702 47 / 333
[00145] An “antibody fragment” refers to a molecule other than an intact antibody comprising a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv and scFab); single-domain antibodies (dAbs); and multispecific antibodies formed from antibody fragments. For a review of certain antibody fragments, see Holliger and Hudson, Nature Biotechnology 23: 1126-1136 (2005).
[00146] The term antigen-binding domain, as used in this document, refers to an amino acid sequence in an antibody, antibody fragment, or fusion protein described in this document, comprising at least one CDR and having a conformation to recognize a target antigen or epitope.
[00147] A “DutaFab”, as used in this document, is a bispecific antibody as disclosed in document WO2012 / 163520. In a DutaFab, a single pair of a VH domain and a VL domain binds specifically to two different epitopes, wherein one paratope comprises amino acid residues of CDR-H2, CDR-L1, and CDR-L3, and the other paratope comprises amino acid residues of CDR-H1, CDR-H3, and CDR-L2. DutaFabs comprise two non-overlapping paratopes within a cognate VH / VL pair. DutaFabs and methods for their generation by screening libraries comprising monospecific Fab fragments are disclosed in document WO2012 / 163520. Here, the term “DutaFab” can refer particularly to a (bispecific) Fab comprising a single pair of a VH domain and a VL domain that specifically binds to two different epitopes, where one paratope comprises amino acid residues of CDRH2, CDR-L1, and CDR-L3, and the other paratope comprises amino acid residues. Petition 870250102232, dated 07 / 11 / 2025, pp. 364 / 702 48 / 333 of CDR-H1, CDR-H3, and CDR-L2. These DutaFabs may be included in the fusion proteins described in this document.
[00148] Here, a “bispecific Fab” or a “DutaFab” that is capable of binding to antigen 1 and antigen 2 in a mutually exclusive manner may, for ease of reading, be simply called a “Dutaflip”, “a Dutaflip arm”, “a Dutaflip portion” or a “Dutaflip domain”. Here, a “bispecific Fab” or a “DutaFab” that is capable of binding to human PD-L1 and human IFN-α2 in a mutually exclusive manner may, for the sake of brevity, be simply called an “anti-huPD-L1 / anti-huIFN-α2 Dutaflip”, an “anti-huPD-L1 / anti-huIFN-α2 Dutaflip arm”, an “anti-huPD-L1 / anti-huIFN-α2 Dutaflip portion” or an “anti-huPD-L1 / anti-huIFN-α2 Dutaflip domain”. The DutaFabs are known in the field as engineered therapeutic Fab fragments that can bind to two targets simultaneously (Beckmann R et al. Nat Commun. 2021 Jan 29;12(1):708. doi: 10.1038 / s41467-021-20949-3).The inventors surprisingly discovered that DutaFabs can also be engineered to allow the mutually exclusive binding of two target epitopes. This can be used for the fusion proteins described in this paper, in which a human IFN-α2 is bound to a bispecific anti-huPD-L1 / anti-huIFN-α2 Fab (DutaFab) and is therefore blocked from binding to its IFNAR1 / 2 receptor when the number of PD-L1 molecules in the environment / on the target cell surface is low. In the presence of a large number of PD-L1 molecules, the anti-huPD-L1 / anti-huIFN-α2 Dutaflip will begin to bind to PD-L1 and the equilibrium will be strongly shifted from the masked huIFN-α2 to the active and unmasked huIFN-α2, resulting in the release of the human IFN-α2 from the bispecific Fab (DutaFab). The anti-huPD-L1 / anti-huIFN-α2 Dutaflip therefore acts as a molecular switch in the fusion proteins provided in this document, releasing the huIFN-α2 portion in the presence of sufficient amounts of the target antigen, PD-L1. Petition 870250102232, dated 07 / 11 / 2025, pp. 365 / 702 49 / 333
[00149] The term blocking, as used in this document, refers to a reduction or elimination of signaling by a protein, particularly in the presence of a fusion protein or antibody described in this document. The binding of a blocking antibody / antigen-binding domain directly interferes with the protein's function in a signaling pathway, such as blocking the binding between a receptor and its ligand. When a protein is blocked, it means that its signaling is reduced or eliminated because it has been bound by a blocking antibody or antigen-binding domain.For example, when used in the context of blocking huPD-L1 binding to huPD1, blocking means that the huPD1 / huPD-L1 signaling level in the presence of the fusion protein or anti-huPD-L1 antibody described in this document is lower than the huPD1 / huPD-L1 signaling level in the absence of the fusion protein or antibody, and the magnitude of the decrease is greater than or equal to 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, 95%, 99%, or 100%. When used in the context of huIFN-α2 signaling blockade, huIFN-α2 signaling blockade means that the level of huIFN-α2 signaling in the presence of the fusion proteins described in this document is lower than the control level (i.e., the signaling level in the absence of the fusion protein) and the magnitude of the decrease is greater than or equal to 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, 95%, 99%, or 100%.The signaling levels of huPD1 / huPD-L1 and huIFN-α2 can be measured using a variety of standard techniques, such as cell-based luciferase reporter assays. Those skilled in the art will know that a variety of assays can be used to measure signaling levels, including, for example, commercially available kits.
[00150] The term “epitope” denotes the site on an antigen, protein or non-protein, to which an antibody binds, for example, an anti-PD-L1 antibody, an anti-IFN-α2 antibody, or an antigen-binding domain. Petition 870250102232, dated 07 / 11 / 2025, pp. 366 / 702 50 / 333 comprised in a fusion protein described in this document. Epitopes can be formed from contiguous stretches of amino acids (linear epitope) and comprise non-contiguous amino acids (conformational epitope), for example, arriving in spatial proximity due to antigen folding, i.e., by the tertiary folding of a protein antigen. Linear epitopes are generally still bound to an antibody or antigen-binding domain after exposure of the protein antigen to denaturing agents, while conformational epitopes are typically destroyed after treatment with denaturing agents. An epitope comprises at least 3, at least 4, at least 5, at least 6, at least 7, or 8-10 amino acids in a unique spatial conformation.
[00151] Screening for antibodies that bind to a specific epitope (i.e., those that bind to the same epitope) can be done using routine methods in the technique, such as, without limitation, alanine screening, peptide blots (see Meth. Mol. Biol. 248 (2004) 443-463), peptide cleavage analysis, epitope excision, epitope extraction, chemical modification of antigens (see Prot. Sci. 9 (2000) 487-496) and cross-blocking (see “Antibodies”, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harb., NY).
[00152] Antigen structure-based antibody profiling (ASAP), also known as modification-assisted profiling (MAP), allows clustering of a multitude of monoclonal antibodies that specifically bind to PD-L1 or IFN-α2 based on the binding profile of each antibody to a multitude of chemically or enzymatically modified antigen surfaces (see, for example, US patent 2004 / 0101920). The antibodies in each cluster bind to the same epitope, which may be a unique epitope, distinctly different from, or partially overlapping with the epitope represented by another cluster. Petition 870250102232, dated 07 / 11 / 2025, pp. 367 / 702 51 / 333
[00153] Furthermore, competitive binding can be used to easily determine whether an antibody or antigen-binding domain binds to the same epitope of PD-L1 or IFN-α2 that, or competes for binding with, a reference anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain, respectively. For example, an “antibody or antigen-binding domain that binds to the same epitope” as a reference anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain refers to an antibody or antigen-binding domain that blocks the binding of the reference anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain to its antigen in a competitive assay by 50% or more, and conversely, the reference antibody or antigen-binding domain blocks the binding of the antibody or antigen-binding domain to its antigen in a competitive assay by 50% or more.Also, for example, to determine whether an antibody binds to the same epitope as a reference anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain, the reference antibody or antigen-binding domain can bind to PD-L1 or anti-IFN-α2, respectively, under saturation conditions. After removing the excess of the reference anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain, the ability of a given anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain to bind to PD-L1 or IFN-α2, respectively, is evaluated.If the anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain is able to bind to PD-L1 or IFN-α2, respectively, after saturation binding of the reference anti-PD-L1 or anti-IFN-α2 antibody, it can be concluded that the anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain in question binds to a different epitope than the reference anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain. However, if the anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain in question is unable to bind to PD-L1 or IFN-α2... Petition 870250102232, dated 07 / 11 / 2025, pp. 368 / 702 52 / 333 α2, respectively, after saturation binding of the reference anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain, then the anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain in question can bind to the same epitope as the epitope bound by the reference anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain. To confirm whether the antibody in question binds to the same epitope or whether its binding is hindered from steric reasons, routine experimentation can be used (e.g., peptide mutation and binding analyses using ELISA, RIA, surface plasmon resonance, flow cytometry, or any other quantitative or qualitative antibody binding assay available in the art). This assay should be performed in two settings, i.e., with both antibodies being the saturating antibody.If, in both configurations, only the first antibody (saturator) or antigen-binding domain is able to bind to PD-L1 or IFN-α2, respectively, then it can be concluded that the anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain in question and the reference anti-PD-L1 or anti-IFN-α2 antibody or antigen-binding domain compete for binding to PD-L1 or IFN-α2, respectively.
[00154] In some respects, two antibodies or antigen-binding domains are considered to be binding to the same epitope or to an overlapping epitope if a 1, 5, 10, 20, or 100-fold excess of one antibody inhibits the binding of the other by at least 50%, at least 75%, at least 90%, or up to 99% or more, as measured in a competitive binding assay (see, for example, Junghans et al., Cancer Res.
[00155] In some respects, two antibodies or antigen-binding domains are considered to bind to the same epitope if essentially all amino acid mutations in the antigen that reduce Petition 870250102232, dated 07 / 11 / 2025, pp. 369 / 702 53 / 333 or eliminate the binding of one antibody also reduce or eliminate the binding of the other. Two antibodies are considered to have "overlapping epitopes" if only a subset of the amino acid mutations that reduce or eliminate the binding of one antibody also reduces or eliminates the binding of the other.
[00156] The term “chimeric” antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.
[00157] The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five main classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), for example, IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. In certain aspects, the antibody is of the IgG1 isotype. In certain aspects, the antibody is of the IgG1 isotype with the P329G, L234A, and L235A mutations to reduce the effector function of the Fc region. In other aspects, the antibody is of the IgG2 isotype. In certain aspects, the antibody is of the IgG4 isotype with the S228P mutation in the hinge region to improve the stability of the IgG4 antibody. The constant heavy chain domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.The light chain of an antibody can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.
[00158] The terms human-derived constant region or human constant region, as used in this application, denote a constant heavy chain region of a human antibody of the IgG1, IgG2, IgG3 or IgG4 subclass and / or a kappa or lambda constant light chain region. Such constant regions are well known in the state of the art and, for example, described by Kabat, EA, et al., Sequences of Proteins of Petition 870250102232, dated 07 / 11 / 2025, pages 370 / 702 54 / 333 Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) (see also, for example, Johnson, G. and Wu, TT, Nucleic Acids Res. 28 (2000) 214-218; Kabat, EA, et al., Proc. Natl. Acad. Sci. USA 72 (1975) 2785-2788). Unless otherwise specified herein, the numbering of amino acid residues in the constant region is in accordance with the EU numbering system, also called the Kabat EU index, as described in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242.
[00159] Effector functions refer to the biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include C1q binding and complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptor); and B cell activation.
[00160] An effective amount of an agent, for example, a pharmaceutical composition, refers to an effective quantity, in dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
[00161] A “Fab molecule” refers to a protein consisting of the VH and CH1 domains of the heavy chain (the “Fab heavy chain”) and the VL and CL domains of the light chain (the “Fab light chain”) of an immunoglobulin.
[00162] The term “crossed” Fab molecule (also referred to as “CrossFab”), as used in this document, refers to a Fab molecule in which the variable domains or the constant domains of the Fab heavy and light chains are exchanged (i.e., substituted for one another), that is, the crossed Fab molecule comprises a peptide chain composed of the variable domain. Petition 870250102232, dated 07 / 11 / 2025, pages 371 / 702 55 / 333 of the VL light chain and the 1 CH1 constant heavy chain domain (VL-CH1, in the N- to C-terminal direction) and a peptide chain composed of the VH variable heavy chain domain and the CL constant light chain domain (VH-CL, in the N- to C-terminal direction). For clarity, in a crossed Fab molecule, where the variable domains of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain comprising the 1 CH1 constant heavy chain domain is referred to as the “heavy chain” of the (crossed) Fab molecule. Conversely, in a crossed Fab molecule, where the constant domains of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain comprising the VH variable heavy chain domain is referred to in this document as the “heavy chain” of the (crossed) Fab molecule.
[00163] In contrast, a “conventional” Fab molecule is understood to be a Fab molecule in its natural form, that is, comprising a heavy chain composed of the variable and constant domains of the heavy chain (VH-CH1, in the N-terminal to C-terminal direction) and a light chain composed of the variable and constant domains of the light chain (VL-CL, in the N-terminal to C-terminal direction).
[00164] The terms “Fc region” and “Fc domain” in this document are used interchangeably and are used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one aspect, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl terminus of the heavy chain. However, antibodies or fusion proteins produced by host cells may undergo post-translational cleavage of one or more, particularly one or two, amino acids from the C-terminal of the heavy chain. Therefore, an antibody or fusion protein produced by a cell Petition 870250102232, dated 07 / 11 / 2025, pages 372 / 702 56 / 333 host by the expression of a specific nucleic acid molecule encoding a complete heavy chain may include the full-length heavy chain or may include a cleaved variant of the full-length heavy chain. This may be the case when the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, EU numbering system). Therefore, the C-terminal lysine (Lys447), or the C-terminal glycine (Gly446) and lysine (Lys447) of the Fc region may or may not be present. Heavy chain amino acid sequences including an Fc region are denoted in this document without the C-terminal glycine-lysine dipeptide, unless otherwise indicated. In one aspect, a heavy chain including an Fc region as specified herein, comprised in an antibody or fusion protein described herein, comprises an additional C-terminal glycine-lysine dipeptide (G446 and K447, EU numbering system).In one aspect, a heavy chain including an Fc region as specified herein, comprised in an antibody or fusion protein described herein, comprises an additional C-terminal glycine residue (G446, numbering according to the EU index). Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991. A “subunit” of an Fc domain, as used herein, refers to one of the two polypeptides that form the dimeric Fc domain, that is, a polypeptide comprising C-terminal constant regions of an immunoglobulin heavy chain, capable of stable self-association.For example, a subunit of an Fc domain of IgG comprises a constant CH2 domain of IgG and a constant CH3 domain of IgG. Petition 870250102232, dated 07 / 11 / 2025, pp. 373 / 702 57 / 333
[00165] “Structure” or “FR” refers to variable domain residues other than complementarity determining regions (CDRs). The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Thus, CDR and FR sequences generally appear in the following sequence in VH (or VL): FR1-CDR-H1(CDR-L1)-FR2-CDRH2(CDR-L2)-FR3-CDR-H3(CDR-L3)-FR4.
[00166] The terms “full-length antibody”, “intact antibody” and “whole antibody” are used interchangeably in this document to refer to an antibody that has a structure substantially similar to a native antibody structure or that has heavy chains containing an Fc region as defined in this document.
[00167] The term “fusion protein,” as used in this document, refers to a hybrid polypeptide comprising whole proteins (e.g., human IFN-α2, IgG-like antibodies) or protein domains (e.g., a Fab, a DutaFab, or an Fc region) of at least two different proteins that are fused together. One protein may be located at the amino-terminal (N-terminal) portion of the fusion protein or at the carboxyl-terminal (C-terminal) portion of the protein, thus forming an “N-terminal fusion (protein)” or a “C-terminal fusion (protein),” respectively. The term “fusion protein,” as used in this document, also encompasses fusion proteins that are composed of more than one polypeptide chain. In a fusion protein composed of more than one polypeptide chain, one or more polypeptide chains may have originated from the fusion of two or more individual polypeptide chains together.In some respects, the polypeptide chains in such a protein can be covalently linked by disulfide bonds. The term "fusion protein" encompasses, for example, proteins obtained by fusing a cytokine to an antibody. It also includes IgGs or molecules. Petition 870250102232, dated 07 / 11 / 2025, pp. 374 / 702 58 / 333 similar to IgG (comprising two heavy chains and two light chains) in which a non-antibody protein is fused to only one polypeptide chain, or to multiple polypeptide chains, of the IgG or IgG-like molecule. The term “fusion protein” in this document also encompasses molecules in which different antigen-binding domains (naturally occurring or engineered) (e.g., Fabs, CrossFabs, DutaFabs), antibody domains (e.g., Fc domains), and non-antibody proteins (including cytokines such as human IFN-α2) are fused together, including molecules in which different antigen-binding domains are fused to an Fc domain, resulting in a molecule similar to an IgG in structure. The term “fusion protein,” as used in this document, particularly encompasses fusion proteins in which: a) A Fab (crossover) is fused at the C-terminal of its heavy chain (directly or via a peptide ligand) to the N-terminal of one of the two subunits of the Fc domain; b) a DutaFab is fused at the C-terminal of its heavy chain (directly or via a peptide ligand) to the N-terminal of the other of the two Fc domain subunits; and (c) A cytokine such as human IFN-αΣ is fused at its C-terminus directly or via a peptide ligand to the N-terminus of the light chain of the second antigen-binding domain.
[00168] By fusion it is understood that the components (e.g., a Fab molecule and an Fc domain subunit) are linked by peptide bonds, either directly or through one or more peptide linkers. Proteins can be easily fused using conventional procedures or produced by recombinant methods or obtained by chemical synthesis (e.g., by introducing direct peptide bonds or by using peptide linkers). Any of the fusion proteins provided in this Petition 870250102232, dated 07 / 11 / 2025, pages 375 / 702 59 / 333 document can be produced by any method known in the art. For example, the fusion proteins provided in this document can be produced by recombinant protein expression and purification, which is especially suitable for fusion proteins comprising a peptide linker, but can also be used for fusion proteins where the domains fuse directly together. By merging the coding sequences encoding separate protein domains (and optionally peptide linkers) at the DNA level into a single coding sequence, it is possible to produce an mRNA transcript that can then be translated into a single polypeptide containing all the desired protein domains (and linkers). Methods for recombinant protein expression and purification are well known and include those described by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).(2012)).
[00169] Glutamine or glutamate residues at the N-terminal of antibody heavy or light chains can be spontaneously converted to pyroglutamate (see, for example, Liu et al., Journal of Pharmaceutical Sciences 97, 2426-2447 (2008), Rehder et al., Journal of Chromatography A 1102, 164-175 (2006), Chelius et al., Anal Chem 78, 2370-2376 (2006)). Therefore, the variable domains disclosed in this document comprising an N-terminal glutamine (Q) or glutamate (E) amino acid residue of an antibody heavy or light chain may comprise an N-terminal pyroglutamate (pyroE) residue instead of the N-terminal Q or E residue. Similarly, antibody heavy or light chains disclosed in this document comprising an N-terminal glutamine (Q) or glutamate (E) amino acid residue may comprise an N-terminal pyroglutamate (pyroE) residue instead of the N-terminal Q or E residue. Consequently, for each heavy chain, light chain, or variable domain sequence of Petition 870250102232, dated 07 / 11 / 2025, pp. 376 / 702 60 / 333 antibody disclosed in this document that contains an N-terminal Q or E residue, the corresponding sequence with an N-terminal pyroE residue is also covered.
[00170] The terms host cell, host cell line, and host cell culture are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transforming cells” and “transformed cells,” which include the primary transformed cell and its derived progeny, regardless of the number of passages. The progeny may not be completely identical in nucleic acid content to the mother cell, but may contain mutations. Mutant progeny that has the same biological function or activity that has been screened or selected in the originally transformed cell is included in this document.
[00171] A “human antibody” is one that has an amino acid sequence that corresponds to that of an antibody produced by a human being or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-coding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
[00172] A “human consensus structure” is a structure that represents the amino acid residues most commonly found in a selection of human immunoglobulin VL or VH structure sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subset of variable domain sequences. Generally, the sequence subset is a subset as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD Petition 870250102232, dated 07 / 11 / 2025, pp. 377 / 702 61 / 333 (1991), vols. 1-3. In one aspect, for VL, the subgroup is the kappa I subgroup as in Kabat et al., supra. In one aspect, for VH, the subgroup is the III subgroup as in Kabat et al., supra.
[00173] A “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human CDRs and amino acid residues from human FRs. In certain respects, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all CDRs correspond to those of a non-human antibody, and all or substantially all FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A “humanized form” of an antibody, for example, a non-human antibody, refers to an antibody that has undergone humanization.
[00174] The term “hypervariable region” or “HVR”, as used in this document, refers to each of the regions of an antibody variable domain that are hypervariable in sequence and that determine antigen-binding specificity, for example, “complementarity-determining regions” (“CDRs”).
[00175] Generally, antibodies or antigen-binding domains comprise six CDRs: three in the VH (CDR-H1, CDR-H2, CDR-H3) and three in the VL (CDR-L1, CDR-L2, CDR-L3). The CDRs exemplified in this document include: (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2) and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)); (b) CDRs occurring at amino acid residues 24-34 (L1), Petition 870250102232, dated 07 / 11 / 2025, pages 378 / 702 62 / 333 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2) and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and (c) antigen contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2) and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)).
[00176] Unless otherwise indicated, CDRs are determined in accordance with Kabat et al., supra. A person skilled in the art will understand that CDR designations may also be determined in accordance with Chothia, supra, McCallum, supra or any other scientifically accepted nomenclature system.
[00177] An “immunoconjugate” is an antibody conjugated to one or more heterologous molecules, including, without limitation, a cytotoxic agent.
[00178] An “individual” or guinea pig is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain respects, the individual or guinea pig is a human.
[00179] The term “Interferon alpha”, “Interferon α”, “IFN alpha” or “IFNα”, as used in this document, refers to any native Interferon alpha from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses unprocessed “whole” Interferon alpha as well as any form of Interferon alpha resulting from processing in the cell, unless otherwise indicated. The term also encompasses natural variants of Interferon alpha, for example, splicing variants or allelic variants. Interferons (IFNs) are a family of proteins that were originally named for their ability to interfere with Petition 870250102232, dated 07 / 11 / 2025, pages 379 / 702 63 / 333 viral replication and propagation. To date, it is known that interferons are also involved in combating bacterial and parasitic infections, inhibiting cell division and promoting or preventing cell differentiation. Interferons are classified based on receptor specificity into three types: type I, type II, and type III. Type I interferons are monomeric proteins and include IFN alpha, IFN beta, and IFN omega, which are products of leukocytes and fibroblasts; IFN kappa, which is expressed by human keratinocytes; IFN epsilon, which is expressed exclusively in the lung, brain, small intestine, and reproductive tissue; and IFN tau, which has been described only in ruminants. The term type I interferon, as used in this document, is intended to refer to members of the type I interferon molecule family that are ligands for IFNAR-I (i.e., members of the type I interferon molecule family that have the ability to bind to IFNAR-I).Examples of type I interferon ligands are alpha interferon 1, 2a, 2b, 4, 5, 6, 7, 8, 10, 14, 16, 17, 21, beta interferon, and omega interferon.
[00180] The interferon alpha family consists of 13 fully translated genes without introns (excluding pseudogenes). Each member includes mature proteins of 165 or 166 amino acid residues, with two conserved disulfide bonds: Cys1-Cys98 and Cys29-Cys138. A high level of sequence homology (70-99%) is exhibited among the various interferon alpha subtypes, and approximately 35% homology exists between these subtypes and IFN beta. Despite the high homology, a shared 3D core structure, and a shared receptor among the different subtypes, their biological activities, including antiproliferative, antiviral, and immunomodulatory activities, differ markedly.
[00181] Of the known subtypes of IFN alpha, only interferon alpha 2 (IFN-α2) has been extensively studied for its pharmaceutical potential. IFN-α2 is known to have anticancer effects. It is mainly used in second-line adjuvant therapy for cancers. Petition 870250102232, dated 07 / 11 / 2025, pages 380 / 702 64 / 333 hematopoietic stem cells. However, this treatment is not always effective and sometimes results in intolerable side effects related to dosage and duration of therapy. There are three alleles: Interferon alpha-2A, Interferon alpha-2B, and Interferon alpha-2C. In nature, the alpha-2B allele is the predominant allele, while the alpha-2A allele is less predominant and alpha-2C is only a minor allelic variant.
[00182] The terms “human IFNα” or “human IFNα-2” may, for ease of reading, also be referred to as “huIFα” or “huIFα-2” in this document. The terms “human interferon-alpha 2”, “human interferon-α 2”, “human IFNα 2” or “human IFNα2”, as used in this document, refer to mature human interferon alpha 2, either from the human IFNα2a allele, having the amino acid sequence presented in SEQ ID NO:79, or from the human IFNα2b allele, having the amino acid sequence presented in SEQ ID NO:80. They relate preferentially to human IFNα2 from the human IFNα2a allele having the amino acid sequence established in SEQ ID NO:79. They may also be related to the complete precursors of the respective human IFN-α2 alleles, namely IFN-α2a or IFN-α2b, which comprise an N-terminal signal peptide. In one aspect, mature human IFN-α2 has the human IFN-α2a precursor sequence SEQ ID NO:81.In one aspect, human IFN-α2 has the sequence of the human IFN-α2b precursor with SEQ ID NO:82. The terms may also be related to functional variants of these proteins.
[00183] These functional variants may be homologous to human IFNα2, typically having at least one amino acid substitution that does not significantly impair the protein's functionality, i.e., the binding and / or activation of the human IFNAR1 / 2 receptor. The sequence identity for such variants is therefore typically greater than 95%, often more than 98%. Functional variants of human IFN-α2 may also comprise one or more amino acid substitutions that prevent glycosylation of human IFN-α2. Petition 870250102232, dated 07 / 11 / 2025, pp. 381 / 702 65 / 333 as disclosed in document WO2016 / 065409A1. It is understood that the polypeptides described in this document may also comprise additional amino acid sequences at the N- or C-terminus, such as a signal peptide, which is also present in natural human IFN-α2 before post-translational processing. Other elements that may be present include various labels or markers that facilitate expression, purification and / or detection, as well as protease recognition sites that allow the cleavage of such additional sequence elements.
[00184] The terms “human IFNα” or “human IFNα-2” may also encompass mutated variants of human IFNα-2 that have amino acid substitutions that reduce their affinity for the IFNAR1 and IFNAR2 receptor complex (IFNAR) and reduced or abolished ability to activate cells that express IFNAR as isolated molecules, but retain the ability to bind to IFNAR and the ability to bind to and activate the IFNAR receptor complex, particularly when fused to a targeting moiety. These variants with reduced affinity for IFNAR may also be referred to as “attenuated huIFα-2” in this document. In some respects, attenuated huIFNα-2 has a selected biological activity of less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, or less than 10% of the biological activity of the wild-type huIFNα-2 from which it is derived (i.e., the wild-type huIFNα-2 whose coding sequence has been mutated to obtain the mutant IFN).Attenuated variants of huIFNα-2 confer reduced biological activity, and therefore reduced off-target activity and off-target toxicity, to the fusion proteins described in this document. Targeting the mutated variants of huIFNα-2 reached by the first and second antigen-binding domains restores the activity of the mutated ligand, with the degree of activity restoration apparently correlated with the level of biological targeting in cells. On the other hand, the introduction of mutations... Petition 870250102232, dated 07 / 11 / 2025, pp. 382 / 702 66 / 333 in the native huIFNa-2 polypeptide sequence may increase immunogenicity. Thus, in one aspect of the fusion proteins described in this document, the huIFNa-2 comprised in the fusion protein is native huIFNa-2. In a particular aspect, the huIFNα-2 comprised in the fusion protein described in this document is huIFNα-2 from SEQ ID NO: 79.
[00185] In one embodiment, human IFN-α2 binds to and / or activates the IFN-α / β receptor (IFNAR), namely IFNAR1 and / or IFNAR2. The terms “IFNAR” and “IFNAR1 / 2” are used interchangeably in this document and refer to the interferon-α / β receptor, a membrane receptor that binds to endogenous type I interferons and consists of the two subunits IFNAR1 and IFNAR2.
[00186] An “isolated” antibody is one that has been separated from a component of its natural environment. In some respects, an antibody is purified to a purity greater than 95% or 99%, as determined by, for example, electrophoretic methods (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic methods (e.g., ion exchange or reverse-phase HPLC). For a review of methods for assessing antibody purity, see, for example, Flatman et al., J. Chromatogr. B 848:79-87 (2007).
[00187] The term “nucleic acid molecule” or “polynucleotide” includes any compound and / or substance comprising a polymer of nucleotides. Each nucleotide is composed of a base, specifically a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T), or uracil (U)), a sugar (i.e., deoxyribose or ribose), and a phosphate group. Frequently, the nucleic acid molecule is described by the base sequence, with said bases representing the primary structure (linear structure) of a nucleic acid molecule. The base sequence is commonly represented from 5' to 3'. In this document, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA), including, Petition 870250102232, dated 07 / 11 / 2025, pp. 383 / 702 67 / 333 for example, complementarity DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), in particular messenger RNA (mRNA), synthetic forms of DNA or RNA and mixed polymers comprising two or more of these molecules. The nucleic acid molecule may be linear or circular. In addition, the term nucleic acid molecule includes sense and antisense strands, as well as single-stranded and double-stranded forms. Furthermore, the nucleic acid molecule described herein may contain naturally occurring or unnaturally occurring nucleotides. Examples of unnaturally occurring nucleotides include nucleotide bases modified with derivatized sugars or phosphate backbones or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules that are suitable as a vector for direct expression of an antibody of the invention in vitro and / or in vivo, for example, in a host or patient.These DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors may be modified or unmodified. For example, mRNA may be chemically modified to enhance the stability of the RNA vector and / or the expression of the encoded molecule, so that the mRNA can be injected into an individual to generate the antibody in vivo (see, for example, Stadler et al, Nature Medicine 2017, published online June 12, 2017, doi:10.1038 / nm.4356 or EP 2 101 823 B1).
[00188] An “isolated” nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that normally contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or in a chromosomal location different from its natural chromosomal location.
[00189] “Isolated nucleic acid encoding a fusion protein” refers to one or more nucleic acid molecules that encode the Petition 870250102232, dated 07 / 11 / 2025, pp. 384 / 702 68 / 333 polypeptides that make up the fusion protein (or fragments thereof), including such nucleic acid molecules in a single vector or separate vectors, and such nucleic acid molecules present in one or more locations in a host cell. Isolated nucleic acid encoding an anti-PD-L1 antibody refers to one or more nucleic acid molecules encoding heavy and light chains of anti-PD-L1 antibodies (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present in one or more locations in a host cell.
[00190] The term “monoclonal antibody,” as used in this document, refers to an antibody obtained from a population of substantially homogeneous antibodies, that is, the individual antibodies that make up the population are identical and / or bind to the same epitope, except for possible variant antibodies, for example, containing naturally occurring mutations or mutations arising during the production of a monoclonal antibody preparation, such variants generally being present in smaller quantities. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is directed against a single determinant on an antigen.Thus, the “monoclonal” modifier indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and should not be interpreted as requiring the production of the antibody by any particular method. For example, monoclonal antibodies according to the present invention can be produced by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage display methods, and methods using transgenic animals containing all or part of the immunoglobulin loci. Petition 870250102232, dated 07 / 11 / 2025, pages 385 / 702 69 / 333 human, such methods and other exemplary methods for producing monoclonal antibodies are described in this document.
[00191] A “naked antibody” refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical composition.
[00192] “Native antibodies” refers to naturally occurring immunoglobulin molecules with varied structures. For example, native IgG antibodies are heterotetrameric glycoproteins of approximately 150,000 Daltons, composed of two identical light chains and two identical heavy chains that are linked by disulfide bonds. From the N- to the C-terminal, each heavy chain has a variable domain (VH), also called a variable heavy domain or variable region of the heavy chain, followed by three constant heavy domains (CH1, CH2, and CH3). Similarly, from the N- to the C-terminal, each light chain has a variable domain (VL), also called a variable light domain or variable region of the light chain, followed by a constant light domain (CL).
[00193] The term “package insert” is used to refer to the instructions normally included in commercial packaging of therapeutic products, which contain information on the indications, use, dosage, administration, combination therapy, contraindications and / or warnings relating to the use of such therapeutic products.
[00194] The terms “peptide ligand” or “peptide linker” are used herein to refer to a peptide comprising one or more amino acids, typically about 2 to 20 amino acids. Peptide ligands are known in the art or are described herein. Suitable non-immunogenic peptide ligands are, for example, (G3S)n (SEQ ID NO:97) or (G4S)n (SEQ ID NO:101) peptide ligands, wherein “n” is Petition 870250102232, dated 07 / 11 / 2025, pages 386 / 702 70 / 333 is generally a number between 1 and 10, typically between 2 and 4, particularly 2. The peptide ligands of particular interest are (GSGGS)n (SEQ ID NO:96), (GGGS)n (SEQ ID NO:97), (GSGGG)n (SEQ ID NO:98), (GGGSG)n (SEQ ID NO:99), (GSSSG)n (SEQ ID NO:100), (GGGGS)n (SEQ ID NO:101) and (GGSGG)n (SEQ ID NO:102), where n represents an integer of at least 1, preferably from 4 to 6.
[00195] “Percentage (%) of amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence, after sequence alignment and the introduction of gaps, if necessary, to achieve the maximum percentage of sequence identity, and not considering any conservative substitutions as part of the sequence identity for alignment purposes. Alignment for the purpose of determining the percentage of amino acid sequence identity can be achieved in several ways known to those skilled in the art, for example, using publicly available computer software such as BLAST, BLAST-2, Clustal W, Megalign software (DNASTAR) or the FASTA program package.Subject matter experts can determine appropriate parameters for aligning sequences, including any algorithms necessary to achieve maximum alignment along the entire length of the sequences being compared. Alternatively, percentile identity values can be generated using the ALIGN-2 sequence comparison computer program. The ALIGN-2 sequence comparison computer program was created by Genentech, Inc., and the source code is filed with the user documentation at the United States Copyright Office, Washington DC, 20559, where it is registered under U.S. Copyright Registration No. Petition 870250102232, dated 07 / 11 / 2025, pages 387 / 702 71 / 333 TXU510087 and is described in document WO 2001 / 007611.
[00196] Unless otherwise indicated, for the purposes described herein, the percentile values of amino acid sequence identity are generated using the ggsearch program from the FASTA package version 36.3.8c or later with a BLOSUM50 comparison matrix. The FASTA program package was created by WR Pearson and DJ Lipman (1988), “Improved Tools for Biological Sequence Analysis”, PNAS 85:2444-2448; WR Pearson (1996) “Effective protein sequence comparison” Meth. Enzymol. 266:227-258; and Pearson et al. (1997) Genomics 46:24-36 and is publicly available from www.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or www.ebi.ac.uk / Tools / sss / fasta. Alternatively, a public server can be accessed at fasta.bioch.virginia.edu / fasta_www2 / index.CGI can be used to compare sequences, using the ggsearch program (global protein:protein) and default options (BLOSUM50; open: -10; ext: -2; Ktup = 2) to ensure that a global alignment, rather than a local one, is performed. The amino acid identity percentage is provided in the output alignment header.
[00197] The term “pharmaceutical composition” or “pharmaceutical formulation” refers to a preparation that is in such a form that allows the biological activity of an active ingredient contained therein to be effective and that does not contain additional components that are unacceptably toxic to an individual to whom the pharmaceutical composition would be administered.
[00198] A “pharmaceutically acceptable vehicle” refers to an ingredient in a pharmaceutical composition or formulation, other than an active ingredient, that is not toxic to an individual. A pharmaceutically acceptable vehicle includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
[00199] The term PD-Lr, as used in this document, Petition 870250102232, dated 07 / 11 / 2025, pp. 388 / 702 72 / 333 refers to any native PD-L1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses unprocessed “full-length” PD-L1 as well as any form of PD-L1 resulting from processing within the cell. The term also encompasses naturally occurring variants of PD-L1, e.g., splice variants or allelic variants. The amino acid sequence of an exemplary human PD-L1 is shown in SEQ ID NO:83.
[00200] The terms “target cell” and “target tissue” in this document refer to a specific type of cell or tissue, respectively, that is the intended recipient of the fusion proteins, antibodies, or treatments described in this document. In particular, they may be a cell or tissue that exhibits a specific receptor or characteristic that makes it susceptible or responsive to the intended effect of the fusion protein, antibody, or treatment. In the context of the fusion proteins and antibodies described in this document, the receptor present in the target cell or target tissue may be particularly PD-L1.
[00201] As used in this document, treatment (and its grammatical variations, such as treating or treating) refers to clinical intervention in an attempt to alter the natural course of a disease in the individual being treated, and may be performed both for prophylaxis and during the course of the clinical pathology. The desirable effects of treatment include, without limitation, prevention of the occurrence or recurrence of the disease, relief of symptoms, reduction of any direct or indirect pathological consequences of the disease, prevention of metastasis, reduction of the rate of disease progression, improvement or palliation of the disease state, and remission or improved prognosis. In some respects, the antibodies of the invention are used to retard the development of a disease or to slow the progression of a disease. Petition 870250102232, dated 07 / 11 / 2025, pp. 389 / 702 73 / 333
[00202] The term “variable region” or “variable domain” refers to the domain of an antibody heavy chain or light chain that is involved in antibody binding to the antigen. The variable heavy chain and light chain (VH and VL, respectively) domains of a native antibody generally have similar structures, with each domain comprising four conserved structural regions (FRs) and three complementarity-determining regions (CDRs). (See, for example, Kindt et al. Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind to a particular antigen can be isolated using a VH or VL domain from an antibody that binds to the antigen to screen a library of VH or VL domains of complementarity, respectively. See, for example, Portolano et al., J. Immunol.150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
[00203] The term “vector,” as used in this document, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is attached. The term includes the vector as a self-replicating nucleic acid structure, as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors have the ability to direct the expression of nucleic acids to which they are operationally attached. These vectors are referred to in this document as “expression vectors.” II. Compositions and Methods
[00204] In one aspect, the invention is based, in part, on the discovery that the PD-L1-targeted IFN-α2 fusion proteins described in this document, which exert IFN-α2 activity when the fusion protein is bound to the PD-L1 target antigen, surprisingly show enhanced antitumor activity, particularly with regard to their ability to inhibit the Petition 870250102232, dated 07 / 11 / 2025, pp. 390 / 702 74 / 333 tumor cell proliferation and tumor growth. They also show improved antitumor activity with respect to the direct or indirect induction of immune cell proliferation and / or activation. They also show an improved side effect profile and better tolerability, particularly when compared to recombinant IFN-α2a or other non-targeted and / or non-attenuated IFN-α2 variants. In certain respects, fusion proteins are provided comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1 and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2. The fusion proteins of the invention are useful, for example, for cancer treatment.
[00205] The invention is further based, in part, on the discovery that the anti-PD-L1 antibodies provided in this document – unlike other PD1 / PD-L1 blocking antibodies that bind to the N-terminal of PD-L1 – surprisingly have the ability to block the PD-L1 and PD1 interaction in an SPR binding assay, even though they bind to the C-terminal domain of PD-L1. This property has the technical effect that these antibodies do not compete with other therapeutic anti-PD-L1 antibodies that block the PD-L1 / PD1 interaction (e.g., Atezolizumab, BMS-936559, Avelumab, Durvalumab) for PD-L1 binding because these bind to the N-terminal domain of PD-L1. As a consequence, the fusion proteins and antibodies according to the invention can be used in combination (concomitantly or sequentially) with these other anti-PD-L1 binding antibodies to treat PD-L1-mediated diseases.The antibodies of the invention are therefore useful, for example, for the diagnosis or treatment of cancer. A. Exemplary molecules of the invention 1. Exemplary Fusion Proteins
[00206] In one aspect, the invention provides fusion proteins. Petition 870250102232, dated 07 / 11 / 2025, pages 391 / 702 75 / 333 PD-L1-targeted IFN-α2 fusion proteins, comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1, and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2. In one aspect, isolated PD-L1-targeted IFNα2 fusion proteins are provided, comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1, and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2. In another aspect, the invention provides fusion proteins comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1, and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, wherein the second antigen-binding domain is a bispecific Fab.In one aspect, the invention provides fusion proteins comprising a human IFN-αΣ, a first antigen-binding domain capable of binding to human PD-L1, and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, wherein the human IFN-α2 is further fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain. In another aspect, the human IFN-αΣ is fused at its C-terminus to the N-terminus of the light chain of the second antigen-binding domain.
[00207] In certain aspects of the fusion proteins comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1 and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, the second antigen-binding domain binds to both human PD-L1 and human IFN-α2 in a mutually exclusive manner, that is, it binds to only one of its two antigens at a time, but not to both at the same time. In certain aspects of the fusion proteins comprising a human IFN-α2, a first Petition 870250102232, dated 07 / 11 / 2025, pages 392 / 702 76 / 333 antigen-binding domain capable of binding to human PD-L1 and a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2, the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 is no longer capable of binding to human IFN-α2 when bound to human PD-L1. In certain aspects, in fusion proteins comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1 and a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2, the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 is no longer capable of binding to human PD-L1 when bound to human IFN-α2.
[00208] In certain aspects of the fusion proteins described in this document, the second antigen-binding domain is blocked from binding to PD-L1 when bound to human IFN-α2 and is blocked from binding to human IFNα2 when bound to PD-L1. In one particular aspect, the affinity of the second antigen-binding domain for human PD-L1 is greater than its affinity for human IFN-α2. In certain aspects, the second antigen-binding domain will preferentially bind to human PD-L1, so that the human IFN-α2 portion will no longer bind to the second antigen-binding domain in the presence of the target antigen, i.e., human PD-L1. In some aspects, the activity of human IFN-α2 is reduced and / or blocked when bound to the second antigen-binding domain. In some aspects, human IFNα2 is inactive when bound to the second antigen-binding domain.In some respects, the second antigen-binding domain blocks the activity of human IFN-α2 when bound to human IFN-α2. In other respects, human IFN-α2 is active when the second antigen-binding domain is bound to huPD-L1 on the target cell. In one respect, the second antigen-binding domain has affinity for both human IFN-α2 and PD-L1. Petition 870250102232, dated 07 / 11 / 2025, pages 393 / 702 77 / 333 human, so that the marker and the therapeutic domain compete for binding to the second antigen-binding domain. In one aspect, the balance between the second antigen-binding domain bound to human IFN-α2 and the second antigen-binding domain bound to human PD-L1 will be strongly shifted towards bound human PD-L1 and towards a portion of unbound and active human IFN-α in the presence of PD-L1 molecules, particularly in the presence of a high number of PD-L1 molecules, particularly on the surface of a target cell.
[00209] In certain aspects, in a fusion protein comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1 and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, the human IFN-α2 portion is bound to the second antigen-binding domain, in particular a bispecific anti-PD-L1 / anti-IFN-α2 Fab, and is therefore blocked from binding to its receptor IFNAR1 / 2 when the number of PD-L1 molecules in the environment or on the target cell surface is low (e.g., below a defined threshold) and the human IFN-α2 is released from the second antigen-binding domain when the number of PD-L1 molecules on the target cell surface is high (e.g., above a defined threshold).In one aspect, in a fusion protein comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1, and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, the human IFN-α2 is bound to the second antigen-binding domain (e.g., a bispecific anti-PD-L1 / anti-IFN-α2 Fab). Human IFN-α2 is therefore blocked from binding to its receptor IFNAR1 / 2 in the presence of cells expressing little or no PD-L1 molecules on their surface, particularly in the vicinity of non-tumor cells. The huIFN-α2 or a variant thereof is released from the second antigen-binding domain and binds to its receptor. Petition 870250102232, dated 07 / 11 / 2025, pages 394 / 702 78 / 333 IFNAR1 / 2 in the presence of cells with high PD-L1 expression, such as tumor cells or immune cells in the tumor microenvironment.
[00210] The fusion proteins provided herein may also be provided in an asymmetric form with a domain crossover in one or more antigen-binding domains of the same antigen specificity, i.e., by exchanging the VH / VL domains (see, for example, documents WO 2009 / 080252 and WO 2015 / 150447), the CH1 / CL domains (see, for example, documents WO 2009 / 080253) or the complete Fab arms (see, for example, documents WO 2009 / 080251, WO 2016 / 016299, see also Schaefer et al., PNAS, 108 (2011) 1187-1191, and Klein et al., MAbs 8 (2016) 1010-20). In one aspect, the fusion protein as described in this document comprises a CrossFab. The term "CrossFab" or "xFab" or "crossed Fab" refers to a Fab fragment in which the variable regions or the constant regions of the heavy and light chains are swapped.A crossed Fab comprises a polypeptide chain composed of the variable light chain (VL) region and the constant heavy chain 1 (CH1) region, and a polypeptide chain composed of the variable heavy chain (VH) region and the constant light chain (CL) region. Asymmetric Fab arms can also be engineered by introducing charged or uncharged amino acid mutations at domain interfaces to direct correct Fab pairing. See, for example, WO 2016 / 172485. This form of protein engineering advantageously promotes the correct assembly of the fusion proteins described in this document when produced in a host cell.
[00211] For ease of reading, the fusion proteins provided in this document are also sometimes referred to in this document as “PD-L1-targeted IFN-α2a fusion protein”, “PD-L1-targeted Dutaflip IFN-α2a fusion protein”, “huPD-L1-targeted human IFN-α2a fusion protein” or “PD-L1-targeted human IFN-α2a fusion protein” or Petition 870250102232, dated 07 / 11 / 2025, pages 395 / 702 79 / 333 variations of the same. Interferon Alpha 2a
[00212] A fusion protein of the invention comprises a human IFNα2, that is, the amino acid sequence of human IFN-α2 is fused to another domain of the fusion protein, either directly (e.g., via a peptide bond) or via a peptide linker. In one aspect, the human IFN-α2 has the sequence of the mature human IFN-α2 of full length, that is, it does not have an N-terminal signal peptide. In one aspect, the human IFN-α2 has the sequence of the mature human IFN-α2 of the human IFN-α2a allele (SEQ ID NO:79). In one aspect, the human IFN-α2 has the sequence of the mature human IFN-α2 of the human IFN-α2b allele (SEQ ID NO:80). In one aspect, the human IFN-α2 has the sequence of the human IFN-α2 precursor, that is, it comprises an N-terminal signal peptide. In one aspect, the human precursor IFN-α2 has the sequence of the human allele IFN-α2a (SEQ ID NO:81). In another aspect, human IFN-α2 has the sequence of the human allele IFN-α2b (SEQ ID NO:82).In one aspect, human IFN-α2 is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2, either directly or via a peptide agent. In another aspect, human IFN-α2 is fused at its C-terminus to the N-terminus of the light chain of the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2. First antigen-binding domain capable of binding to human PD-L1.
[00213] A fusion protein of the invention comprises a first antigen-binding domain, in particular a Fab, which is capable of binding to human PD-L1. In one aspect of the fusion protein provided in this document, the first antigen-binding domain is monospecific for human PD-L1, that is, it is capable of binding only to one antigen or epitope on human PD-L1. In certain aspects, the first antigen-binding domain Petition 870250102232, dated 07 / 11 / 2025, pages 396 / 702 The 80 / 333 antigen-binding domain is not capable of binding to any antigen or epitope other than an antigen or epitope in human PD-L1. In one aspect, the first antigen-binding domain is capable of specifically binding to human PD-L1. In specific embodiments, the first antigen-binding domain capable of binding to human PD-L1 is a crossed Fab molecule, i.e., a Fab molecule in which the variable VH and VL domains or the constant CH1 and CL domains of the Fab heavy and light chains are exchanged / substituted with each other. In such embodiments, the second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2 has a conventional Fab domain structure (i.e., without domain crossing) as described in this document.
[00214] In alternative embodiments, the first antigen-binding domain capable of binding to human PD-L1 is a conventional Fab molecule (i.e., without domain crossing). In such embodiments, the second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2 is a crossed Fab molecule, as described in this document, i.e., a Fab molecule in which the variable domains VH and VL or the constant domains CHI and CL of the Fab heavy and light chains are exchanged / substituted for one another.
[00215] The first antigen-binding domain that is capable of binding to human PD-L1 is able to direct the fusion protein to a target site, for example, to a specific type of tumor cell or immune cell in the tumor microenvironment that expresses human PD-L1. A cell that expresses PD-L1 is sometimes also referred to in this document as a “target cell”.
[00216] The first antigen-binding domain of the fusion protein may incorporate any of the features, individually or in combination, described in this document in relation to the fusion protein and the antigen-binding domains contained therein, unless it is Petition 870250102232, dated 07 / 11 / 2025, pages 397 / 702 81 / 333 scientifically clearly irrational or impossible.
[00217] Thus, in one aspect, the invention provides a fusion protein comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1 and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, wherein the second antigen-binding domain is a bispecific Fab, particularly a DutaFab, and the human IFN-α2 is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain, wherein the: The first antigen-binding domain capable of binding to human PDL1 comprises: (i) (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23, or (ii) (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:29, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:30, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:31.
[00218] In another aspect, the invention provides a fusion protein comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1 and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, wherein the first antigen-binding domain capable of binding to human PD-L1 comprises: (i) (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (c) CDR-L3 comprising the amino acid sequence of Petition 870250102232, dated 07 / 11 / 2025, pp. 398 / 702 82 / 333 SEQ ID NO:26, or (ii) (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:32, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:33, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:34.
[00219] In certain respects, the first antigen-binding domain of the fusion protein described in this document comprises: (i) (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:26; or (ii) (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:29; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:30; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:31; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:32; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:33; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:34.
[00220] In one aspect, a fusion protein of the invention comprises a first antigen-binding domain comprising (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23; and (b) a VL domain that Petition 870250102232, dated 07 / 11 / 2025, pp. 399 / 702 83 / 333 comprises at least one, at least two, or all three of the selected VL CDR sequences from (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:26.
[00221] In another aspect, a fusion protein of the invention comprises a first antigen-binding domain comprising (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:29, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:30, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:31; and (b) a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:32, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:33, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:34.
[00222] In one aspect, the invention provides a fusion protein comprising a first antigen-binding domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:26.
[00223] In another aspect, the invention provides a fusion protein comprising a first antigen-binding domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ Petition 870250102232, dated 07 / 11 / 2025, pp. 400 / 702 84 / 333 (a) CDR-H2 comprising the amino acid sequence of SEQ ID NO:29; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:30; (c) CDR-H3 comprising the amino acid sequence of SEQID NO:31; (d) CDR-L1 comprising the amino acid sequence of SEQID NO:32; (e) CDR-L2 comprising the amino acid sequence of SEQID NO:33; and (f) CDR-L3 comprising the amino acid sequence of SEQID NO:34.
[00224] In any of the aspects provided in this document, a fusion protein is humanized, that is, the domains of the fusion protein that are derived from immunoglobulins are humanized. In one aspect, the first antigen-binding domain of a fusion protein additionally comprises a human acceptor structure, for example, a human immunoglobulin structure or a human consensus structure.
[00225] In one aspect, the first antigen-binding domain of a fusion protein described in this document comprises one or more of the CDR sequences of the VH of SEQ ID NO:27 or the VH of SEQ ID NO:35. In another aspect, the first antigen-binding domain of a fusion protein, as described in this document, comprises one or more CDR sequences of the VL of SEQ ID NO:28 or the VL of SEQ ID NO:36. In certain aspects, the first antigen-binding domain of a fusion protein described in this document comprises (i) the CDR sequences of the VH of SEQ ID NO:27 and the CDR sequences of the VL of SEQ ID NO:28 or (ii) the CDR sequences of the VH of SEQ ID NO:35 and the CDR sequences of the VL of SEQ ID NO:36.
[00226] In a further aspect, a fusion protein as described in this document comprises a first antigen-binding domain comprising: I. the amino acid sequences CDR-H1, CDR-H2 and CDR- H3 of the VH domain of SEQ ID NO:27 and the amino acid sequences CDR-L1, Petition 870250102232, dated 07 / 11 / 2025, pp. 401 / 702 85 / 333 CDR-L2 and CDR-L3 of the VL domain of SEQ ID NO:28, or ii. the amino acid sequences CDR-H1, CDR-H2 and CDR- H3 of the VH domain of SEQ ID NO:35 and the amino acid sequences CDR-L1, CDR-L2, and CDR-L3 of the VL domain of SEQ ID NO:36.
[00227] In one aspect, the first antigen-binding domain of a fusion protein as described in this document comprises (a) CDR-H1 comprising the amino acid sequence SEQ ID NO:21; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22;(c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23;(d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24;(e) (f) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:26, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:27, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:28. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:27. In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:28.
[00228] In one aspect, the first antigen-binding domain of a fusion protein as described in this document comprises (a) CDR-H1 comprising the amino acid sequence SEQ ID NO:29; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:30;(c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:31;(d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:32;(e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:33; and (f) Petition 870250102232, dated 07 / 11 / 2025, pp. 402 / 702 86 / 333 CDR-L3 comprising the amino acid sequence of SEQ ID NO:34, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:35, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:36. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:35. In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:36.
[00229] In another aspect, the first antigen-binding domain of a fusion protein, as described in this document, comprises a variable heavy chain (VH) domain sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:27 or with the amino acid sequence of SEQ ID NO:35. In one aspect, the first antigen-binding domain of a fusion protein comprises a variable heavy chain (VH) domain sequence with at least 95% sequence identity with the amino acid sequence of SEQ ID NO:27 or with the amino acid sequence of SEQ ID NO:35.In certain aspects, a VH sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-huPD-L1 antigen-binding domain comprising that sequence retains the ability to bind to human PD-L1. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in SEQ ID NO:27 or SEQ ID NO 35. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (or... Petition 870250102232, dated 07 / 11 / 2025, pp. 403 / 702 87 / 333, i.e., in FRs). Optionally, the first antigen-binding domain of a fusion protein, as described in this document, comprises the VH sequence in SEQ ID NO:27 or SEQ ID NO:35, including post-translational modifications of that sequence. In a particular aspect, VH comprises (i) (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO:21, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO:22, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO:23 or (ii) (a) CDR-H1, comprising the amino acid sequence of SEQ ID NO:29, (b) CDR-H2, comprising the amino acid sequence of SEQ ID NO:30, and (c) CDR-H3, comprising the amino acid sequence of SEQ ID NO:31.
[00230] In another aspect, a fusion protein is provided as described in this document, comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1 and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, wherein the first antigen-binding domain comprises a variable (VL) light chain domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:28 or with the amino acid sequence of SEQ ID NO:36. In one aspect, the first antigen-binding domain of the fusion protein comprises a variable (VL) light chain domain sequence that has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:28 or with the amino acid sequence of SEQ ID NO:36.In certain respects, a VL sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-PD-L1 antigen-binding domain comprising that sequence retains the ability to bind PD-L1. In certain respects, a total. Petition 870250102232, dated 07 / 11 / 2025, pp. 404 / 702 88 / 333 of 1 to 10 amino acids were substituted, inserted, and / or deleted in SEQ ID NO:28 or SEQ ID NO:36. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the first antigen-binding domain of a fusion protein comprises the VL sequence in SEQ ID NO:28 or SEQ ID NO:36, including post-translational modifications of that sequence. In one particular aspect, the VL comprises (i) (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:24, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:25, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:26 or (ii) (a) CDR-L1, comprising the amino acid sequence of SEQ ID NO:32, (b) CDR-L2, comprising the amino acid sequence of SEQ ID NO:33, and (c) CDR-L3, comprising the amino acid sequence of SEQ ID NO:34.
[00231] In certain aspects, a fusion protein is provided comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1, and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, wherein the first antigen-binding domain comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above. In one particular aspect, the first antigen-binding domain comprises the VH and VL sequences at SEQ ID NO:27 and SEQ ID NO:28, respectively, including post-translational modifications of those sequences. In another aspect, the first antigen-binding domain comprises the VH and VL sequences at SEQ ID NO:35 and SEQ ID NO:36, respectively, including post-translational modifications of those sequences. Second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2.
[00232] The fusion protein of the invention comprises a second Petition 870250102232, dated 07 / 11 / 2025, pages 405 / 702 89 / 333 antigen-binding domain, particularly a bispecific Fab, which is capable of binding to human PD-L1 and human IFN-α2. In one aspect, the second antigen-binding domain is capable of specifically binding to human PD-L1 and human IFN-α2. In one aspect, the second antigen-binding domain is capable of binding to human IFN-α2, so that human IFN-α2 is blocked from binding to its receptor IFNAR. In one aspect, the second antigen-binding domain is capable of binding to human IFN-α2, so that human IFN-α2 is blocked from binding to its receptor IFNAR and from activating the IFNα signaling pathway. In one aspect, the second antigen-binding domain binds to human PD-L1 and human IFN-α2 in a mutually exclusive manner, that is, it binds only to one of its two saved antigens at a time, but not to both at the same time.In other words, although the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 has bound to human PD-L1, it is not capable of binding to human IFN-α2, and although it has bound to human IFN-α2, it is not capable of binding to human PD-L1. In one aspect of the invention, the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 binds to human IFN-α2, thus preventing IFN-α2 from binding to its receptor. In some embodiments, the second antigen-binding domain releases human IFN-α2 in the presence of human PD-L1, preferentially binding to human PD-L1 and thus allowing human IFN-α2 in the fusion protein to bind to its natural receptor.
[00233] In certain respects, the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 is a DutaFab. In one aspect, the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 comprises a paratope of human IFN-α2 and a paratope of human PD-L1 within a cognate pair of a variable light chain domain (VL domain) and a heavy chain domain. Petition 870250102232, dated 07 / 11 / 2025, pages 406 / 702 90 / 333 variable (VH domain), wherein (a) the human IFN-α2 paratope comprises CDR-H2, CDR-L1 and CDR-L3 amino acid residues of the antigen-binding domain, and wherein the human PD-L1 paratope comprises CDR-H1, CDR-H3 and CDR-L2 amino acid residues of the antigen-binding domain, or (b) the human PD-L1 paratope comprises CDR-H2, CDR-L1 and CDR-L3 amino acid residues of the antigen-binding domain, and wherein the human IFN-α2 paratope comprises CDR-H1, CDR-H3 and CDR-L2 amino acid residues of the antigen-binding domain.In one particular aspect, the second antigen-binding domain capable of binding to PDL1 and human IFN-α2 comprises a human IFN-α2 paratope and a human PD-L1 paratope within a cognate pair of a variable light chain domain (VL domain) and a variable heavy chain domain (VH domain), wherein the human IFN-α2 paratope comprises amino acid residues of CDR-H2, CDR-L1, and CDR-L3 from the antigen-binding domain, and wherein the PD-L1 paratope comprises amino acid residues of CDR-H1, CDR-H3, and CDR-L2 from the antigen-binding domain.
[00234] In certain aspects, the second antigen-binding domain is blocked from binding to human PD-L1 when bound to human IFNα2 and is blocked from binding to it when bound to human PD-L1. In one particular aspect, the affinity of the second antigen-binding domain for human PD-L1 is greater than its affinity for human IFN-α2. In certain aspects, the second antigen-binding domain will preferentially bind to human PD-L1, so that the human IFN-α2 portion bound to the second antigen-binding domain will be released in the presence of the human target antigen PD-L1. In some aspects, human IFN-α2 is blocked from binding to IFNAR when bound to bispecific Fab and is able to bind to IFNAR when bispecific Fab is bound to PD-L1. In certain aspects, the second antigen-binding domain is able to bind to PD-L1 Petition 870250102232, dated 07 / 11 / 2025, pages 407 / 702 91 / 333 human and human IFN-α2 is bound to IFN-α2 within the fusion protein in the absence of nearby PD-L1. In certain aspects, the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 releases IFN-α2 from the fusion protein in the presence of human PD-L1 in the target cell / target tissue. In certain aspects, the human IFN-α2 of the fusion proteins described in this document is bound to the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 in the absence of nearby human PD-L1. In certain aspects, the human IFN-α2 of the fusion proteins described in this document is released from the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 and / or is activated in the presence of human PD-L1 in the target cell / target tissue.
[00235] In certain aspects, in fusion proteins comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1 and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, the human IFN-α2 is bound to the bispecific anti-PD-L1 / anti-IFN-α2 Fab and thus blocked from binding to its receptor IFNAR1 / 2 when the number of PD-L1 molecules in the environment / on the target cell surface is below a defined threshold, and the human IFN-α2 is released from the bispecific Fab when the number of PD-L1 molecules on the target cell surface is above a defined threshold.In one aspect, in the fusion proteins of the invention comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1 and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, the human IFN-α2 is bound to the bispecific anti-PD-L1 / anti-IFN-α2 Fab and thus blocked from binding to its IFNAR1 / 2 receptor in the vicinity of cells expressing few or no PD-L1 molecules on their surface, particularly in the vicinity of non-tumor cells. When there are a sufficient number of PD-L1 molecules. Petition 870250102232, dated 07 / 11 / 2025, pp. 408 / 702 92 / 333 present (for example, in tumor tissue expressing PD-L1), human IFN-α2 is released from the bispecific Fab and binds to its IFNAR1 / 2 receptor on tumor cells and / or immune cells expressing PD-L1 in the tumor microenvironment.
[00236] In specific embodiments, the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 has the domain structure of a conventional Fab molecule, i.e., it has the domain structure of a native Fab (i.e., without domain crossing). In specific embodiments, the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 is not a CrossFab. In such embodiments, the first antigen-binding domain capable of binding to human PD-L1 is a crossFab molecule, as described in this document, i.e., a Fab molecule in which the variable domains VH and VL or the constant domains CH1 and CL of the Fab heavy and light chains are exchanged / substituted with each other.
[00237] In alternative embodiments, the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 is a cross-linked Fab molecule, as described in this document, i.e., a Fab molecule in which the variable VH and VL domains or the constant CH1 and CL domains of the Fab heavy and light chains are exchanged / substituted for one another. In such embodiments, the first antigen-binding domain capable of binding to human PD-L1 is preferably a conventional Fab molecule.
[00238] In one aspect, the invention provides a fusion protein comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1 and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, wherein the second antigen-binding domain comprises: Petition 870250102232, dated 07 / 11 / 2025, pages 409 / 702 93 / 333 (i) at least one, at least two, at least three, at least four, at least five or all six CDRs selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1;(b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2;(c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3;(d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4;(e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, (ii) at least one, at least two, at least three, at least four, at least five or all six CDRs selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1;(b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2;(c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3;(d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:9;(e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, or (iii) at least one, at least two, at least three, at least four, at least five or all six CDRs selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1;(b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2;(c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3;(d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4;(e) (f) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6.
[00239] In another aspect, a fusion protein of the invention comprises a second antigen-binding domain comprising: (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) CDR-H1 that Petition 870250102232, dated 07 / 11 / 2025, pp. 410 / 702 94 / 333 comprises the amino acid sequence of SEQ ID NO:1, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; and (b) a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, (b) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3;and (b) a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:9, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, or (c) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; and (b) a VL domain comprising at least one, at least two, or all three VL CDR sequences selected from (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6.; Petition 870250102232, dated 07 / 11 / 2025, pp. 411 / 702 95 / 333
[00240] In another aspect, the invention provides a fusion protein comprising a second antigen-binding domain comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) CDR-L1 comprising the amino acid sequence of SEQID NO:4; (e) CDR-L2 comprising the amino acid sequence of SEQID NO:5; and (f) CDR-L3 comprising the amino acid sequence of SEQID NO:6, (b) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) CDR-L1 comprising the amino acid sequence of SEQID NO:9; (e) CDR-L2 comprising the amino acid sequence of SEQID NO:5; and (f) CDR-L3 comprising the amino acid sequence of SEQID NO:6, or (c) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) CDR-H3 comprising the amino acid sequence of SEQID NO:3; (d) CDR-L1 comprising the amino acid sequence of SEQID NO:4; (e) CDR-L2 comprising the amino acid sequence of SEQID NO:11; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6.
[00241] In any of the aspects provided in this document, a given fusion protein is humanized, that is, the domains of the fusion protein that are derived from immunoglobulins are humanized. In one aspect, the second antigen-binding domain of a protein of Petition 870250102232, dated 07 / 11 / 2025, pp. 412 / 702 96 / 333 fusion further comprises a human acceptor structure, for example, a human immunoglobulin structure or a human consensus structure.
[00242] In another aspect, a second antigen-binding domain of a fusion protein, as described in this document, comprises one or more CDR sequences of the VH of SEQ ID NO:7. In another embodiment, a second antigen-binding domain comprises one or more CDR sequences of the VL of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12. In another embodiment, a second antigen-binding domain comprises the CDR sequences of the VH of SEQ ID NO:7 and the CDR sequences of the VL of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12. In a particular aspect, a second antigen-binding domain comprises the CDR sequences of the VH of SEQ ID NO:7 and the CDR sequences of the VL of SEQ ID NO:8.
[00243] In a further aspect, the second antigen-binding domain of a fusion protein according to the invention comprises the amino acid sequences CDR-H1, CDR-H2, and CDR-H3 of the VH domain of SEQ ID NO:7 and the amino acid sequences CDR-L1, CDR-L2, and CDR-L3 of the VL domain of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12. In another aspect, the second antigen-binding domain of a fusion protein, as described herein, comprises the amino acid sequences CDR-H1, CDR-H2, and CDR-H3 of the VH domain of SEQ ID NO:7 and the amino acid sequences CDR-L1, CDR-L2, and CDR-L3 of the VL domain of SEQ ID NO:8.
[00244] In one aspect, the second antigen-binding domain of a fusion protein comprises one or more CDR amino acid sequences of the heavy chain of the VH domain of SEQ ID NO:7 and a structure of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the amino acid structural sequence of the VH domain of SEQ ID NO:7. In one aspect, the second Petition 870250102232, dated 07 / 11 / 2025, pp. 413 / 702 The antigen-binding domain of a fusion protein comprises the three CDR amino acid sequences of the heavy chain of the VH domain of SEQ ID NO:7 and a structure of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the amino acid structural sequence of the VH domain of SEQ ID NO:7. In one aspect, the second antigen-binding domain of a fusion protein comprises the three CDR amino acid sequences of the heavy chain of the VH domain of SEQ ID NO:7 and a structure of at least 95% sequence identity with the amino acid structural sequence of the VH domain of SEQ ID NO:7. In another aspect, the second antigen-binding domain of a fusion protein comprises the three CDR amino acid sequences of the heavy chain of the VH domain of SEQ ID NO:7 and a structure of at least 98% sequence identity with the amino acid structural sequence of the VH domain of SEQ ID NO:7.
[00245] In one aspect, the second antigen-binding domain of a fusion protein comprises one or more CDR amino acid sequences of the VL domain light chain of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12 and a structure of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the amino acid structural sequence of the VL domain of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12. In one aspect, the second antigen-binding domain of a fusion protein comprises the three CDR amino acid sequences of the VL domain light chain of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12 and a structure of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the amino acid structural sequence of the VL domain of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12. In one aspect, the second antigen-binding domain of a fusion protein comprises the three sequences Petition 870250102232, dated 07 / 11 / 2025, pp. 414 / 702 98 / 333 of the CDR amino acid sequences of the VL domain light chain of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12 and a structure of at least 95% sequence identity with the amino acid structural sequence of the VL domain of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12. In another aspect, the second antigen-binding domain of a fusion protein comprises the three CDR amino acid sequences of the VL domain light chain of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12 and a structure of at least particularly 98% sequence identity with the amino acid structural sequence of the VL domain of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12.
[00246] In one aspect, the second antigen-binding domain of a fusion protein comprises one or more CDR amino acid sequences of the VL domain light chain of SEQ ID NO:8 and a structure of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the amino acid structural sequence of the VL domain of SEQ ID NO:8. In one aspect, the second antigen-binding domain of a fusion protein comprises the three CDR amino acid sequences of the VL domain light chain of SEQ ID NO:8 and a structure of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the amino acid structural sequence of the VL domain of SEQ ID NO:8.In one aspect, the second antigen-binding domain of a fusion protein comprises the three CDR amino acid sequences of the VL domain light chain of SEQ ID NO:8 and a structure of at least 95% sequence identity with the amino acid structural sequence of the VL domain of SEQ ID NO:8. In another aspect, the second antigen-binding domain of a fusion protein comprises the three CDR amino acid sequences of the VL domain light chain of SEQ ID NO:8 and a structure of at least 98% sequence identity with the structural sequence of... Petition 870250102232, dated 07 / 11 / 2025, pp. 415 / 702 99 / 333 amino acids of the VH domain of SEQ ID NO:8.
[00247] In one aspect, the second antigen-binding domain of a fusion protein comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5; (e) and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:7, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:8. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:7.In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:8.
[00248] In one aspect, the second antigen-binding domain of a fusion protein comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:9; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5; (e) and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:7, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, Petition 870250102232, dated 07 / 11 / 2025, pp. 416 / 702 100 / 333 97%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:10. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:7. In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:10.
[00249] In one aspect, the second antigen-binding domain of a fusion protein comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11; (e) and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:7, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:12. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:7.In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:12.
[00250] In one aspect, the second antigen-binding domain of a fusion protein comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (f) CDR-L3 comprising the Petition 870250102232, dated 07 / 11 / 2025, pp. 417 / 702 101 / 333 amino acid sequence of SEQ ID NO:6, and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:7, and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:8, wherein the second antigen-binding domain of a fusion protein is capable of binding to human PD-L1 and human IFNα2. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:7. In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:8.In one aspect, the second antigen-binding domain of a fusion protein capable of binding to human PD-L1 and human IFN-α2 has a dissociation constant (Kd) that is up to 10 times reduced or up to 10 times increased when compared to the dissociation constant (Kd) of an antigen-binding domain comprising a VH sequence of SEQ ID NO:7 and a VL sequence of SEQ ID NO:8.
[00251] In another aspect, the second antigen-binding domain of a fusion protein, as described in this document, comprises a variable heavy chain (VH) domain sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:7. In one aspect, the second antigen-binding domain of a fusion protein comprises a variable heavy chain (VH) domain sequence with at least 95% sequence identity with the amino acid sequence of SEQ ID NO:7. In certain respects, a VH sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but a linkage domain to Petition 870250102232, dated 07 / 11 / 2025, pages 418 / 702 The 102 / 333 anti-huPD-L1 / huIFN-α2 antigen comprising this sequence retains the ability to bind to human PD-L1 and human IFN-α2. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in SEQ ID NO:7. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the second antigen-binding domain of a fusion protein comprises the VH sequence in SEQ ID NO:7, including post-translational modifications of that sequence. In one particular aspect, the VH comprises one, two, or three CDRs selected from: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3.In another aspect, a fusion protein is provided comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1, and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, wherein the second antigen-binding domain comprises a variable light chain (VL) domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:8. In one aspect, the second antigen-binding domain of the fusion protein comprises a variable light chain (VL) domain sequence with at least 95% sequence identity with the amino acid sequence of SEQ ID NO:8.In certain respects, a VL sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-huPD-L1 / huIFN-α2 antigen-binding domain comprising that sequence retains the ability to bind human PD-L1 and human IFN-α2. In certain respects, a total of 1 to 10 amino acids were... Petition 870250102232, dated 07 / 11 / 2025, pp. 419 / 702 103 / 333 substituted, inserted, and / or deleted in SEQ ID NO:8. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the second antigen-binding domain of a fusion protein comprises the VL sequence in SEQ ID NO:8, including post-translational modifications of that sequence. In one particular aspect, the VL comprises one, two, or three CDRs selected from: (a) CDR-L1, which comprises the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:9, (b) CDR-L2, which comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:11, and (c) CDR-L3, which comprises the amino acid sequence of SEQ ID NO:6. In a very particular aspect, the VL comprises one, two, or three CDRs selected from among: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6.
[00252] In another aspect, a fusion protein is provided comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1, and a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, wherein the second antigen-binding domain comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above. In one aspect, the second antigen-binding domain comprises the VH and VL sequences in SEQ ID NO:7 and SEQ ID NO:8, SEQ ID NO:10 or SEQ ID NO:12, respectively, including post-translational modifications of these sequences. In one aspect, the second antigen-binding domain comprises the VH and VL sequences in SEQ ID NO:7 and SEQ ID NO:8, respectively, including post-translational modifications of these sequences.
[00253] In a further aspect of the invention, a protein of Petition 870250102232, dated 07 / 11 / 2025, pages 420 / 702 104 / 333 Fusion according to any of the above aspects comprises domains derived from a monoclonal antibody, including a chimeric, humanized or human antibody. In one aspect, a fusion protein according to any of the above aspects comprises at least one antibody fragment, for example, an Fv, Fab, Fab', scFv, diacorpo or F(ab')2 fragment.
[00254] In a further aspect, the fusion protein according to either of the above aspects comprises antibody-derived antigen-binding domains that are of the IgG1 isotype / subclass and comprises an Fc domain comprising two subunits having the amino acid sequence of SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:87 or SEQ ID NO:88, or parts of the amino acid sequence of SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:87 or SEQ ID NO:88. In another aspect, the fusion protein according to either of the above aspects comprises antibody-derived domains that are of the IgG1 isotype / subclass and comprises a constant heavy chain domain of SEQ ID NO:93 or SEQ ID NO:94, or the constant parts of the heavy chain amino acid sequence of SEQ ID NO:93 or SEQ ID NO:94. In one aspect, additionally, the C-terminal glycine (Gly446) is present. In one aspect, additionally, C-terminal glycine (Gly446) and C-terminal lysine (Lys447) are present.
[00255] In particular aspects, the invention provides PD-L1-targeted IFN-α2 fusion proteins comprising a human IFN-α2, a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of binding to both human PD-L1 and human IFN-α2, and an Fc domain composed of a first and a second subunit (as shown in Figure 1), wherein a) the first antigen-binding domain is a Fab cross-linked and is fused at the C-terminal of its heavy chain to the N-terminal of one of the two subunits of the Fc domain, b) the second antigen-binding domain is a DutaFab and is fused at the C-terminal Petition 870250102232, dated 07 / 11 / 2025, pp. 421 / 702 105 / 333 of its heavy chain to the N-terminus of the other of the two Fc domain subunits, ec) human IFN-α2 is wild-type human IFN-α2 and is fused at its C-terminus to the N-terminus of the light chain of the second antigen-binding domain.
[00256] In a further aspect of the invention, a fusion protein is provided comprising a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2, a human IFN-α2, and an Fc domain composed of a first and a second subunit, wherein the second antigen-binding domain is a bispecific Fab, and wherein the fusion protein is composed of: (a) a first polypeptide comprising (a1) the heavy chain of the first antigen-binding domain, fused at its C-terminus to the N-terminus of one of the subunits (e.g., the first subunit) of the Fc domain, and (a2) one of the subunits (e.g., the first subunit) of the Fc domain; (b) a second polypeptide, comprising the light chain of the first antigen-binding domain; (c) a third polypeptide, comprising (c1) the heavy chain of the second antigen-binding domain, fused at its C-terminus to the N-terminus of the other subunit (e.g., the second subunit) of the Fc domain, and (c2) the other subunit (e.g., the second subunit) of the Fc domain; and (d) a fourth polypeptide, comprising (d1) human IFN-α2, fused at its C-terminus to the N-terminus of the light chain of the second antigen-binding domain, and (d2) the light chain of the second antigen-binding domain.
[00257] In one aspect, a fusion protein as described Petition 870250102232, dated 07 / 11 / 2025, pages 422 / 702 106 / 333 in this document comprises a first polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:37, a second polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:38, a third polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:39, and a fourth polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:39. NO:40.In a further aspect, the fusion protein comprises a first polypeptide comprising an amino acid sequence with SEQ ID NO:37, a second polypeptide comprising an amino acid sequence with SEQ ID NO:38, a third polypeptide comprising an amino acid sequence with SEQ ID NO:39, and a fourth polypeptide comprising an amino acid sequence with SEQ ID NO:40.
[00258] In a further aspect, a fusion protein as described in this document comprises a first polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:41, a second polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:42, a third polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:43, and a fourth polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:44. In one aspect Petition 870250102232, dated 07 / 11 / 2025, pp. 423 / 702 107 / 333 additionally, the fusion protein comprises a first polypeptide comprising an amino acid sequence of SEQ ID NO:41, a second polypeptide comprising an amino acid sequence of SEQ ID NO:42, a third polypeptide comprising an amino acid sequence of SEQ ID NO:43, and a fourth polypeptide comprising an amino acid sequence of SEQ ID NO:44.
[00259] In a further aspect, a fusion protein as described in this document comprises a first polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:45, a second polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:46, a third polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:47, and a fourth polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:48.In a further aspect, the fusion protein comprises a first polypeptide comprising an amino acid sequence with SEQ ID NO:45, a second polypeptide comprising an amino acid sequence with SEQ ID NO:46, a third polypeptide comprising an amino acid sequence with SEQ ID NO:47, and a fourth polypeptide comprising an amino acid sequence with SEQ ID NO:48.
[00260] In a further aspect, a fusion protein as described in this document comprises a first polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% Petition 870250102232, dated 07 / 11 / 2025, pp. 424 / 702 108 / 333 identical to the amino acid sequence of SEQ ID NO:49, a second polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:50, a third polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:51, and a fourth polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:52.In a further aspect, the fusion protein comprises a first polypeptide comprising an amino acid sequence with SEQ ID NO:49, a second polypeptide comprising an amino acid sequence with SEQ ID NO:50, a third polypeptide comprising an amino acid sequence with SEQ ID NO:51, and a fourth polypeptide comprising an amino acid sequence with SEQ ID NO:52.
[00261] In a further aspect, a fusion protein as described in this document comprises a first polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:53, a second polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:54, a third polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:55, and a fourth polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:56. In an additional aspect, the fusion protein comprises a first polypeptide that Petition 870250102232, dated 07 / 11 / 2025, pp. 425 / 702 109 / 333 comprises an amino acid sequence with SEQ ID NO:53, a second polypeptide comprising an amino acid sequence with SEQ ID NO:54, a third polypeptide comprising an amino acid sequence with SEQ ID NO:55, and a fourth polypeptide comprising an amino acid sequence with SEQ ID NO:56.
[00262] In a further aspect, a fusion protein as described in this document comprises a first polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:57, a second polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:58, a third polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:59, and a fourth polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:60.In a further aspect, the fusion protein comprises a first polypeptide comprising an amino acid sequence with SEQ ID NO:57, a second polypeptide comprising an amino acid sequence with SEQ ID NO:58, a third polypeptide comprising an amino acid sequence with SEQ ID NO:59, and a fourth polypeptide comprising an amino acid sequence with SEQ ID NO:60.
[00263] In a particular aspect, the invention provides a fusion protein comprising a) a first antigen-binding domain capable of binding to human PD-L1, b) a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 and capable of blocking human IFN-α2 from binding to IFNAR, c) a human IFN-α2 and d) an Fc domain Petition 870250102232, dated 07 / 11 / 2025, pp. 426 / 702 110 / 333 composed of a first and a second subunit, in which i. the first antigen-binding domain is a Fab and is fused at the C-terminus of its Fab heavy chain to the N-terminus of the first Fc domain subunit; ii. the second antigen-binding domain is a bispecific Fab (in particular a DutaFab) and is fused at the C-terminus of its Fab heavy chain to the N-terminus of the second Fc domain subunit, and iii. human IFN-α2 is fused at its C-terminus to the N-terminus of the light chain of the second antigen-binding domain by means of a peptide linker, and in which A. The first antigen-binding domain capable of binding to human PD L1 comprises a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:26; and B. The second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 comprises a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the sequence of Petition 870250102232, dated 07 / 11 / 2025, pp. 427 / 702 111 / 333 amino acids of SEQ ID NO:4, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5 and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6.
[00264] In a further aspect, the invention provides a fusion protein comprising a) a first antigen-binding domain capable of binding to human PD-L1, b) a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 and capable of blocking human IFN-α2 from binding to IFNAR, c) a human IFN-α2, d) an Fc domain composed of a first and a second subunit, wherein i. the first antigen-binding domain is a Fab and is fused at the C-terminus of its Fab heavy chain to the N-terminus of the first Fc domain subunit; ii. the second antigen-binding domain is a bispecific Fab (in particular a DutaFab) and is fused at the C-terminus of its Fab heavy chain to the N-terminus of the second Fc domain subunit, and iii. human IFN-α2 is fused at its C-terminus to the N-terminus of the light chain of the second antigen-binding domain by means of a peptide linker, and in which A. wherein the first antigen-binding domain capable of binding to human PD-L1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28, and B. The second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 comprises a VH domain comprising the amino acid sequence SEQ ID NO:7 and a VL domain comprising the amino acid sequence SEQ ID NO:8. Petition 870250102232, dated 07 / 11 / 2025, pp. 428 / 702 112 / 333
[00265] In another aspect, a fusion protein according to any of the above aspects may incorporate any of the features, individually or in combination, as described in Sections 2-8 below. 2. Example of anti-PD-L1 antibodies
[00266] In one aspect, the invention provides antibodies that bind to human PD-L1. In one aspect, isolated antibodies that bind to human PD-L1 are provided. In one aspect, the invention provides antibodies that specifically bind to human PD-L1. In certain aspects, an anti-huPD-L1 antibody binds to the C-terminal domain of human PD-L1. In certain aspects, an anti-huPD-L1 antibody does not compete with Atezolizumab for binding to PD-L1. In one aspect, an anti-huPD-L1 antibody blocks the binding of PD-L1 to PD1. In one aspect, an anti-huPD-L1 antibody blocks the binding of PD-L1 to PD1, particularly at a concentration of at least 1-10 nM. In one aspect, an anti-huPD-L1 antibody blocks the PD1 / PD-L1 interaction, particularly at a concentration of at least 1-10 nM. In another aspect, an anti-huPD-L1 antibody binds to human PD-L1 with an affinity of < 1.1 nM, in particular < 0.8 nM.
[00267] In one aspect, the invention provides an antihuPD-L1 antibody comprising: (i) a VH domain comprising a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:22 and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:23; and (ii) a VL domain comprising (a) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (b) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:25 and (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO:26. Petition 870250102232, dated 07 / 11 / 2025, pp. 429 / 702 113 / 333
[00268] In any aspect provided herein, an anti-huPD-L1 antibody is humanized. In one aspect, an anti-huPD-L1 antibody further comprises a human acceptor structure, for example, a human immunoglobulin structure or a human consensus structure.
[00269] In another aspect, an anti-huPD-L1 antibody comprises one or more of the HV CDR sequences of SEQ ID NO:27. In another embodiment, an anti-huPD-L1 antibody comprises one or more of the VL CDR sequences of SEQ ID NO:28. In another embodiment, an anti-huPD-L1 antibody comprises the HV CDR sequences of SEQ ID NO:27 and the VL CDR sequences of SEQ ID NO:28.
[00270] In another aspect, an anti-huPD-L1 antibody comprises the amino acid sequences CDR-H1, CDR-H2 and CDR-H3 of the VH domain of SEQ ID NO:27 and the amino acid sequences CDR-L1, CDR-L2 and CDRL3 of the VL domain of SEQ ID NO:28.
[00271] In one aspect, an anti-huPD-L1 antibody comprises one or more of the heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:27 and a structure of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the amino acid structural sequence of the VH domain of SEQ ID NO:27. In one aspect, the anti-huPD-L1 antibody comprises the three amino acid sequences of the heavy chain CDR of the VH domain of SEQ ID NO:27 and a structure of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the amino acid structural sequence of the VH domain of SEQ ID NO:27. In one aspect, the anti-huPD-L1 antibody comprises the three amino acid sequences of the heavy chain CDR of the VH domain of SEQ ID NO:27 and a structure of at least 95% sequence identity with the sequence Petition 870250102232, dated 07 / 11 / 2025, pp. 430 / 702 114 / 333 amino acid structure of the VH domain of SEQ ID NO:27. In another aspect, the anti-huPD-L1 antibody comprises the three amino acid sequences of the heavy chain CDR of the VH domain of SEQ ID NO:27 and a structure of at least 98% sequence identity with the amino acid structural sequence of the VH domain of SEQ ID NO:27.
[00272] In one aspect, an anti-huPD-L1 antibody comprises one or more of the CDR light chain amino acid sequences of the VL domain of SEQ ID NO:28 and a structure of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the amino acid structural sequence of the VL domain of SEQ ID NO:28. In one aspect, the anti-huPD-L1 antibody comprises the three CDR light chain amino acid sequences of the VL domain of SEQ ID NO:28 and a structure of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the amino acid structural sequence of the VL domain of SEQ ID NO:28. In another aspect, the anti-huPD-L1 antibody comprises the three CDR light chain amino acid sequences of the VL domain of SEQ ID NO:28 and a structure of at least 95% sequence identity with the amino acid structural sequence of the VL domain of SEQ ID NO:28.In another aspect, the anti-huPD-L1 antibody comprises the three amino acid sequences of the CDR light chain of the VL domain of SEQ ID NO:28 and a structure of at least 98% sequence identity with the amino acid structural sequence of the VH domain of SEQ ID NO:28.
[00273] In one aspect, the anti-huPD-L1 antibody comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21;(b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22;(c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23;(d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24;(e) Petition 870250102232, dated 07 / 11 / 2025, pp. 431 / 702 115 / 333 (f) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:26 and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:27 and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:28. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:27. In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:28. In another aspect, the anti-huPD-L1 antibody comprises a VH domain that has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:27 and a VL domain that has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:28.
[00274] In one aspect, the anti-huPD-L1 antibody comprises (a) CDR-H1 comprising the amino acid sequence SEQ ID NO:21;(b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22;(c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23;(d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24;(e) (f) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:26 and a VH domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:27 and a VL domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:28; wherein the antibody specifically binds to human PD-L1. In one aspect, the domain Petition 870250102232, dated 07 / 11 / 2025, pp. 432 / 702 116 / 333 VH has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:27. In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:28. In one aspect, the antibody binds to PD-L1 with a dissociation constant (Kd) that is up to 10 times reduced or up to 10 times increased when compared with the dissociation constant (Kd) of an antibody comprising a VH sequence of SEQ ID NO:27 and a VL sequence of SEQ ID NO:28.
[00275] In another aspect, an anti-huPD-L1 antibody comprises a variable heavy chain (VH) domain sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:27. In one aspect, an anti-huPD-L1 antibody comprises a variable heavy chain (VH) domain sequence with at least 95% sequence identity with the amino acid sequence of SEQ ID NO:27. In certain respects, a VH sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-huPD-L1 antibody comprising that sequence retains the ability to bind to human PD-L1. In certain respects, a total of 1 to 10 amino acids were substituted, inserted, and / or deleted in SEQ ID NO:27.In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-PD-L1 antibody comprises the VH sequence at SEQ ID NO:27, including post-translational modifications of that sequence. In one particular aspect, VH comprises one, two, or three CDRs selected from: (a) CDR-H1 comprising the amino acid sequence at SEQ ID NO:21, (b) CDR-H2 comprising the amino acid sequence at SEQ ID NO:22, and (c) CDR-H3 comprising a. Petition 870250102232, dated 07 / 11 / 2025, pp. 433 / 702 117 / 333 amino acid sequence of SEQ ID NO:23. In another aspect, an anti-huPD-L1 antibody is provided, wherein the antibody comprises a variable light chain (VL) domain sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO:28. In one aspect, an anti-huPD-L1 antibody comprises a variable light chain (VL) domain sequence with at least 95% sequence identity with the amino acid sequence of SEQ ID NO:28. In certain aspects, a VL sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-huPD-L1 antibody comprising that sequence retains the ability to bind to PD-L1. In certain aspects, a total of 1 to 10 amino acids were substituted, inserted, and / or deleted in SEQ ID NO:28.In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-huPD-L1 antibody comprises the VL sequence at SEQ ID NO:28, including post-translational modifications of that sequence. In one particular aspect, the VL comprises one, two, or three CDRs selected from: (a) CDR-L1 comprising the amino acid sequence at SEQ ID NO:24, (b) CDR-L2 comprising the amino acid sequence at SEQ ID NO:25, and (c) CDR-L3 comprising the amino acid sequence at SEQ ID NO:26.
[00276] In another aspect, an anti-huPD-L1 antibody is provided, wherein the antibody comprises a VH sequence as in any of the aspects provided above, and a VL sequence as in any of the aspects provided above. In one aspect, the antibody comprises VH and VL sequences in SEQ ID NO:27 and SEQ ID NO:28, respectively, including post-translational modifications of these sequences.
[00277] In a further aspect of the invention, an anti-antibody Petition 870250102232, dated 07 / 11 / 2025, pp. 434 / 702 118 / 333 huPD-L1, according to any of the above aspects, is a monoclonal antibody, including a chimeric, humanized or human antibody. In one aspect, an anti-huPD-L1 antibody is an antibody fragment, for example, an Fv, Fab, Fab', scFv, diabody or F(ab')2 fragment.
[00278] In one aspect, an anti-huPD-L1 antibody according to any of the above aspects is a DutaFab. In one aspect, an anti-huPD-L1 antibody comprises a human PD-L1 paratope and a non-binding paratope (i.e., a paratope that does not bind to any epitope) within a cognate pair of a variable light chain domain (VL domain) and a variable heavy chain domain (VH domain), wherein the non-binding paratope comprises amino acid residues of CDR-H2, CDR-L1 and CDR-L3 of the antigen-binding domain, and wherein the PD-L1 paratope comprises amino acid residues of CDR-H1, CDR-H3 and CDR-L2 of the antigen-binding domain.
[00279] In another aspect, the antibody is a full-length antibody, for example, an intact IgG1 antibody or another class or isotype of antibody, as defined herein.
[00280] In a further aspect, the antibody as described in this document is of the IgG1 isotype / subclass and comprises a constant heavy chain domain of SEQ ID NO:93 or the constant portions of the heavy chain amino acid sequence of SEQ ID NO:142. In another aspect, the antibody according to either of the above aspects comprises a constant heavy chain domain of SEQ ID:93 and the heavy chain amino acid sequence of SEQ ID NO:142. In one aspect, additionally, the C-terminal glycine (Gly446) is present. In one aspect, additionally, the C-terminal glycine (Gly446) and the C-terminal lysine (Lys447) are present.
[00281] In one aspect, an anti-huPD-L1 antibody is provided Petition 870250102232, dated 07 / 11 / 2025, pp. 435 / 702 119 / 333 comprising a heavy chain with the amino acid sequence SEQ ID NO:142 and a light chain with the amino acid sequence SEQ ID NO:143.
[00282] In another aspect, an anti-huPD-L1 antibody according to any of the above aspects may incorporate any of the features, individually or in combination, as described in Sections 3-8 below. 3. Antibody Affinity
[00283] In certain respects, an antibody or antigen-binding domain provided here has a dissociation constant (Kd) of < 1 μM, < 100 nM, < 10 nM, < 1 nM or < 0.1 nM, (e.g., 10-8M or less, e.g., from 10-8M to 10-10M, e.g., from 10-9M to 10-10M).
[00284] In one aspect, Kd is measured using a BIACORE® surface plasmon resonance assay. For example, an assay using a BIACORE®-2000 or BIACORE®-3000 (BIACORE, Inc., Piscataway, NJ) is performed at 25 °C with CM5 antigen chips immobilized in ~10 response units (RU). In one aspect, carboxymethylated dextran biosensor chips (CM5, BIACORE, Inc.) are activated with N-ethyl-N(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS), according to the supplier's instructions. The antigen is diluted with 10 mM sodium acetate, pH 4.8, at 5 μg / ml (~0.2 μM) before injection at a flow rate of 5 μL / minute to achieve approximately 10 response units (RU) of bound protein. After antigen injection, 1 M ethanolamine is injected to block the unreacted groups.For kinetic measurements, serial double dilutions of Fab (0.78 nM to 500 nM) are injected into PBS with 0.05% polysorbate 20 surfactant (TWEEN-20™) (PBST) at 25 °C at a flow rate of approximately 25 μL / min. Association rates (kon) and dissociation rates (koff) are calculated using a Langmuir binding model. Petition 870250102232, dated 07 / 11 / 2025, pp. 436 / 702 120 / 333 simple one-to-one (BIACORE® Evaluation Software version 3.2) simultaneously adjusting the association and dissociation sensorgrams. The equilibrium dissociation constant (Kd) is calculated as the koff / kon ratio. See, for example, Chen et al., J. Mol. Biol. 293:865-881 (1999). If the rate exceeds 106M1s-1 by the surface plasmon resonance assay above, then the activation rate can be determined using a fluorescence quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm bandpass) at 25 °C of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing antigen concentrations as measured in a spectrometer, such as a flow-stop spectrophotometer (Aviv Instruments) or an SLM-AMINCO™ 8000 series spectrophotometer (ThermoSpectronic) with a shake cuvette.
[00285] In one aspect, the Kd for the binding of an anti-PD-L1 / anti-IFN-α2 antigen-binding domain to IFN-α2 is measured using a BIACORE® surface plasmon resonance assay. For example, an assay using a Biacore 8K or 8K instrument (Cytiva) is performed at 25 °C. Human anti-Fab antibody (Cytiva; catalog number 28958325) is immobilized on a CM5 chip according to the manufacturer's instructions. antiPD-L1 / anti-IFN-α2a DutaFabs 100 nM are captured (10 μL / min, 60 s) and 0 nM, 10 nM, 50 nM and 150 nM of unlabeled huIFN-α2a (SEQ ID NO:79) are transported at 30 μL / min for 120 s, followed by a 240-second dissociation window at a flow rate of 30 μL / min. The surface is regenerated by injecting 10 mM glycine, pH 2, for 60 seconds at a flow rate of 30 μL / min. Binding curves are evaluated using Biacore 8K evaluation software (Cytiva) and a 1:1 Langmuir binding model is used to calculate binding properties. 4. Antibody Fragments
[00286] In certain respects, a fusion protein provided in this Petition 870250102232, dated 07 / 11 / 2025, pp. 437 / 702 121 / 333 document comprises one or more antibody fragments. In certain respects, an antibody provided in this document is an antibody fragment.
[00287] In one aspect, the antibody fragment is a Fab, Fab', Fab'-SH, or F(ab')2 fragment, in particular a Fab fragment. Digestion of intact antibodies with papain produces two identical antigen-binding fragments, called “Fab” fragments, each containing the variable heavy and light chain domains (VH and VL, respectively) and also the constant light chain domain (CL) and the first constant heavy chain domain (CH1). The term “Fab fragment” therefore refers to an antibody fragment comprising a light chain comprising a VL domain and a CL domain, and a heavy chain fragment comprising a VH domain and a CH1 domain. “Fab' fragments” differ from Fab fragments by the addition of residues at the carboxy-terminus of the CH1 domain, including one or more cysteines from the hinge region of the antibody. Fab'-SH are Fab' fragments in which the cysteine residue(s) of the constant domains have a free thiol group.Treatment with pepsin produces an F(ab')2 fragment that has two antigen-binding sites (two Fab fragments) and a portion of the Fc region. For discussion of Fab and F(ab')2 fragments comprising salvage receptor-binding epitope residues and having an increased in vivo half-life, see U.S. Patent No. 5,869,046.
[00288] In certain aspects, the antibody fragment is a DutaFab. A DutaFab is a Fab in which a single pair of a VH domain and a VL domain is capable of specifically binding to two different epitopes, wherein one paratope comprises amino acid residues of CDR-H2, CDR-L1, and CDR-L3, and the other paratope comprises amino acid residues of CDR-H1, CDR-H3, and CDR-L2. In one aspect, the DutaFab comprises two non-overlapping paratopes within a cognate VH / VL pair and binds to both epitopes. Petition 870250102232, dated 07 / 11 / 2025, pp. 438 / 702 122 / 333 different in a mutually exclusive way (“Dutaflip”).
[00289] In another aspect, the antibody fragment is a diabody, a triabody, or a tetrabody. “Diabodies” are antibody fragments with two antigen-binding sites that can be bivalent or bispecific. See, for example, EP 404097; WO 1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).
[00290] In a further aspect, the antibody fragment is a single-chain Fab fragment. A “single-chain Fab fragment” or “scFab” is a polypeptide consisting of an antibody variable heavy chain (VH) domain, an antibody constant heavy chain 1 (CH1) domain, an antibody variable light chain (VL) domain, an antibody constant light chain (CL) domain, and a linker, wherein said antibody domains and said linker have one of the following orders in the N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1, or d) VL-CH1-linker-VH-CL. In particular, said linker is a polypeptide of at least 30 amino acids, preferably between 32 and 50 amino acids. The aforementioned single-chain Fab fragments are stabilized by means of a natural disulfide bond between the CL domain and the CH1 domain.Furthermore, these single-chain Fab fragments can be further stabilized by generating interchain disulfide bonds through the insertion of cysteine residues (e.g., position 44 in the variable heavy chain and position 100 in the variable light chain, according to Kabat numbering).
[00291] In another aspect, the antibody fragment is a single-chain variable fragment (scFv). A “single-chain variable fragment” or “scFv” is a fusion protein of the variable domains of the chains Petition 870250102232, dated 07 / 11 / 2025, pp. 439 / 702 123 / 333 heavy (VH) and light (VL) fragments of an antibody, connected by a linker. In particular, the linker is a short polypeptide of 10 to 25 amino acids and is usually rich in glycine for flexibility, as well as serine or threonine for solubility, and can connect the N-terminal of the VH with the C-terminal of the VL, or vice versa. This protein maintains the specificity of the original antibody despite the removal of the constant regions and the introduction of the linker. For a review of scFv fragments, see, for example, Plückthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Patents Nos. 5,571,894 and 5,587,458.
[00292] In another aspect, the antibody fragment is a single-domain antibody. “Single-domain antibodies” are antibody fragments comprising all or a portion of the variable heavy-chain domain or all or a portion of the variable light-chain domain of an antibody. In certain aspects, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, for example, U.S. Patent No. 6,248,516 B1).
[00293] Antibody fragments can be produced by various techniques, including, but not limited to, proteolytic digestion of an intact antibody, as well as recombinant production by recombinant host cells (e.g., E. coli), as described in this document. 5. Chimeric and Humanized Antibodies
[00294] In certain respects, an antibody provided herein is a chimeric antibody. In certain respects, a fusion protein provided herein comprises a chimeric antibody or a fragment of a chimeric antibody. Certain chimeric antibodies are described, for example, in U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). In one example, an antibody Petition 870250102232, dated 07 / 11 / 2025, pages 440 / 702 124 / 333 A chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate such as a monkey) and a human constant region. In a further example, a chimeric antibody is a “class-switched” antibody in which the class or subclass has been altered from that of the original antibody. Chimeric antibodies include antigen-binding fragments.
[00295] In certain respects, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans while maintaining the specificity and affinity of the non-human antibody of origin. Generally, a humanized antibody comprises one or more variable domains in which the CDRs (or a portion thereof) are derived from a non-human antibody, and the FRs (or a portion thereof) are derived from human antibody sequences. A humanized antibody will optionally also comprise at least a portion of a human constant region. In some respects, some FR residues in a humanized antibody are replaced by corresponding residues from a non-human antibody (e.g., the antibody from which the CDR residues are derived), for example, to restore or improve the antibody's specificity or affinity.
[00296] Humanized antibodies and methods for producing them are reviewed, for example, in Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and are further described, for example, in Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:1002910033 (1989); U.S. Patent Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describing specificity-determining region (SDR) grafting); Padlan, Mol. Immunol. 28:489498 (1991) (describing “surface recomposition”); Dall'Acqua et al., Methods 36:43-60 (2005) (describing “FR scrambling”); and Osbourn et Petition 870250102232, dated 07 / 11 / 2025, pp. 441 / 702 125 / 333 al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing the “guided selection” approach for FR shuffling).
[00297] Human structural regions that can be used for humanization include, without limitation: structural regions selected using the “best fit” method (see, for example, Sims et al., J. Immunol. 151: 2296 (1993)); structural regions derived from the consensus sequence of human antibodies from a particular subset of variable light or heavy chain regions (see, for example, Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al. J. Immunol., 151:2623 (1993)); mature human structural regions (somatically mutated) or human germline structural regions (see, for example, Almagro and Fransson, Front. Biosci. 13: 1619-1633 (2008)); and structural regions derived from screening FR libraries (see, for example, Baca et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996)). 6. Human antibodies
[00298] In certain respects, an antibody provided in this document is a human antibody. In other respects, a fusion protein provided in this document comprises a human antibody or a fragment of a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are described in general terms in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
[00299] Human antibodies can be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with variable human regions in response to antigenic exposure. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace endogenous immunoglobulin loci, or which are present Petition 870250102232, dated 07 / 11 / 2025, pp. 442 / 702 126 / 333 extrachromosomally or randomly integrated into the animal's chromosomes. In such transgenic mice, endogenous immunoglobulin loci have generally been inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). See also, for example, U.S. Patents Nos. 6,075,181 and 6,150,584 describing XENOMOUSE™ technology; U.S. Patent No. 5,770,429 describing HuMab® technology; U.S. Patent No. 7,041,870 describing KM MOUSE® technology; and U.S. Patent Application Publication No. US 2007 / 0061900, describing VelociMouse® technology. Variable human regions of intact antibodies generated by such animals can be further modified, for example, by combining them with a different constant human region.
[00300] Human antibodies can also be produced by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, for example, Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Techniques and Applications of Monoclonal Antibody Production, pages 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991).) Human antibodies generated by means of human B-cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103: 3557-3562 (2006). Additional methods include those described, for example, in U.S. Patent No. 7,189,826 (describing the production of human monoclonal IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) (describing human-human hybridomas).Human hybridoma technology (Triome technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology. Petition 870250102232, dated 07 / 11 / 2025, pp. 443 / 702 127 / 333 27(3):185-91 (2005).
[00301] Human antibodies can also be generated by isolating selected variable domain sequences from human-derived phage display libraries. Such variable domain sequences can then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below. 7. Library-derived antibodies
[00302] In certain aspects, an antibody or antigen-binding domain, as described in this document, is derived from a library. In other aspects, a fusion protein provided in this document comprises an antibody, in particular an antibody fragment, such as a Fab or a DutaFab derived from a library. The antibodies of the invention can be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. Methods for screening combinatorial libraries are reviewed, for example, in Lerner et al. in Nature Reviews 16:498-508 (2016). For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies that have the desired binding characteristics. Such methods are reviewed, for example, in Frenzel et al. in mAbs 8:1177-1194 (2016); Bazan et al. in Human Vaccines and Immunotherapeutics 8:1817-1828 (2012) and Zhao et al.in Critical Reviews in Biotechnology 36:276-289 (2016) as well as in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and in Marks and Bradbury in Methods in Molecular Biology 248:161-175 (Lo, ed., Human Press, Totowa, NJ, 2003).
[00303] In certain phage display methods, VH and VL gene repertoires are cloned separately by polymerase chain reaction (PCR) and randomly recombined into phage libraries, which Petition 870250102232, dated 07 / 11 / 2025, pp. 444 / 702 128 / 333 can then undergo screening for antigen-binding phage, as described by Winter et al. in Annual Review of Immunology 12: 433-455 (1994). Phages generally display antibody fragments, such as single-chain Fv fragments (scFv) or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the need to construct hybridomas. Alternatively, the virgin repertoire can be cloned (e.g., from humans) to provide a single source of antibodies for a wide range of self and non-self antigens without any immunization, as described by Griffiths et al. in EMBO Journal 12: 725-734 (1993).Furthermore, virgin libraries can also be made synthetically by cloning non-rearranged V gene segments from stem cells and using PCR primers containing random sequences to encode the highly variable CDR3 regions and to perform in vitro rearrangement, as described by Hoogenboom and Winter in the Journal of Molecular Biology 227: 381-388 (1992). Patent publications describing human antibody phage libraries include, for example: US Patents Nos. 5,750,373; 7,985,840; 7,785,903 and 8,679,490, as well as Publications of... US Patent Nos. 2005 / 0079574, 2007 / 0117126, 2007 / 0237764 and 2007 / 0292936.
[00304] Additional examples of known methods in the art for screening combinatorial libraries for antibodies with one or more desired activities include ribosome and mRNA display, as well as methods for displaying and selecting antibodies in bacteria, mammalian cells, insect cells, or yeast cells. Methods for yeast surface display are reviewed, for example, in Scholler et al. in Methods in Molecular Biology 503:135-56 (2012) and in Cherf et al. in Methods in Molecular Biology 1319:155-175 (2015), as well as in Zhao et al. in Methods in Molecular Biology 889:73-84 (2012). Methods for ribosome display Petition 870250102232, dated 07 / 11 / 2025, pp. 445 / 702 129 / 333 are described, for example, in He et al. in Nucleic Acids Research 25:51325134 (1997) and in Hanes et al. in PNAS 94:4937-4942 (1997).
[00305] Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments in this document. 8. Multispecific antibodies
[00306] In certain respects, an antibody provided in this document is a multispecific antibody, for example, a bispecific antibody. “Multispecific antibodies” are monoclonal antibodies that have binding specificities for at least two different sites, i.e., different epitopes on different antigens or different epitopes on the same antigen. In certain respects, the multispecific antibody has three or more binding specificities. In certain respects, one of the binding specificities is for human PD-L1 and the other specificity is for any other antigen. In certain respects, bispecific antibodies can bind to two (or more) different epitopes of human PD-L1. Multispecific (e.g., bispecific) antibodies can also be used to target cytotoxic agents or cells in cells expressing human PD-L1. Multispecific antibodies can be prepared as full-length antibodies or antibody fragments.
[00307] Techniques for producing multispecific antibodies include, but are not limited to, recombinant co-expression of two pairs of immunoglobulin heavy and light chains with different specificities (see Milstein and Cuello, Nature 305: 537 (1983)) and “knob-in-hole” engineering (see, for example, U.S. Patent No. 5,731,168 and Atwell et al., J. Mol. Biol. 270:26 (1997)). Multispecific antibodies can also be produced by engineering electrostatic orientation effects to produce heterodimeric Fc antibody molecules (see, for example, WO Petition 870250102232, dated 07 / 11 / 2025, pp. 446 / 702 130 / 333 2009 / 089004); crosslinking of two or more antibodies or fragments (see, for example, U.S. Patent No. 4,676,980 and Brennan et al., Science, 229: 81 (1985)); using leucine zippers to produce bispecific antibodies (see, for example, Kostelny et al., J. Immunol., 148(5):1547-1553 (1992) and WO 2011 / 034605); using common light chain technology to circumvent the problem of light chain mismatch (see, for example, WO 98 / 50431); using “diabody” technology to make bispecific antibody fragments (see, for example, Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and using single-chain Fv dimers (scFv) (see, for example, Gruber et al., J. Immunol., 152:5368 (1994)); and preparing trispecific antibodies as described, for example, in Tutt et al. J. Immunol. 147: 60 (1991).
[00308] Engineered antibodies with three or more antigen-binding sites, including, for example, “Octopus antibodies” or DVD-Ig, are also included in this document (see, for example, WO 2001 / 77342 and WO 2008 / 024715). Other examples of multispecific antibodies with three or more antigen-binding sites can be found in WO 2010 / 115589, WO 2010 / 112193, WO 2010 / 136172, WO 2010 / 145792 and WO 2013 / 026831. The bispecific antibody or antigen-binding fragment thereof also includes a dual-action Fab or DAF comprising an antigen-binding site that binds to human PD-L1 as well as another different antigen, or two different epitopes of PD-L1 (see, for example, US documents 2008 / 0069820 and WO 2015 / 095539).
[00309] Multispecific antibodies can also be provided in an asymmetric form with a domain crossover in one or more binding arms of the same antigen specificity, i.e., by exchanging the VH / VL domains (see, for example, WO 2009 / 080252 and WO 2015 / 150447), the CH1 / CL domains (see, for example, WO 2009 / 080253) or the arms Petition 870250102232, dated 07 / 11 / 2025, pp. 447 / 702 131 / 333 Complete Fabs (see, for example, WO 2009 / 080251, WO 2016 / 016299; see also Schaefer et al., PNAS, 108 (2011) 1187-1191, and Klein et al., MAbs 8 (2016) 1010-20). In one aspect, the multispecific antibody comprises a CrossFab. The term “CrossFab” or “xFab” or “crossed Fab” refers to a Fab in which the variable regions or the constant regions of the heavy and light chains are exchanged. A CrossFab comprises a polypeptide chain composed of the variable region of the light chain (VL) and the constant region of the heavy chain 1 (CH1), and a polypeptide chain composed of the variable region of the heavy chain (VH) and the constant region of the light chain (CL). Asymmetric Fab arms can also be engineered by introducing charged or uncharged amino acid mutations at domain interfaces to target correct Fab pairing. See, for example, WO 2016 / 172485.
[00310] Several additional molecular formats for multispecific antibodies are known in the art and are included in this document (see, for example, Spiess et al., Mol Immunol 67 (2015) 95-106).
[00311] A particular type of multispecific antibodies, also included herein, are bispecific antibodies designed to bind simultaneously to a surface antigen on a target cell, for example, a tumor cell and / or an immune cell in the tumor microenvironment, and to an invariant activating component of the T cell receptor complex (TCR), such as CD3, for redirection of T cells to kill target cells. Therefore, in certain respects, an antibody provided in this document is a multispecific antibody, particularly a bispecific antibody, wherein one of the binding specificities is for human PD-L1 and the other is for CD3.
[00312] Examples of bispecific antibody formats that may be useful for this purpose include, without limitation, so-called “BiTE” (bispecific T-cell coupling) molecules, in which two Petition 870250102232, dated 07 / 11 / 2025, pp. 448 / 702 132 / 333 scFv molecules are fused by a flexible ligand (see, for example, WO 2004 / 106381, WO 2005 / 061547, WO 2007 / 042261 and WO 2008 / 119567, Nagorsen and Bauerle, Exp Cell Res 317, 1255-1260 (2011)); diabodies (Holliger et al., Prot Eng 9, 299-305 (1996)) and derivatives thereof, such as tandem diabodies (“TandAb”; Kipriyanov et al., J Mol Biol 293, 41-56 (1999)); “DART” (dual affinity redirection) molecules that are based on the diabody format but feature a C-terminal disulfide bridge for additional stabilization (Johnson et al., J Mol Biol 399, 436-449 (2010)), and so-called triomabs, which are whole hybrid mouse / rat IgG molecules (reviewed in Seimetz et al., Cancer Treat Rev 36, 458-467 (2010)). Particular formats of bispecific T-cell antibodies included in this document are described in WO 2013 / 026833, WO 2013 / 026839, WO 2016 / 020309; Bacac et al., Oncoimmunology 5(8) (2016) e1203498. 9. Antibody Variants
[00313] In certain respects, amino acid sequence variants of the antibodies and antigen-binding domains provided in this document are contemplated. For example, it may be desirable to alter the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of an antibody can be prepared by introducing appropriate modifications to the nucleotide sequence encoding the antibody or by synthesizing peptides. Such modifications include, for example, deletions from and / or insertions and / or substitutions of residues within the antibody amino acid sequences. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, for example, antigen binding. a) Replacement, Insertion, and Deletion Variants
[00314] In certain aspects, antibody variants are provided. Petition 870250102232, dated 07 / 11 / 2025, pp. 449 / 702 133 / 333 and antigen-binding domain variants with one or more amino acid substitutions. Sites of interest for substitutional mutagenesis include CDRs and FRs. Conservative substitutions are shown in Table 1 under the heading “preferred substitutions”. More substantial changes are provided in Table 1 under the heading “exemplary substitutions” and as further described below with reference to amino acid side chain classes. Amino acid substitutions can be introduced into an antibody of interest and the products can be screened for a desired activity, e.g., retained / enhanced antigen binding, decreased immunogenicity, or enhanced ADCC or CDC. Table 1 Original Residue Exemplary Substitutions Preferred Substitutions Wing (A) Val; Read; Ile Val Arg (R) Lys; Gln; Asn Lys Asn(N)Gln; His; Asp, Lys; Arg Gln Asp (D) Glu; Asn Glu Cys (C) Ser; Ala Ser Gln (Q) Asn; Glu Asn Glu (E) Asp; Gln Asp Gly (G) Ala Ala His (H) Asn; Gln; Lys; Arg Arg Ile (I) Leu; Val; Met; Allah; Phe; Norleucine Leu Leu (L) Norleucine; Ile; Val; Met; Allah; Phe Ile Lys (K) Arg; Gln; Asn Arg Met (M) Leu; Phe; Ile Leu Phe (F) Trp; Read; Val; Ile; Allah; Tyr Tyr Pro (P) Ala Ala Ser(S) Thr Thr Petition 870250102232, dated 07 / 11 / 2025, pages 450 / 702 134 / 333 Original Residue Exemplary Substitutions Preferred Substitutions Thr (T) Val; Ser Ser Trp (W) Tyr; Phe Tyr Tyr (Y) Trp; Phe; Thr; Ser Phe Val (V) Ile; Leu; Met; Phe; Ala; Norleucine Leu
[00315] Amino acids can be grouped according to common side chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acid: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe.
[00316] Non-conservative substitutions will involve replacing a member of one of these classes with a member of another class.
[00317] A type of substitutional variant involves the replacement of one or more residues in a hypervariable region of a source antibody (e.g., a humanized or human antibody). Generally, the resulting variant(s) selected for further study will have modifications (e.g., enhancements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the source antibody and / or will have substantially retained certain biological properties of the source antibody. An exemplary substitutional variant is an affinity-matured antibody, which can be conveniently generated, for example, using phage display-based affinity maturation techniques, such as those described in this document. Briefly, one or more CDR residues are mutated and the variant antibodies are displayed on the phage and screened for a particular biological activity (e.g., affinity of Petition 870250102232, dated 07 / 11 / 2025, pp. 451 / 702 135 / 333 connection).
[00318] Alterations (e.g., substitutions) can be made to CDRs, for example, to improve antibody affinity. Such alterations can be made to CDR “hotspots,” i.e., residues encoded by codons that mutate at high frequency during the somatic maturation process (see, for example, Chowdhury, Methods Mol. Biol. 207:179-196 (2008)) and / or residues that come into contact with the antigen, with the resulting VH or VL variant being tested for binding affinity. Affinity maturation through construction and re-selection from secondary libraries has been described, for example, in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, (2001).In some aspects of affinity maturation, diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-targeted mutagenesis). A secondary library is then created. The library then undergoes screening to identify any antibody variants with the desired affinity. Another method for introducing diversity involves CDR-targeted approaches, in which multiple CDR residues (e.g., 4–6 residues at a time) are randomized. The CDR residues involved in antigen binding can be specifically identified, for example, using mutagenesis or alanine screening modeling. CDR-H3 and CDR-L3, in particular, are frequently targeted.
[00319] In certain respects, substitutions, insertions, or deletions may occur in one or more CDRs, provided that such changes do not substantially reduce the antibody's ability to bind to the antigen. For example, conservative changes (e.g., conservative substitutions as provided in this document) that do not reduce Petition 870250102232, dated 07 / 11 / 2025, pp. 452 / 702 136 / 333 Substantially, binding affinity can be made in CDRs. Such alterations may, for example, be outside the antigen-contact residues in the CDRs. In certain variant sequences of VH and VL given above, each CDR is either unaltered or contains more than one, two, or three amino acid substitutions.
[00320] A useful method for identifying residues or regions of an antibody or antigen-binding domain that can be targeted by mutagenesis is called alanine-scavenging mutagenesis, as described by Cunningham and Wells (1989) Science, 244:1081-1085. In this method, a target residue or group of residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced with a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine if the antibody-antigen interaction is affected. Additional substitutions can be introduced at the amino acid sites, demonstrating functional sensitivity to the initial substitutions. Alternatively or additionally, a crystal structure of an antigen-antibody complex can be used to identify points of contact between the antibody and the antigen.Such contact residues and neighboring residues can be targeted or disposed of as candidates for replacement. The variants can undergo screening to determine if they contain the desired properties.
[00321] Amino acid sequence insertions include amino and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing one hundred or more residues, as well as intrasequential insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other variants of antibody molecule insertion include fusion to the N- or C-terminal of the antibody with an enzyme (e.g., for ADEPT). Petition 870250102232, dated 07 / 11 / 2025, pages 453 / 702 137 / 333 (antibody-targeted enzyme prodrug therapy) or a polypeptide that increases the serum half-life of the antibody. b) Glycosylation Variants
[00322] In certain respects, a fusion protein or antibody provided in this document is altered to increase or decrease the extent to which the antibody is glycosylated. The addition or deletion of glycosylation sites to an antibody can be conveniently accomplished by altering the amino acid sequence so that one or more glycosylation sites are created or removed.
[00323] When the antibody comprises an Fc region, the oligosaccharide attached to it can be altered. Native antibodies produced by mammalian cells generally comprise a branched, biantennary oligosaccharide that is usually linked by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, for example, Wright et al. TIBTECH 15:26-32 (1997). The oligosaccharide may include various carbohydrates, for example, mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose linked to a GlcNAc in the “stem” of the biantennary oligosaccharide structure. In some respects, modifications of the oligosaccharide in an antibody of the invention can be made to create antibody variants with certain enhanced properties.
[00324] In one aspect, antibody and fusion protein variants are provided having a non-fucosylated oligosaccharide, i.e., an oligosaccharide structure that does not have fucose attached (directly or indirectly) to an Fc region. Such a non-fucosylated oligosaccharide (also known as an “afucosylated” oligosaccharide) is particularly an N-linked oligosaccharide that does not have a fucose residue attached to the first GlcNAc in the stem of the biantenna oligosaccharide structure. In one aspect, antibody variants are provided having an increased proportion of oligosaccharides Petition 870250102232, dated 07 / 11 / 2025, pp. 454 / 702 138 / 333 non-fucosylated oligosaccharides in the Fc region compared to a non-fucosylated or native antibody. For example, the proportion of non-fucosylated oligosaccharides may be at least about 20%, at least about 40%, at least about 60%, at least about 80%, or even about 100% (i.e., no fucosylated oligosaccharides are present). The percentage of non-fucosylated oligosaccharides is the (average) amount of oligosaccharides without fucose residues, relative to the sum of all oligosaccharides bound to Asn 297 (e.g., complex, hybrid, and high-mannose structures), as measured by MALDI-TOF mass spectrometry, as described in document WO 2006 / 082515, for example.Asn297 refers to the asparagine residue located at position 297 in the Fc region (EU numbering of Fc region residues); however, Asn297 may also be located approximately ± 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such antibodies possessing an increased proportion of non-fucosylated oligosaccharides in the Fc region may have improved binding to the FcYRIIIa receptor and / or improved effector function, in particular improved ADCC function. See, for example, US 2003 / 0157108; US 2004 / 0093621.
[00325] Examples of cell lines capable of producing antibodies with reduced fucosylation include Lec13 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); US 2003 / 0157108; and WO 2004 / 056312, especially in Example 11), and knockout cell lines, such as the alpha-1,6-fucosyltransferase gene, FUT8, CHO knockout cells (see, for example, Yamane-Ohnuki et al. Biotech. Bioeng. 87:614-622 (2004); Kanda, Y. et al., Biotechnol. Bioeng., 94(4):680-688 (2006); and WO 2003 / 085107), or cells with reduced or abolished activity of a transporter or synthesis protein. of GDP-fucose (see, for example, US2004259150, US2005031613, US2004132140, US2004110282). Petition 870250102232, dated 07 / 11 / 2025, pages 455 / 702 139 / 333
[00326] In a further aspect, antibody variants are provided with bisected oligosaccharides, for example, where a biantennary oligosaccharide linked to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function, as described above. Examples of such antibody variants are described, for example, in Umana et al., Nat Biotechnol 17, 176-180 (1999); Ferrara et al., Biotechn Bioeng 93, 851-861 (2006); WO 99 / 54342; WO 2004 / 065540, WO 2003 / 011878.
[00327] Antibody variants that have at least one galactose residue in the oligosaccharide linked to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, for example, in WO 1997 / 30087; WO 1998 / 58964; and WO 1999 / 22764. c) Variants of the Fc region
[00328] In certain respects, one or more amino acid modifications may be introduced into the Fc region of a fusion protein or antibody provided in this document, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) comprising an amino acid modification (e.g., a substitution) at one or more amino acid positions.
[00329] In certain respects, the invention contemplates a fusion protein or antibody variant that has some, but not all, effector functions, making it a desirable candidate for applications where the in vivo antibody half-life is important, but certain effector functions (such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)) are unnecessary or deleterious. In vitro and / or in vivo cytotoxicity assays can be conducted for Petition 870250102232, dated 07 / 11 / 2025, pp. 456 / 702 140 / 333 confirm the reduction / depletion of CDC and / or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the antibody does not bind to FcyR (therefore, probably does not have ADCC activity), but retains the ability to bind to FcRn. The primary cells for mediating ADCC, NK cells, express only FcyRIII, while monocytes express FcyRI, FcyRII, and FcyRIII. FcR expression in hematopoietic cells is briefly described in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991). Non-limiting examples of in vitro assays for evaluating the ADCC activity of a molecule of interest are described in U.S. Patent No. 5,500,362 (see, for example, Hellstrom, I. et al. Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82: 1499-1502 (1985); 5,821,337 (see Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)).Alternatively, non-radioactive assay methods may be employed (see, for example, ACTI™ non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA); and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMCs) and Natural Killer (NK) cells. Alternatively or additionally, the ADCC activity of the molecule of interest may be evaluated in vivo, for example, in an animal model such as that disclosed in Clynes et al., Proc. Nat'l Acad. 2006 / 029879 and WO 2005 / 100402., J. Immunol. Methods 202:163 (1996); Cragg, MS et al., Blood 101: 1045-1052 (2003); and Cragg, MS and MJ Glennie, Blood 103:2738 Petition 870250102232, dated 07 / 11 / 2025, p. 457 / 702. 141 / 333 2743 (2004)). FcRn binding and in vivo clearance / half-life determinations can also be performed using methods known in the art (see, for example, Petkova, SB et al., Intl Immunol. 18(12):1759-1769 (2006); WO 2013 / 120929 Al).
[00330] Antibodies or fusion proteins with reduced effector function include those with substitution of one or more residues in the Fc region 238, 265, 269, 270, 297, 327 and 329 (US Patent No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more amino acid positions 265, 269, 270, 297 and 327, including the so-called Fc “DANA” mutant with substitution of residues 265 and 297 for alanine (US Patent No. 7,332,581).
[00331] Certain antibody variants with improved or decreased binding to FcRs are described. (See, for example, U.S. Patent No. 6,737,056; WO 2004 / 056312, and Shields et al., J. Biol. Chem. 9(2): 6591-6604 (2001).)
[00332] In certain respects, a fusion protein or antibody variant comprises an Fc region with one or more amino acid substitutions that enhance ADCC, for example, substitutions at positions 298, 333 and / or 334 of the Fc region (EU residue numbering).
[00333] In certain aspects, a fusion protein or antibody variant comprises an Fc region with one or more amino acid substitutions that decrease FcyR binding, for example, substitutions at positions 234 and 235 of the Fc region (EU residue numbering). In one aspect, the substitutions are L234A and L235A (LALA). In certain aspects, the antibody variant further comprises D265A and / or P329G in an Fc region derived from a human IgG1 Fc region. In one aspect, the substitutions are L234A, L235A, and P329G (LALA-PG) in an Fc region derived from a human IgG1 Fc region. (See, for example, WO Petition 870250102232, dated 07 / 11 / 2025, pages 458 / 702 142 / 333 2012 / 130831). In another aspect, the substitutions are L234A, L235A and D265A (LALA-DA) in an Fc region derived from a human IgG1 Fc region.
[00334] In some respects, changes are made to the Fc region that result in altered (i.e., enhanced or decreased) C1q binding and / or Complement-Dependent Cytotoxicity (CDC), for example, as described in U.S. Patent No. 6,194,551, WO 99 / 51642, and Idusogie et al. J. Immunol. 164: 4178-4184 (2000).
[00335] Antibodies with increased half-lives and enhanced binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)), are described in document US2005 / 0014934 (Hinton et al.). These antibodies comprise an Fc region with one or more substitutions that enhance the binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more residues in the Fc region: 238, 252, 254, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, or 434, for example, substitution of residue 434 of the Fc region (see, for example, U.S. Patent No. 7,371,826; Dall'Acqua, WF, et al. J. Biol. Chem. 281 (2006) 23514-23524).
[00336] Residues in the Fc region critical for the mouse Fc-FcRn interaction have been identified by site-directed mutagenesis (see, for example, Dall'Acqua, WF, et al. J. Immunol 169 (2002) 51715180). Residues I253, H310, H433, N434, and H435 (EU numbering of residues) are involved in the interaction (Medesan, C., et al., Eur. J. Immunol. 26 (1996) 2533; Firan, M., et al., Int. Immunol. 13 (2001) 993; Kim, JK, et al., Eur. J. Immunol. 24 (1994) 542). Residues I253, H310, and H435 were considered critical for the interaction of human Fc with murine FcRn (Kim, JK, et al., Eur. J. Immunol. 29 (1999) 2819). Studies of the human Fc-human FcRn complex showed that residues I253, S254, H435, and Y436 are crucial for the Petition 870250102232, dated 07 / 11 / 2025, pp. 459 / 702 143 / 333 interaction (Firan, M., et al., Int. Immunol. 13 (2001) 993; Shields, RL, et al., J. Biol. Chem. 276 (2001) 6591-6604). In Yeung, YA, et al. (J. Immunol. 182 (2009) 7667-7671) several mutants of residues 248 to 259 and 301 to 317 and 376 to 382 and 424 to 437 were reported and examined.
[00337] In certain aspects, a fusion protein or antibody variant comprises an Fc region with one or more amino acid substitutions that reduce FcRn binding, for example, substitutions at positions 253 and / or 310 and / or 435 of the Fc region (EU residue numbering). In certain aspects, the fusion protein or antibody variant comprises an Fc region with amino acid substitutions at positions 253, 310, and 435. In one aspect, the substitutions are I253A, H310A, and H435A in an Fc region derived from a human IgG1 Fc region. See, for example, Grevys, A., et al., J. Immunol. 194 (2015) 5497-5508.
[00338] In certain aspects, a fusion protein or antibody variant comprises an Fc region with one or more amino acid substitutions that reduce FcRn binding, for example, substitutions at positions 310 and / or 433 and / or 436 of the Fc region (EU residue numbering). In certain aspects, the antibody variant comprises an Fc region with amino acid substitutions at positions 310, 433, and 436. In one aspect, the substitutions are H310A, H433A, and Y436A in an Fc region derived from a human IgG1 Fc region. (See, for example, WO 2014 / 177460 Al).
[00339] In certain respects, a fusion protein or antibody variant comprises an Fc region with one or more amino acid substitutions that increase FcRn binding, for example, substitutions at positions 252 and / or 254 and / or 256 of the Fc region (EU residue numbering). In certain respects, the fusion protein or antibody variant comprises an Fc region with amino acid substitutions at positions 252, 254 and 256. Petition 870250102232, dated 07 / 11 / 2025, pages 460 / 702 144 / 333 In one aspect, the substitutions are M252Y, S254T, and T256E in an Fc region derived from a human IgG1 Fc region. See also Duncan & Winter, Nature 322:738-40 (1988); U.S. Patent No. 5,648,260; U.S. Patent No. 5,624,821; and WO 94 / 29351 on other examples of Fc region variants.
[00340] In certain aspects, the invention also contemplates fusion proteins or antibody variants comprising different antigen-binding moieties, which can be fused to one or the other of the two Fc domain subunits, such that the two Fc domain subunits will typically comprise two non-identical polypeptide chains. Recombinant co-expression of these polypeptides and subsequent dimerization can lead to various possible combinations of the two polypeptides. To improve the yield and purity of fusion proteins or antibody variants in recombinant production, it will be advantageous to introduce a modification in the Fc domain of the respective fusion protein or antibody variant that promotes the association of the desired polypeptides.
[00341] Consequently, in particular aspects, the Fc domain of the fusion protein or antibody variant described herein comprises a modification that promotes the association of the first and second subunits of the Fc domain. The most extensive protein-protein interaction site between the two subunits of a human IgG Fc domain is in the CH3 domain of the Fc domain. Thus, in one aspect, the said modification is in the CH3 domain of the Fc domain.
[00342] There are several approaches to modifications in the CH3 domain of the Fc domain in order to enhance heterodimerization, which are well described, for example, in WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012058768, WO 2013157954, WO Petition 870250102232, dated 07 / 11 / 2025, pp. 461 / 702 145 / 333 2013096291. Typically, in all these approaches, the CH3 domain of the first subunit of the Fc domain and the CH3 domain of the second subunit of the Fc domain are both complementarily engineered, so that each CH3 domain (or the heavy chain comprising it) can no longer homodimerize with itself, but is forced to heterodimerize with the other complementarily engineered CH3 domain (so that the first and second CH3 domains heterodimerize and no homodimer between the first two or the second two CH3 domains is formed).These different approaches to enhanced heavy chain heterodimerization are contemplated as different alternatives in combination with heavy-light chain modifications (e.g., VH and VL exchange / substitution in a linking arm and the introduction of oppositely charged amino acid substitutions at the CH1 / CL interface) in the fusion protein or antibody variant described in this document, which reduces heavy / light chain mismatch and Bence Jones-type byproducts.
[00343] In certain respects, the aforementioned modification that promotes the association of the first and second subunits of the Fc domain is a modification called “knob-into-hole”, which comprises a “knob” modification in one of the two subunits of the Fc domain and a “hole” modification in the other of the two subunits of the Fc domain.
[00344] Knob-into-hole technology is described, for example, in US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a protrusion (“knob”) at the interface of a first polypeptide and a corresponding cavity (“hole”) at the interface of a second polypeptide, so that the protrusion can be positioned in the cavity in such a way as to promote heterodimer formation and hinder homodimer formation. The protrusions are constructed by the substitution of small chains Petition 870250102232, dated 07 / 11 / 2025, pages 462 / 702 146 / 333 amino acid side chains at the interface of the first polypeptide are replaced by larger side chains (e.g., tyrosine or tryptophan). Compensatory cavities of identical or similar size to the protrusions are created at the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine).
[00345] Thus, in certain aspects, in the CH3 domain of one Fc domain subunit of the fusion protein or antibody variant described herein, an amino acid residue is replaced by an amino acid residue with a larger side chain volume, thus generating a protrusion within the CH3 domain of this subunit that can be positioned in a cavity within the CH3 domain of the other subunit, and in the CH3 domain of the other Fc domain subunit, an amino acid residue is replaced by an amino acid residue with a smaller side chain volume, thus generating a cavity within the CH3 domain of this subunit within which the protrusion within the CH3 domain of the first subunit can be positioned.
[00346] In one aspect, the amino acid residue with the largest side chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), and tryptophan (W). In another aspect, the amino acid residue with the smallest side chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T), and valine (V). The bulge and the cavity can be made by altering the nucleic acid that encodes the polypeptides, for example, by site-specific mutagenesis or by peptide synthesis.
[00347] In certain aspects, in the (CH3 domain of) first subunit of the Fc domain (the “hole” subunit) of the fusion proteins described herein, the tyrosine residue at position 407 is replaced by a valine residue (Y407V), and in the (CH3 domain of) second subunit of the Fc domain Petition 870250102232, dated 07 / 11 / 2025, pp. 463 / 702 147 / 333 (the “knobs” subunit) the threonine residue at position 366 is replaced by a tryptophan residue (T366W).
[00348] In one aspect, in the first subunit of the Fc domain, additionally, the threonine residue at position 366 is replaced by a serine residue (T366S) and the leucine residue at position 368 is replaced by an alanine residue (L368A) (numbering according to the EU Kabat index).
[00349] In certain aspects, in the first subunit of the Fc domain, additionally, the tyrosine residue at position 349 is replaced by a cysteine residue (Y349C) (numbering according to the EU Kabat index) and, in the second subunit of the Fc domain, additionally, the serine residue at position 354 is replaced by a cysteine residue (S354C) or the glutamic acid residue at position 356 is replaced by a cysteine residue (E356C) (particularly, the serine residue at position 354 is replaced by a cysteine residue). The introduction of these two cysteine residues results in the formation of a disulfide bridge between the two subunits of the Fc domain, further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).
[00350] In certain respects, the first Fc domain subunit comprises the amino acid substitutions Y349C, T366S, L368A, and Y407V (numbering according to the EU Kabat index), and the second Fc domain subunit comprises the amino acid substitutions S354C and T366W. In certain respects, the second antigen-binding domain that is capable of binding to human PD-L1 and human IFN-α2 is fused (directly or via a peptide linker) to the second Fc domain subunit comprising the “knob” modification.
[00351] Other CH3 modification techniques to enhance heterodimerization are contemplated as alternatives according to the invention and are described, for example, in documents WO 96 / 27011, WO Petition 870250102232, dated 07 / 11 / 2025, pp. 464 / 702 148 / 333 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012 / 058768, WO 2013 / 157954, WO 2013 / 096291.
[00352] In one aspect, the heterodimerization approach described in EP 1870459 is used. This approach is based on the introduction of amino acids with opposite charges at specific amino acid positions in the CH3 / CH3 domain interface between the two Fc domain subunits. A particular aspect of the fusion protein or antibody variant described here is the amino acid mutations R409D; K370E in one of the two CH3 domains (of the Fc domain) and amino acid mutations D399K; E357K in the other of the CH3 domains of the Fc domain (numbering according to the EU Kabat index).
[00353] In another aspect, the fusion protein or antibody variant described herein comprises the amino acid mutations T366S, L368A, Y407V in the CH3 domain of the first Fc domain subunit and the amino acid mutation T366W in the CH3 domain of the second Fc domain subunit and, additionally, the amino acid mutations D399K; E357K in the CH3 domain of the first Fc domain subunit and the amino acid mutations R409D; K370E in the CH3 domain of the second Fc domain subunit (numbering according to the EU Kabat index).
[00354] In certain respects, the fusion protein or antibody variant described herein comprises amino acid mutations Y349C, T366S, L368A, Y407V in the CH3 domain of the first Fc domain subunit and amino acid mutations S354C, T366W in the CH3 domain of the second Fc domain subunit, or said fusion protein or antibody variant described herein comprises amino acid mutations S354C, T366S, L368A, Y407V in the CH3 domain of the first Fc domain subunit and amino acid mutations Y349C, T366W in the CH3 domains of the second Fc domain subunit. Petition 870250102232, dated 07 / 11 / 2025, pages 465 / 702 149 / 333 Fc domain subunit and, additionally, amino acid mutations D399K; E357K in the CH3 domain of the first Fc domain subunit and amino acid mutations R409D; K370E in the CH3 domain of the second Fc domain subunit (all numbering according to the EU Kabat index).
[00355] In one aspect, the heterodimerization approach described in WO 2013 / 157953 is used alternatively. In one aspect, one CH3 domain comprises the T366K amino acid mutation and the other CH3 domain comprises the L351D amino acid mutation (numbering according to the EU Kabat index). In a further aspect, the former CH3 domain also comprises the L351K amino acid mutation, and / or the latter CH3 domain also comprises an amino acid mutation selected from Y349E, Y349D and L368E (particularly L368E) (numbering according to the EU Kabat index).
[00356] In one aspect, the heterodimerization approach described in WO 2012 / 058768 is used alternatively. In one aspect, a first CH3 domain comprises mutations of amino acids L351Y, Y407A and a second CH3 domain comprises mutations of amino acids T366A, K409F. In a further aspect, the second CH3 domain comprises an additional amino acid mutation at the T411, D399, S400, F405, N390, or K392 position, for example, selected from a) T411N, T411R, T411Q, T411K, T411D, T411E or T411W, b) D399R, D399W, D399Y or D399K, c) S400E, S400D, S400R, or S400K, d) F405I, F405M, F405T, F405S, F405V or F405W, e) N390R, N390K or N390D, f) K392V, K392M, K392R, K392L, K392F or K392E (numbering according to the EU Kabat index). In a further aspect, a first CH3 domain comprises amino acid mutations L351Y, Y407A and a second CH3 domain comprises amino acid mutations T366V, K409F.In an additional aspect, a first CH3 domain comprises the Y407A amino acid mutation and a second CH3 domain. Petition 870250102232, dated 07 / 11 / 2025, pp. 466 / 702 150 / 333 comprises amino acid mutations T366A, K409F. In an additional aspect, the second CH3 domain also comprises amino acid mutations K392E, T411E, D399R and S400R (numbering according to the EU Kabat index).
[00357] In one aspect, the heterodimerization approach described in WO 2011 / 143545 is used alternatively, for example, with the modification of amino acids at a selected position of the group consisting of 368 and 409 (numbering according to the EU Kabat index).
[00358] In one aspect, the heterodimerization approach described in WO 2011 / 090762, which also uses the knobs-into-holes technology described above, is used alternatively. In one aspect, a first CH3 domain comprises the amino acid mutation T366W and a second CH3 domain comprises the amino acid mutation Y407A. In one aspect, a first CH3 domain comprises the amino acid mutation T366Y and a second CH3 domain comprises the amino acid mutation Y407T (numbering according to the EU Kabat index).
[00359] In one aspect, the fusion protein or antibody variant described in this document or its Fc domain is of the IgG2 subclass and the heterodimerization approach described in WO 2010 / 129304 is used alternatively.
[00360] In an alternative aspect, a modification-promoting association of the first and second Fc domain subunits comprises a modification that mediates electrostatic orientation effects, for example, as described in PCT publication WO 2009 / 089004. Generally, this method involves replacing one or more amino acid residues at the interface of the two Fc domain subunits with charged amino acid residues, so that homodimer formation becomes electrostatically unfavorable. Petition 870250102232, dated 07 / 11 / 2025, pp. 467 / 702 151 / 333 but electrostatically favorable heterodimerization. In one of these aspects, a first CH3 domain comprises the substitution of amino acids from K392 or N392 by a negatively charged amino acid (e.g., glutamic acid (E) or aspartic acid (D), particularly K392D or N392D) and a second CH3 domain comprises the substitution of amino acids from D399, E356, D356 or E357 by a positively charged amino acid (e.g., lysine (K) or arginine (R), particularly D399K, E356K, D356K or E357K, and more particularly D399K and E356K). In a further aspect, the first CH3 domain further comprises the substitution of amino acids from K409 or R409 by a negatively charged amino acid (e.g., glutamic acid (E) or aspartic acid (D), particularly K409D or R409D).In another aspect, the first CH3 domain additionally or alternatively comprises the substitution of amino acids of K439 and / or K370 by a negatively charged amino acid (e.g., glutamic acid (E) or aspartic acid (D)) (all numbering according to the EU Kabat index).
[00361] In an additional aspect, the heterodimerization approach described in WO 2007 / 147901 is used alternatively. In one aspect, a first CH3 domain comprises amino acid mutations K253E, D282K and K322D and a second CH3 domain comprises amino acid mutations D239K, E240K and K292D (numbering according to the EU Kabat index).
[00362] In yet another aspect, the heterodimerization approach described in document WO 2007 / 110205 can be used as an alternative.
[00363] In one aspect, the first subunit of the Fc domain comprises K392D and K409D amino acid substitutions, and the second subunit of the Fc domain comprises D356K and D399K amino acid substitutions (numbering according to the EU Kabat index). Petition 870250102232, dated 07 / 11 / 2025, pages 468 / 702 152 / 333
[00364] The C-terminal of the antibody or fusion protein heavy chain, as reported herein, may be a complete C-terminal terminating with PGK amino acid residues. The C-terminal of the heavy chain may be a shortened C-terminal in which one or two C-terminal amino acid residues have been removed. In a preferred aspect, the C-terminal of the heavy chain is a shortened PG C-terminal termination. In one aspect of all aspects as reported herein, an antibody or fusion protein comprising a heavy chain including a C-terminal CH3 domain as specified herein comprises the C-terminal glycine-lysine dipeptide (G446 and K447, EU amino acid position index numbering).In one aspect of all aspects as reported herein, an antibody comprising a heavy chain including a C-terminal CH3 domain, as specified herein, comprises a C-terminal glycine residue (G446, EU amino acid position index numbering). d) Cysteine-engineered antibody variants
[00365] In certain aspects, it may be desirable to create cysteine-engineered antibodies, for example, THIOMAB™ antibodies, in which one or more residues of an antibody are replaced by cysteine residues. In particular aspects, the replaced residues occur at accessible sites of the antibody. By replacing these residues with cysteine, reactive thiol groups are positioned at accessible sites of the antibody and can be used to conjugate the antibody to other moieties, such as drug moieties or drug-linkant moieties, to create an immunoconjugate, as further described herein. Cysteine-engineered antibodies can be generated as described, for example, in U.S. Patent Nos. 7,521,541,830,930, 7,855,275, 9,000,130, or WO 2016040856. e) Antibody derivatives Petition 870250102232, dated 07 / 11 / 2025, pages 469 / 702 153 / 333
[00366] In certain respects, a fusion protein or antibody provided in this document may be further modified to contain additional non-protein moieties that are known in the art and readily available. Moieties suitable for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymer, polyamino acids (homopolymers or random copolymers) and dextran or poly(n-vinylpyrrolidone)polyethylene glycol, propylene glycol homopolymers, propylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol and mixtures thereof.Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer can have any molecular weight and can be branched or unbranched. The number of polymers linked to the antibody can vary, and if more than one polymer is linked, they can be the same or different molecules. In general, the number and / or type of polymers used for derivatization can be determined based on considerations that include, but are not limited to, particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc. B. Recombinant Methods and Compositions
[00367] Antibodies or fusion proteins, as described in this document, can be produced using recombinant methods and compositions, for example, as described in US patent 4,816,567. For these methods, one or more isolated nucleic acids encoding an antibody or a fusion protein are provided.
[00368] In the case of a native antibody or antibody fragment Petition 870250102232, dated 07 / 11 / 2025, pages 470 / 702 154 / 333 native, two nucleic acids are required, one for the light chain or a fragment thereof and one for the heavy chain or a fragment thereof. Such nucleic acid(s) encode(s) an amino acid sequence comprising the VL and / or an amino acid sequence comprising the VH of the antibody (e.g., the light and / or heavy chain(s) of the antibody). These nucleic acids may be in the same expression vector or in different expression vectors.
[00369] In the case of a bispecific antibody with heterodimeric heavy chains, four nucleic acids are required: one for the first light chain, one for the first heavy chain comprising the first heteromonomeric polypeptide of the Fc region, one for the second light chain, and one for the second heavy chain comprising the second heteromonomeric polypeptide of the Fc region. In the case of a fusion protein as described herein, four nucleic acids are more commonly required: one for the first light chain, one for the first heavy chain comprising the first heteromonomeric polypeptide of the Fc region, one for the second light chain comprising IFN-α2, and one for the second heavy chain comprising the second heteromonomeric polypeptide of the Fc region. The four nucleic acids may be comprised in one or more nucleic acid molecules or expression vectors.Such nucleic acid(s) encode(s) an amino acid sequence comprising the first VL and / or an amino acid sequence comprising the first VH, including the first heteromonomeric Fc region, and / or an amino acid sequence comprising the second VL and / or an amino acid sequence comprising the second VH, including the second heteromonomeric Fc region of the antibody (e.g., the first and / or second light chain and / or the first and / or second heavy chain of the antibody). These nucleic acids may be in the same expression vector or in vectors of... Petition 870250102232, dated 07 / 11 / 2025, pp. 471 / 702 155 / 333 different expressions, normally these nucleic acids are located in two or three expression vectors, i.e., a vector may comprise more than one of these nucleic acids. Examples of such bispecific antibodies are CrossMabs (see, for example, Schaefer, W. et al., PNAS, 108 (2011) 111871191). For example, one of the heteromonomeric heavy chains comprises the so-called “knob mutations” (T366W and optionally one of S354C or Y349C) and the other comprises the so-called “hole mutations” (T366S, L368A and Y407V and optionally Y349C or S354C) (see, for example, Carter, P. et al., Immunotechnol. 2 (1996) 73), according to the EU index numbering.
[00370] In one aspect, isolated nucleic acids encoding an antibody or a fusion protein are provided, as used in the methods provided in this document.
[00371] In one aspect, a method is provided for producing a PD-L1-targeted huIFN-α2a fusion protein, as described in this document, wherein the method comprises culturing a host cell comprising nucleic acid(s) encoding the fusion protein, as provided above, under conditions suitable for fusion protein expression and optionally recovering the fusion protein from the host cell (or host cell culture medium). In another aspect, a method is provided for producing an anti-huPD-L1 antibody, wherein the method comprises culturing a host cell comprising nucleic acid(s) encoding the antibody, as provided above, under conditions suitable for antibody expression and optionally recovering the antibody from the host cell (or host cell culture medium).
[00372] For the recombinant production of a PD-L1-targeted huIFN-α2a fusion protein and / or an anti-PD-L1 antibody, the nucleic acids encoding the fusion protein or the antibody, respectively, for example, as described above, are isolated and inserted into one or more Petition 870250102232, dated 07 / 11 / 2025, pages 472 / 702 156 / 333 vectors for further cloning and / or expression in a host cell. Such nucleic acids can be easily isolated and sequenced using conventional procedures (e.g., using oligonucleotide probes that are capable of specifically binding to genes encoding the heavy and light chains of the fusion protein or antibody) or produced by recombinant methods or obtained by chemical synthesis.
[00373] Suitable host cells for cloning or expression of fusion protein- or antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, fusion proteins or antibodies can be produced in bacteria, particularly when glycosylation and Fc effector function are not required. For expression of antibody fragments and polypeptides in bacteria, see, for example, US 5,648,237, US 5,789,199, and US 5,840,523. (See also Charlton, KA, in: Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa, NJ (2003), pp. 245-254, describing the expression of antibody fragments in E. coli.) After expression, the fusion protein or antibody can be isolated from the bacterial cell paste in a soluble fraction and can be subsequently purified.
[00374] In addition to prokaryotes, eukaryotic microbes, such as filamentous fungi or yeasts, are suitable hosts for cloning or expression of antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, TU, Nat. Biotech. 22 (2004) 1409-1414; and Li, H. et al., Nat. Biotech. 24 (2006) 210-215.
[00375] Host cells suitable for the expression of (glycosylated) antibodies and / or fusion proteins are also derived from multicellular organisms (invertebrates and vertebrates). Examples of cells Petition 870250102232, dated 07 / 11 / 2025, pages 473 / 702 157 / 333 of invertebrates include plant and insect cells. Several baculovirus strains have been identified and can be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.
[00376] Plant cell cultures can also be used as hosts. See, for example, US documents 5,959,177, US 6,040,498, US 6,420,548, US 7,125,978 and US 6,417,429 (describing the PLANTIBODIES™ technology for producing antibodies in transgenic plants).
[00377] Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted to grow in suspension can be useful. Other examples of useful mammalian host cell lines are SV40-transformed monkey kidney CV1 cell line (COS-7); human embryonic kidney cell line (293 or 293T cells, as described, for example, in Graham, FL et al., J. Gen Virol. 36 (1977) 59-74); baby hamster kidney cells (BHK); mouse Sertoli cells (TM4 cells, as described, for example, in Mather, JP, Biol. Reprod. 23 (1980) 243-252); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); Canine renal cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells (as described, for example, in Mather, JP et al., Annals NY Acad. Sci. 383 (1982) 44-68); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (Urlaub, G. et al., Proc. Natl. Acad. Sci. USA 77 (1980) 42164220); and myeloma cell lines such as Y0, NS0, and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, for example, Yazaki, P. and Wu, AM, Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa,. Petition 870250102232, dated 07 / 11 / 2025, pages 474 / 702 158 / 333 NJ (2004), pp. 255-268.
[00378] In one aspect, the host cell is eukaryotic, for example, a Chinese hamster ovary cell (CHO) or a lymphoid cell (e.g., Y0, NS0, Sp20 cell). C. Essays
[00379] Fusion proteins provided in this document, antigen-binding domains for use in fusion proteins provided in this document, and anti-huPD-L1 antibodies provided in this document can be identified, screened, or characterized for their physical / chemical properties and / or biological activities by various assays known in the art. 1. Bond tests and other tests
[00380] In one aspect, an antibody of the invention is tested for its antigen-binding activity, for example, by known methods such as ELISA, Western blot, etc.
[00381] In another aspect, competition assays can be used to identify an antibody that competes with Atezolizumab, Durvalumab, and Avelumab for binding to PD-L1. In certain aspects, such a competitive antibody binds to the epitope (e.g., a linear or conformational epitope) that is bound by Atezolizumab, Durvalumab, and / or Avelumab. In another aspect, competition assays can be used to identify an antibody that does not compete with Atezolizumab, Durvalumab, and / or Avelumab for binding to PD-L1. In certain aspects, this non-competitive antibody binds to a different epitope (e.g., a linear or conformational epitope) than the one that is bound by Atezolizumab, Durvalumab, and Avelumab. Detailed illustrative methods for mapping an epitope to which an antibody binds are provided in Morris (1996) “Epitope Mapping Protocols”, in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ). Petition 870250102232, dated 07 / 11 / 2025, pp. 475 / 702 159 / 333
[00382] In an exemplary competition assay, immobilized PD-L1 is incubated in a solution comprising a first labeled antibody that binds to PD-L1 (e.g., Atezolizumab, BMS-936559, Avelumab, Durvalumab) and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to PD-L1. The second antibody may be present in a hybridoma supernatant. As a control, immobilized PD-L1 is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions permissive for binding of the first antibody to PD-L1, the excess unbound antibody is removed and the amount of marker associated with immobilized PD-L1 is measured.If the amount of immobilized PD-L1-associated marker is substantially reduced in the test sample compared to the control sample, this indicates that the second antibody is competing with the first antibody for binding to PD-L1. See Harlow and Lane (1988) Antibodies: A Laboratory Manual ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). Alternatively, competition can also be examined using an SPR assay, as described in Example 7e. 2. Activity trials
[00383] In one aspect, assays are provided to identify anti-huPD-L1 antibodies that possess biological activity. Biological activity may include, for example, blocking the PD-1 / PDL1 interaction or internalization (into a cell) after PD-L1 binding. Antibodies with such biological activity in vivo and / or in vitro are also provided.
[00384] In certain respects, an antibody of the invention is tested for such biological activity. An exemplary assay to identify whether an antibody blocks the PD-1 and PD-L1 interaction may be the PD1 / PD-L1 blocking bioassay (Promega). Petition 870250102232, dated 07 / 11 / 2025, pages 476 / 702 160 / 333
[00385] In an exemplary assay to determine the internalization of an anti-huPD-L1 antibody, live cell imaging can be used. For this, cells expressing PD-L1 are placed in contact with anti-huPD-L1 antibodies and a suitable reagent to label the antibody with a detectable marker, for example, a fluorescence marker. Internalization is then detected using live cell imaging.
[00386] In one aspect, assays are provided to identify PD-L1-targeted huIFN-α2a fusion proteins with biological activity. Biological activity may include, for example, IFNα activity, inhibition of tumor growth, induction of IFNα-mediated release of immunomodulatory cytokines, upregulation of PD-L1 and / or MHCI and / or secretion, such as IFNγ IL6, CXCL10, etc., and / or the ability to enhance the activation and / or proliferation of different immune cells, such as NK cells, DC cells, or T cells. Antibodies with such biological activity in vivo and / or in vitro are also provided.
[00387] Such an activity assay may be an in vitro human HEK-blue IFNAR1 / 2 reporter cell assay, as described in Examples 12 and 13. For this assay, a high-huPD-l1 expression HEKBlue IFNα / β reporter cell line is generated by transfecting HEK-Blue IFNα / β cells (Invivogen, catalog number hkb-IFNa / β) with a vector containing full-length cDNA encoding human PD-L1 and selecting cells with high cell surface expression of PD-L1 to establish stable cell clones. Quantification of cell surface PD-L1 is possible, for example, using a microsphere-based quantification kit (BD, catalog number 340495). As a second reporter cell line, wild-type HekBlue-IFNα / β cells are used, which exhibit low PD-L1 expression on the cell surface («300 PD-L1 molecules / cell on the cell surface»). Petition 870250102232, dated 07 / 11 / 2025, pages 477 / 702 The autoregulated activity of the fusion proteins provided in this document can be demonstrated by independently contacting the two reporter cell lines with a fusion protein to be tested at a series of titrations of different concentrations. Fusion proteins can only activate IFNAR1 / 2 receptors when huPD-L1 is present in sufficient quantity on the cell surface for the PD-L1 binding side of the Dutaflip arm to bind to huPD-L1 on the cell surface, thus releasing IFN-α2α and leaving it free to bind to its receptor on the cell surface. Each concentration of the fusion protein is placed in contact with an aliquot of reporter cells in a suitable medium and incubated for a defined period at 37 °C. After IFN-α2α binds to IFNAR1 / 2 receptors, the JAK / STAT / ISGF3 pathway is activated, ultimately leading to the expression of the reporter gene, which is under the control of the ISG54 promoter, which contains an IFN-stimulated response element (ISRE).The SEAP (secreted alkaline phosphatase) reporter gene is produced by the cell and secreted into the medium. Its quantity correlates with the extent of IFNAR1 / 2 receptor activation. SEAP levels in the medium can be measured using a SEAP detection reagent such as QUANTI-Blue™, and the color change of the detection reagent due to SEAP activity can be measured with a spectrophotometer at optical density (OD) at 640 nm.
[00388] In certain embodiments, a fusion protein or an antibody of the invention is tested for such biological activity as described, for example, in the examples below. D. Methods and Compositions for Diagnosis and Detection
[00389] In certain respects, any of the antihuPD-L1 antibodies provided in this document is useful for detecting the presence of huPD-L1 in a biological sample. The term “detection,” as used in this document, encompasses quantitative or qualitative detection. In certain Petition 870250102232, dated 07 / 11 / 2025, pp. 478 / 702 162 / 333 aspects, a biological sample comprises a cell or tissue, such as tumor tissue or tumor cells.
[00390] In one aspect, an anti-huPD-L1 antibody is provided for use in a diagnostic or detection method. In a further aspect, a method is provided for detecting the presence of huPD-L1 in a biological sample. In certain aspects, the method comprises contacting the biological sample with an anti-huPD-L1 antibody, as described herein, under conditions permissive to the binding of the anti-huPD-L1 antibody to human PD-L1 and detecting whether a complex is formed between the anti-huPD-L1 antibody and human PD-L1. This method may be an in vitro or in vivo method. In one aspect, an anti-huPD-L1 antibody is used to select individuals eligible for therapy with an anti-huPD-L1 antibody, for example, where human PD-L1 is a biomarker for patient selection.
[00391] In certain respects, labeled anti-huPDL1 antibodies are provided. The markers include, but are not limited to, markers or portions that are directly detected (such as fluorescent, chromophore, electron-dense, chemiluminescent, and radioactive markers), as well as portions, such as enzymes or ligands, that are indirectly detected, for example, through an enzymatic reaction or molecular interaction. Exemplary markers include, but are not limited to, the radioisotopes 32P, 14C, 125I, 3H, and 131I, fluorophores such as rare earth chelates or fluorescein and derivatives thereof, rhodamine and derivatives thereof, dansyl, umbelliferone, luciferases, for example, firefly luciferase and bacterial luciferase (U.S. Patent No. 4,737).456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, saccharide oxidases, for example, glucose oxidase, galactose oxidase and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled to an enzyme that uses hydrogen peroxide to oxidize a dye precursor, such as. Petition 870250102232, dated 07 / 11 / 2025, pages 479 / 702 163 / 333 HRP, lactoperoxidase or microperoxidase, biotin / avidin, spin markers, bacteriophage markers, stable free radicals and the like. E. Pharmaceutical Compositions
[00392] In a further aspect, pharmaceutical compositions are provided comprising any of the antibodies provided herein, for example, for use in any of the therapeutic methods below. In one aspect, a pharmaceutical composition comprises any of the antibodies provided herein and a pharmaceutically acceptable carrier. In another aspect, a pharmaceutical composition comprises any of the antibodies provided herein and at least one additional therapeutic agent, for example, as described below.
[00393] Pharmaceutical compositions of a fusion protein provided herein or of an anti-huPD-L1 antibody provided herein are prepared by mixing such antibody having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized compositions or aqueous solutions.Pharmaceutically acceptable vehicles are generally non-toxic to receptors at the dosages and concentrations employed and include, but are not limited to: buffers, such as histidine, phosphate, citrate, acetate, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkylparabens, such as methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight polypeptides (less than about 10 residues); proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine. Petition 870250102232, dated 07 / 11 / 2025, pages 480 / 702 164 / 333 Monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG). Pharmaceutically acceptable vehicles exemplified in this document also include interstitial drug dispersing agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, soluble human PH-20 hyaluronidase glycoproteins such as rHuPH20 (HYLENEX®, Halozyme, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in U.S. Patent Publications No. 2005 / 0260186 and 2006 / 0104968. In one aspect, an sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinases.
[00394] Examples of lyophilized antibody compositions are described in U.S. Patent No. 6,267,958. Aqueous antibody compositions include those described in U.S. Patent No. 6,171,586 and WO 2006 / 044908, the latter compositions including a histidine acetate buffer.
[00395] The pharmaceutical composition described herein may also contain more than one active ingredient, as necessary for the particular indication to be treated, preferably those with complementary activities that do not adversely affect each other. Such active ingredients are appropriately present in combination in amounts that are effective for the intended purpose.
[00396] The active ingredients can be trapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively, in Petition 870250102232, dated 07 / 11 / 2025, pages 481 / 702 165 / 333 colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
[00397] Pharmaceutical compositions for sustained release may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, the matrices of which are in the form of molded articles, for example, films or microcapsules.
[00398] Pharmaceutical compositions to be used for in vivo administration are generally sterile. Sterility can be easily achieved, for example, by filtration through sterile filtration membranes. F. Therapeutic methods and routes of administration
[00399] Any of the fusion proteins or antihuPD-L1 antibodies provided here can be used in therapeutic methods.
[00400] In one aspect, a fusion protein or an anti-huPD-L1 antibody is provided for use as a medicament. In other aspects, a fusion protein or an anti-huPD-L1 antibody is provided for use in the treatment of cancer. In certain aspects, a fusion protein or an anti-huPD-L1 antibody is provided for use in a treatment method. In certain aspects, the invention provides a fusion protein or an anti-huPD-L1 antibody for use in a treatment method for an individual with cancer, comprising administering to the individual an effective amount of the fusion protein or the anti-huPD-L1 antibody. In one of these aspects, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent (for example, one, two, three, four, five, or six additional therapeutic agents), for example, as described below. In other aspect...
Claims
1. A FUSION PROTEIN, characterized by comprising: a. a first antigen-binding domain capable of binding to human PD-L1; b. a second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2; and c. a human IFN-α2; wherein i. the second antigen-binding domain is a bispecific Fab; and ii. the human IFN-α2 is fused at its C-terminus to the N-terminus of the heavy chain or light chain of the second antigen-binding domain.
2. Fusion protein, according to claim 1, characterized in that the first antigen-binding domain is monospecific for human PD-L1.
3. Fusion protein, according to claim 1 or 2, characterized in that the second antigen-binding domain is capable of blocking human IFN-α2 from binding to IFNAR.
4. FUSION PROTEIN, according to claims 1 to 3, characterized by human IFN-α2 being blocked from binding to IFNAR when bound to the bispecific Fab and being able to bind to IFNAR when the bispecific Fab is bound to PD-L1.
5. FUSION PROTEIN, according to any one of claims 1 to 4, characterized in that the first antigen-binding domain capable of binding to human PD-L1 is a Fab.
6. FUSION PROTEIN, according to any one of claims 1 to 5, characterized in that the bispecific Fab is a DutaFab. Petition 870250102232, dated 07 / 11 / 2025, p. 651 / 702 2 / 6 7. FUSION PROTEIN, according to any one of claims 1 to 6, characterized by the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 comprising a human PD-L1 paratope and a human IFN-α2 paratope within a cognate pair of a variable light chain domain (VL domain) and a variable heavy chain domain (VH domain), wherein the human IFN-α2 paratope comprises amino acid residues of CDR-H2, CDR-L1 and CDR-L3 of the antigen-binding domain, and wherein the human PD-L1 paratope comprises amino acid residues of CDR-H1, CDR-H3 and CDR-L2 of the antigen-binding domain.
8. Fusion protein, according to any one of claims 1 to 7, characterized in that the fusion protein further comprises an Fc domain composed of a first and a second subunit.
9. FUSION PROTEIN, according to any one of claims 1 to 8, characterized by the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 comprising: a. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; b. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID Petition 870250102232, dated 07 / 11 / 2025, p.652 / 702 3 / 6 NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:9, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; c. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; or d.a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:13, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:14, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:15, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:16, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:17, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:
18.
10. FUSION PROTEIN, according to any one of claims 1 to 9, characterized by the second antigen-binding domain capable of binding to human PD-L1 and human IFN-α2 comprising: a. a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:8; b. a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:10; c. a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:12; or d. a VH domain comprising the amino acid sequence of SEQ ID NO:19 and a VL domain comprising the amino acid sequence of SEQ ID NO:
20.
11. FUSION PROTEIN, according to any one of claims 1 to 10, characterized by the first antigen-binding domain capable of binding to human PD-L1 comprising: a. a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:26; or b.a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:29, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:30, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:31, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:32, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:33, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:
34.
12. FUSION PROTEIN, according to any of claims 1 to 11, characterized by the first antigen-binding domain capable of binding to human PD-L1 comprising: a. a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28; or b. a VH domain comprising the amino acid sequence of SEQ ID NO:35 and a VL domain comprising the amino acid sequence of SEQ ID NO:
36.
13. FUSION PROTEIN, according to any one of claims 1 to 12, characterized by: the first antigen-binding domain capable of binding to human PDL1 comprising a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28, and the second antigen-binding domain capable of binding to human PDL1 and human IFN-α2 comprising a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:
8.
14. ANTIBODY that binds to human PD-L1, characterized by the antibody comprising a variable heavy chain (VH) domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23, and a variable light chain (VL) domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25 and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:
26.
15. ANTIBODY, according to claim 14, Petition 870250102232, dated 07 / 11 / 2025, p. 655 / 702 6 / 6 characterized by comprising a VH sequence of SEQ ID NO:27 and a VL sequence of SEQ ID NO:
28.
16. ISOLATED NUCLEIC ACID, characterized by encoding the fusion protein, as defined in any one of claims 1 to 13, or the antibody, as defined in claim 14 or 15.
17. HOST CELL, characterized by comprising the nucleic acid as defined in claim 16.
18. METHOD, characterized by producing the fusion protein, as defined in any one of claims 1 to 13, or the antibody, as defined in claim 14 or 15, under conditions suitable for antibody expression.
19. METHOD, according to claim 18, characterized by further comprising recovering the fusion protein or antibody from the host cell.
20. PHARMACEUTICAL COMPOSITION, characterized by comprising the antibody, as defined in any one of claims 1 to 13, or the antibody, as defined in claim 14 or 15, and a pharmaceutically acceptable carrier.
21. Fusion protein, according to any one of claims 1 to 13, antibody, according to claim 14 or 15, or pharmaceutical composition, according to claim 20, characterized in that it is for use as a medicament.
22. Fusion protein, according to any one of claims 1 to 13, the antibody, according to claim 14 or 15, or the pharmaceutical composition, according to claim 20, characterized in that it is for use in the treatment of cancer.
